Part I: Design and Synthesis of Novel Drugs to Treat Asthma By Targeting GABAA Receptors in the Lung Part II: Design and Synthesis of Novel Α2/α3 Subtype Selective GABAAR Ligands  for CNS Disorders by Jahan, Rajwana
University of Wisconsin Milwaukee 
UWM Digital Commons 
Theses and Dissertations 
5-1-2019 
Part I: Design and Synthesis of Novel Drugs to Treat Asthma By 
Targeting GABAA Receptors in the Lung Part II: Design and 
Synthesis of Novel Α2/α3 Subtype Selective GABAAR Ligands for 
CNS Disorders 
Rajwana Jahan 
University of Wisconsin-Milwaukee 
Follow this and additional works at: https://dc.uwm.edu/etd 
 Part of the Organic Chemistry Commons 
Recommended Citation 
Jahan, Rajwana, "Part I: Design and Synthesis of Novel Drugs to Treat Asthma By Targeting GABAA 
Receptors in the Lung Part II: Design and Synthesis of Novel Α2/α3 Subtype Selective GABAAR Ligands 
for CNS Disorders" (2019). Theses and Dissertations. 2081. 
https://dc.uwm.edu/etd/2081 
This Dissertation is brought to you for free and open access by UWM Digital Commons. It has been accepted for 
inclusion in Theses and Dissertations by an authorized administrator of UWM Digital Commons. For more 
information, please contact open-access@uwm.edu. 
Part I 
 
DESIGN AND SYNTHESIS OF NOVEL DRUGS TO TREAT ASTHMA BY 
TARGETING GABAA RECEPTORS IN THE LUNG 
  
Part II 
DESIGN AND SYNTHESIS OF NOVEL α2/α3 SUBTYPE SELECTIVE GABAAR 






A Dissertation Submitted in  
Partial Fulfillment of the  
Requirements for the Degree of 
Doctor of Philosophy  
in Chemistry 
at 







DESIGN AND SYNTHESIS OF NOVEL DRUGS TO TREAT ASTHMA BY 
TARGETING GABAA RECEPTORS IN THE LUNG 
  
Part II 
DESIGN AND SYNTHESIS OF NOVEL α2/α3 SUBTYPE SELECTIVE GABAAR 






The University of Wisconsin-Milwaukee, 2019 




     Asthma is a major healthcare challenge affecting an estimated 300 million people globally. 
Over $56 billion in asthma-related healthcare expenses occur in the United States annually. 
Moreover, asthma accounts for the majority of missed school/work days, Doctor and emergency 
room visits, and patient hospitalizations in young persons. Consequently, asthma continues to be 
a significant healthcare burden in terms of morbidity, productivity, and medical costs. Beta 2-
adrenergic agonists and inhaled corticosteroids (ICs) are the most commonly prescribed treatments 
for the acute and chronic management of asthma. Both agents present efficacy, compliance, and 
adverse side effect concerns. 
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        Hence, there is an unmet need for asthma therapies with novel mechanisms of action to better 
control the disease with decreased adverse side effects. Previously, it was demonstrated that airway 
smooth muscle (ASM) cells express GABAA receptors (GABAAR's) of the α4 and α5 subunits. 
Agonists of these GABAAR subtypes can relax ASM acutely. Targeting the limited and 
overlapping α subunits with subtype selective GABAAR agonists would effect both ASM 
relaxation and suppression of inflammation in the absence of any off-target CNS activity. 
Bz/GABAAergic agents have been proven to be safe and have a long clinical safety record. As a 
result, targeting Bz/GABAAR in the lung and the peripheral nervous system (PNS) would be a 
novel and effective strategy in a management of asthma in patients. In this vein, novel GABAAR 
positive allosteric modulators designed specifically for α4/α6 subunit selectivity were synthesized 
using iterative computational analyses. In addition, a series of deuterated analogs at key metabolic 
sites (C-3 and C-8 of the imidazobenzodiazepine scaffold) were synthesized to increase the drugs 
stability so that the drug stays in the body for a longer time to permit lower doses and still effect 
its anti-asthmatic properties for a longer duration, presumably with less side effects. Furthermore, 
a library of α4 subtype selective GABAAR ligands which were more hydrophilic to prevent blood 
brain barrier (BBB) penetration reduced CNS side effects. To obtain better in vitro and in vivo 
stability, bioisosteric moieties to replace the labile C-3 ester functional groups were designed and 
synthesized. Preclinical assays such as microsomal stability, cytotoxicity, and sensorimotor 
impairment have been studied on these novel analogs. Several ligands exhibited the desired 
properties required for better management of asthma. The results of studies in several models of 
asthma in vivo reinforces the novel hypothesis, which rests on relaxation of airway smooth muscle 
(ASM), a decrease in airway hyperresponsiveness (AHR), and a decrease in airway eosinophils, 
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as well as modulating inflammatory cells. These ligands may be potential treatments for childhood 





     Nonselective ligands of the α1-3,5βγ 2 subtypes of GABAARs, such as diazepam have been used 
in the clinic for more than five decades for various central nervous system (CNS) disorders. These 
drugs exhibit various adverse CNS effects including sedation, ataxia, amnesia, tolerance, and 
addiction, which are believed to be mediated by α1 subtypes of GABAARs. As a result, these 
drugs are not applicable to all patients and have limited long-term applications. Despite their 
adverse CNS effects due to non-selective GABAAR efficacy, novel ligands with better subtype 
selectivity, efficacy and reduced adverse effects are now emerging to be suitable replacements for 
these benzos. The GABAAR agonists that possess superior α2/α3 subtype selectivity over the α1 and 
α5 subtypes are considered to be a promising avenue for development of novel GABAAR ligands 
to treat various CNS disorders including inflammatory pain, anxiety, neuropathic pain, and 
epilepsy, while avoiding side effects such as, ataxia, amnesia, tolerance and dependence. 
  
          Previously, it had been shown the α2/α3 subtype selective Bz/GABAAR positive allosteric 
modulator (PAM) HZ-166 exhibited anticonvulsant, antihyperalgesic and anxiolytic properties 
while being devoid of sedation, ataxia, dependence and tolerance. However, the C-3 ester function 
in HZ-166 was too labile for studies of ADME toxicity.  Consequently, research here was carried 
out to prepare new ligands with better efficacy and stability, which resulted in several new lead 
compounds including a 1,3-oxazole (KRM-II-81) and a 1,2,4-oxadiazole (MP-III-80). These 
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bioisosteres were synthesized to overcome the problems with the metabolically labile ester 
functions. Among them KRM-II-81 exhibited prominent anxiolytic, anticonvulsant, 
antihyperalgesia, and antidepressant activity. An improved synthetic route was developed to better 
access the key ligand (HZ-166) in gram quantities for further optimization of this "privileged" 
scaffold. Synthesis of several new ester bioisosteres, importantly, those which contained deuterium 
in the scaffold at key metabolic sites, resulted in d1-MP-III-80, d3-MP-III-80, d5-MP-III-80, as 
well as a few 3-alkyl-1,2,4-oxadiazole derivatives. The in vitro and in vivo evaluation of these 
new ligands look promising and further investigations in vivo are underway. It is felt these new 
α2/α3 subtype selective ligands will result in novel compounds for development into  effective 
treatments  for anxiety disorders, for depression, for pain syndromes and for treatment of epilepsies 
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The term ‘asthma’ was first used by Homer (800 BC) in his  book The Iliad, which in Greek 
(ásthma) means panting and shortness of breath.20 Hippocrates (400 BC) first defined the disease 
asthma to the medical community through the Corpus Hippocraticum.20 As it appears, asthma is 
not new, and it has been around for many many centuries, but modern asthma that we now know 
has rapidly evolved over the past several decades. It has become a global health problem affecting 
people from all ages and ethnic groups, especially children and the elderly.21 The cause behind the 
increase in asthma reports is not ethnic nor genetic in nature, rather it is the combined effects of 
many risk factors which includes genetic, environmental, and lifestyle.  
 
Asthma is a chronic lung disease, which is characterized by recurring inflammation and narrowing 
of the airways that results in frequent and involuntary wheezing and shortness of breath. Asthma 
exhibits several major features; inflammation, mucous production, airflow obstruction, and airway 
hyper-responsiveness.22 The results of inflammation can range from discomfort in breathing to a 
life-threatening condition. As a result, asthma accounts for the majority of missed school/work 
days, doctor and emergency room visits, and patient hospitalizations in young persons.23,3,24 The 
severity and rate of recurrence of asthma varies among individuals. The World Health 
Organization (WHO) identifies asthma as one of the major noncommunicable diseases.25 Asthma 
is a life-long condition in the majority of asthmatic individuals and the symptoms can be kept 
under control but there is no cure for it as yet.26 It can affect anyone from children to elderly and 
under-control asthma can flare up at any moment without warning, which can cause severe to 
morbid acute respiratory inflammation. In many cases the triggers of asthma are not visible and 
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asthmatic triggers may vary from person to person, which makes it a challenge to predict and 
control. Another problem with asthma is that the triggers responsible for asthma attacks are in the 
asthmatics, surroundings (outside in the environment or inside the household) and thus the 
exposure seems to be inevitable in many cases. Some of the triggers may be seasonal and for those 
affected by the seasonal triggers (e.g. flower or grass pollen), a certain time of the year may be 
more dangerous than the remaining time of the year. With rapid development and urbanization, 
many people who lead strictly urban lifestyles have less and less exposure to the elements of nature 
and may eventually develop sensitivity towards many common natural substances. In addition, 
due to urbanization, most of the children grow up in a household or surroundings with a higher 
level of hygiene and spends less time outside. This results in fewer infections in the early ages. 
Thus, these children do not develop immunity to many of the germs or triggers that they become 
exposed to as they get older. This argument is known as “The Hygiene Hypothesis”,27 which has 
been reported as a possible origin of some asthmatics. 
 
This ill-educated immune system could also lead to sensitivity to various common germs or 
molecules present in the surroundings. As a result, this type of asthma is more prevalent in western 






Figure 1. Schematic diagram illustrating the heterogeneity of airway diseases in terms of triggers, pattern of 
airway inflammation, associated diseases, airway physiology and the specific underlying pathological 
abnormality (modified from the figures in Wardlaw, et al.5 and Green, et al.6).  
 
A proper definition and classification of asthma is troublesome since asthma is a heterogenous 
disease and there is lack of consensus for such an accurate classification. Recent developments in 
the recognition of phenotypes and sub-phenotypes of asthma based on the pattern of airway 
inflammation have facilitated a systematic understanding of the disease.6 By understanding the 
link between phenotype and pathology, it would be helpful to comprehend the pathogenesis and 
aetiology. The first classification of asthma was based on aetiology by Rackemann in 1921,31 
which divided asthma into two subclasses, namely extrinsic and intrinsic asthma. Afterwards, 
several other causative phenotypes have been identified, for example aspirin-sensitive and 
occupational asthma.6 Further subclassification based on the different patterns of airflow 
obstructions includes ‘brittle asthma’, ‘irreversible asthma’, and ‘the morning dripper’.32 Asthma 
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management guidelines usually classify asthma based on the severity of the disease and amount of 
required treatments to maintain proper lung function and to control symptoms.33 More recent 
classification of asthma is based on the nature of underlying airway inflammation.34,35 It has also 
been suggested from experimental evidence that identification of such inflammatory phenotypes 
might be a useful guide for asthma management for individual patients.36,37 A schematic diagram, 
which illustrates the heterogeneity of asthma is illustrated in Figure 1.5 
 
Examination of Figure 1 depicts how a number of triggers can result in inflammatory responses 
that may range from highly eosinophilic to highly neutrophilic in origin. This is, presumably, the 
relationship between the extent of involvement of the innate (Th1) and adaptive (Th2) immune 
responses. Certain triggers such as allergens and small molecular weight chemicals cause 
syndromes such as extrinsic or occupational asthma and are mainly eosinophilic in origin. On the 
other hand, triggers such as bacterial or viral infections cause syndromes non-eosinophilic 
(neutrophilic) in origin. The triggers for some syndromes such as eosinophilic intrinsic asthma 
(and eosinophilic bronchitis) or non-eosinophilic asthma are not known or vary among individuals. 
To simplify, responses from all the eosinophilic and non-eosinophilic (neutrophilic) triggers can 
be termed as bronchial inflammation, represented as the grey box in the middle of Figure 1. Out 
of this grey box originates different physiological responses depending on the subject.5  
 
If you take away from the broader picture of airway disease as a whole, there is a considerable 
extent of heterogeneity within the symptoms of asthma itself.38 There are many descriptive terms 
to describe the heterogeneity depending on the clinical presentation or aetiology that is used to 
describe the disease.39,40,41,42 Based on clinical patterns, asthma can be categorized into chronic 
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(mild, moderate or severe), acute severe, brittle, nocturnal, premenstrual, and steroid resistant 
phenotypes. Similarly, based on the nature of triggers, asthma can be categorized as extrinsic or 
intrinsic (absence or presence of specific IgE to allergens), occupational (small molecule 
chemicals), infective (virus, bacteria or fungi), aspirin sensitivity, smoking, exercise etc. 
phenotypes. The infiltration of airway smooth muscle (ASM) by mast cells is specifically an effect 
in the asthma phenotype. As a result, to be precise, ‘classical asthma’ can be defined as a condition 
wherein the following indications are co-present: variable airflow obstruction, airway hyper-
responsiveness (AHP), and mast cell infiltration of the airway smooth muscle (ASM).5,38,39,41-43 
 
Asthma affects more than 300 million individuals globally and in the United States as stated above 
and one in every 12 persons suffers from asthma.44,21 The number of asthmatic patients is predicted 
to be over 400 million by the year 2025, globally.45  
 
According to the National Health Interview Survey (NHIS) 2011,46 approximately 39.5 million 
people (12.9% of the population), which includes 10.5 million children (14.0% of child 
population), in the United States alone have been diagnosed with asthma. It is a lifelong condition 
in approximately 40 million individuals in the United States in 2012.21,47 Over 11.5 million 
asthmatic individuals, which includes approximately 3 million children have had at least one 
asthma attack in 2015.48 
 
Every year asthma attacks result in approximately 180,000 deaths globally.49 Consequently, there 
is a huge impact on society, not only in terms of expenses but from productivity as well. As 
indicative by these statistics, there is considerable indirect costs (e.g., cost lost from absenteeism 
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from work, disability, and mortality), as well as direct costs (e.g., emergency room visits, 
hospitalization, medications, investigative treatments etc.) are associated with asthma incidents.  
Besides, there are some unquantifiable or intangible costs associated with asthma. It is difficult to 
get an accurate confirmation of the negative effect on life-styles in this situation. For example, in 
2013, approximately 13.8 million missed school days were due to asthma incidents.50 According 
to a report published in 2010, the US spent approximately $56 billion for asthma care which was 
several-fold higher than the expense in 1994 (about $12 billion).51 
 
During the last decade (2001-2011) asthma incidents increased by an alarming 28%, which 
indicates asthma was not under control. As a result, more than half a million hospitalizations, and 
about 2 million emergency room visits occur each year (some are often fatal) and more than 14 
million doctor visits occur each year due to asthma incidents.52 According to the WHO, in 2004 
the worldwide asthma costs may have exceeded the cost associated with TB and HIV/AIDS 
combined.53,21 
 
The current options for short-term (acute) and long-term (chronic) management of asthma are 
primarily based on short acting beta agonists (SABA) and long acting beta agonists (LABA) along 
with inhaled corticosteroids (ICS). The β2-adrenergic agonists such as salbutamol or salmeterol 
act as bronchodilators by activating the β2-adreno receptors (β2AR), while corticosteroids, such as 
beclomethasone dipropionate, act as anti-inflammatory agents, which reduce inflammation caused 
during an asthma attack. Both types of treatment have their limitation due to efficacy, compliance 
and side effect concerns. For example, for long term management of asthma, The Food and Drug 
Administration (FDA) has recommended avoiding LABA’s if possible and suggested the use of 
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LABA’s only in combination with corticosteroids due to the effect that LABA’s had on increased 
asthma related deaths.54 Furthermore, this drug it is reserved for patients whose asthma cannot be 
maintained by other available treatments.54 On the other hand, inhaled glucocorticoids, which are 
the best available option for asthma treatments have both oropharyngeal and systemic side effects 
including adrenal suppression, growth suppression, thinning or bruising of the skin, cataract 
formation, increased mortality, and loss of asthma control effects.4,55-60 In addition, there is the  
possibility of osteoporosis and growth problems associated with long-term use of corticosteroids.61 
Furthermore, orally available leukotriene receptor antagonists are commonly used to manage 
asthma symptoms;62 however up to 78% of patients do not respond to this alternative therapy.61,63 
In addition, it is very common to encounter an incident wherein improper use of inhalers results in 
incorrect dosing, oral infections, and poor patient compliance.4 
 
As a result, it can be inferred that the global asthma problem has been exacerbated over the last 
several decades. The current asthma management and/or treatment options are not good enough 
for the necessary treatment of clinical long-term treatment of asthma. There are certainly unmet 
demands for new asthma management programs. The medical community needs strategies to treat 
and/or control asthma to overcome imprecise dosing, as well as reduce adverse CNS side effects.  
 
1.2 GABAA Receptors 
Gamma-aminobutyric acid (GABA; Figure 2) is a neurotransmitter that plays an inhibitory role in 
the central nervous system (CNS). In addition, GABA is also involved in several other 
physiological functions in the peripheral nervous system including the mediation of the paracrine 
signaling. The overall involvement and mechanism of the role of GABA in neurotransmission is 
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rather complex. However, it has been investigated in detail and as a result its role as a central 
neurotransmitter has been fully established, which employed extensive electrophysiological, 
neurochemical, pharmacological, and molecular biology techniques. GABA is known to be 
involved in many CNS disorders and degenerative diseases including anxiety disorders, sleep 
disorders, schizophrenia, major depressive disorder, bipolar depression and PTSD.64-68 The 
combination of excitatory and inhibitory transmission regulates the overall activity of the brain. 
Excitatory transmitters, such as glutamic acid (Glu) depolarize neurons via a large number of 
receptor subtypes, while the inhibitory transmitter effects of GABAA receptors hyperpolarizes 
neurons also via several receptors.69,70  
                                                  
                                                  Figure 2. γ-Aminobutyric acid (GABA) 
 
Beside the central nervous system (CNS), GABA also regulates a wide range of physiologically 
important functions in the peripheral nervous system (PNS),71,72 as suggested by an increasing 
number of studies. GABA receptors have been found in a large number of peripheral tissues 
including the endocrine glands, smooth muscles, and the female reproductive system, which are 
all parts of the peripheral nervous system (PNS).73Although, the peripheral GABA receptors and 
GABAergic synaptic mechanisms are interesting drug targets, the majority of the GABA based 
drug discovery programs at UWM, target the central GABA-regulated synapses.73 It has also been 
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suggested that GABA plays a crucial role in the hearing mechanism, as indicated by an age-related 
significant reduction in GABA in the central nucleus of the inferior colliculus (CIC) in rats.73,74 
Since GABA receptors are the most abundant inhibitory neurotransmitters in the CNS, they control 
17-20% of all neurons in the brain.75 The physiological actions of GABA under study here are 
implemented via GABAA receptors, which are contained in chloride ion channels, whose 
properties are mediated by GABA. The action of GABAA receptors can be modulated by many 
drug molecules that bind to distinct allosteric binding sites on GABAA receptor in channels.
76 
Inferred from the pharmacological effects of such drug molecules, it can be concluded that GABAA 
receptors are involved in multifunctional roles including but not limited to controlling inhibition 
of neurons in the CNS,77,78 which control anxiety.79,80 They also help to monitor feeding and 
drinking behavior,81,82 cognition, the internal body clock, memory and learning, neuropathic pain, 
epilepsy and others.83-87  
GABAA receptors are heteropentameric in nature, which consists of a large N-terminal 
extracellular domain and four transmembrane (TM) domains.88-90 The extra cellular region 
contains sites for potential glycosylation, and a ‘Cys-loop’ connecting two conserved cysteine 
residues via a covalent disulfide bond. In addition, there is one intracellular loop connecting TM3 
to TM4 (Figure 3). Five individual subunits combine to form a chloride ion channel (Figure 4). 
Each GABAAR protein is a polypeptide of approximately 50 kD in size and each subunit is 







Figure 3. Proposed topology of a GABAA receptor subunit. The extracellular domain begins with the N-
terminus and M1-M4 represents the four transmembrane domains (modified from the figures in Burt, et al.91 







Figure 4. Longitudinal (A) and cross-sectional (B) Schematic representations of the ligand-gated ion channel. 
The number 1-4 refer to the M1-M4 segments. The M2 segment contributes to the majority of the pore lining 
within the membrane lipid bilayer (modified from the figures in Keramidas, et al92. and Clayton et al.).7,9 
However, much of this ion channel topography was developed by Werner Sieghart. 
 
In the mammalian nervous system a total of six major alpha, three beta, three gamma, three ro, as 
well as one of delta, epsilon, pi, and theta each have been sequenced, which results in a set of 19 
(i.e., α1-6, β1-3, γ1-3, δ, ε, θ, π, ρ1-3) different subunits. This collection of different subunits of GABAA 
receptors is the largest among ion channel receptors.93,94 It is inferred from experimental evidence 
that this set of 19 subunits might be the complete set of subunits in the human since no new receptor 
subunit genes were found in the human genome.95 On the other hand, additional subunit types have 
been identified in nonmammalian species.93,96,97 
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Theoretically, if all the subunits could co-assemble with each other, randomly, more than 150,000 
GABAA receptor subtypes with different compositions and arrangements could be formed.
98 Due 
to restrictions during the assembly of GABAA receptors, not all theoretically possible subtypes can 
actually form. It is probable that around 500 different subunits actually exist in the brain.94 In 
addition, only a few subunits are abundant in number. The majority of the subunits are comprised 
of alpha, beta, and gamma subunits. Occasionally, the gamma unit is replaced by either of delta, 
epsilon, or pi subunits.94 It is known that the GABAA receptors, which are modulated by  
benzodiazepine allosteric binding sites are located in the alpha, beta, and gamma ion channels, 
which contain two alpha, two beta and a gamma-units forming a hetero-pentameric receptor. In 
these receptors the four alternating alpha and beta (2 alpha + 2 beta) subunits are connected by a 
gamma unit in a ratio depicted here (α:β:γ = 2:2:1).90,99-103 Nonetheless, GABAA receptors are 
highly heterogeneous and are widely distributed throughout the brain. Despite its ubiquitous nature 
in the brain, each subunit has a distinct regional and cellular distribution. Often a special class of 
cells or tissues express a small sub-set of GABAA receptor subunits, preferentially.
104 For example, 
α5β3γ2 subtypes are located primarily in the hippocampus of the CNS and a small amount in the 
spinal cord. 
In the synaptic cleft and within the pore of a GABAAR there are numerous binding sites. A number 
of ligands of various classes can bind to these sites and activate the GABAAR complex. These 
compounds include β-carbolines, barbiturates, ethanol, benzodiazepines, picrotoxin, as well as 
endogenous molecules such as neurosteroids.105,106 The synaptic cleft of the α1-6β1-3γ2 subunit, 
viewed from an  extracellular region is depicted in Figure 5. The αβαβγ subunits are arranged in a 
clockwise manner from such view point (Figure 5). GABA binding sites are located at the two α-
β+ interfaces while benzodiazepines bind to the γ
-α+ interface.107,108 Recent studies by Sieghart have 
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located a CGS 9895 binding site (termed PQ) at the β-α+ interface.109,110 In addition to these known 
ligands, a number of pyrroloquinolines also have been found to bind and activate this GABAAR 




Figure 5. Absolute subunit arrangement of the 122 GABAA receptor when viewed from the synaptic cleft.  
The GABA binding sites are located at the +- subunit interfaces and the Bz modulatory binding site is located 
at the +- subunit interface.  The part of the schematically drawn subunits marked by the + indicates loop C 






Figure 6. Conformational impact of GABA binding to the α1β3γ2L GABAA receptor. a) Cryo-EM map of the 
PTX/GABA-bound α1β3γ2L receptor viewed from the extracellular space (left) and parallel to the membrane 
plane (right). b) One GABA-binding pocket viewed from the extracellular space. GABA is shown in ball-and-
stick representation with the atoms colored as follows: carbon, khaki; oxygen, red; nitrogen, blue. c) The cryo-
EM map of the α1β3γ2 GABA receptor in complex with diazepam (DZP, teal) viewed parallel to the membrane 
plane. d) Views of the benzodiazepine binding site at the α1+/γ2− interface showing  DZP binding mode (modified 





Figure 7. The cryo-EM structure of the human α5β3 GABAA receptor. a, b Surface views parallel to the plasma 
membrane (a) or from the extracellular space down the five-fold pseudo-symmetry axis (b) of the cryo-EM 
density map of the human α5β3 GABAA receptor in complex with Nb25 reveals a distinct assembly of one α 
(red) and four β subunits (purple), and three bound Nb25s (green). c, d The α5β3 GABAA receptor viewed 
parallel to the plasma membrane (c) or from the extracellular space down the five-fold pseudo-symmetry axis 
with three Nb25s bound (d). N-linked glycans are shown in ball and stick representation. e GABA-binding site 
at β( + )/α(−) interface with density at 3σ contour level. Dashed links indicate salt bridges or hydrogen bond. 
The residues in β( + ), α(−) and GABA are depicted in sticks. (modified from the figure in Liu, et al.)11 
 
 
In the present work ligands that bind to this α1β3γ2 site are not wanted, since this receptor site is 
known to mediate sedation, amnesia, ataxia, and anticonvulsant activity, as well as addiction, 
and/or dependence. The cryo-EM map of the α1β3γ2 receptor with the binding site of diazepam is 
illustrated in Figure 6.10  Depicted in Figure 7 is the cryo-EM map of the α5β3 receptor bound to 
Nb25s.11 However, there is no structure of diazepam in this binding site so that the Bz receptor is 






Diazepam (Valium), which is a traditional benzodiazepine (BZD), contains the pendent phenyl 
ring and binds non-selectively to the α1-3,5β1-3γ2 GABAA receptors
7,107,108 at the BzR site. They 
(BZDs) bind at the interface between the α and γ2 subunits of the ion channel.
104 Benzodiazepines 
(BZDs, see Figure 6) have been prescribed for various CNS disorders including anxiety, 
convulsions, and muscle relaxation117,118 for over 45 years. The BZDs allosterically enhance the 
action of GABA on the GABAA ion channel by increasing the frequency of channel opening. This 
means, BZDs do not cause any effect on their own and can only modulate an ongoing GABAAergic 
process.104 Thus, BZDs exhibit much less toxicity than other drugs. This class of compounds has 
several advantages including the ready absorption through the GI tract and they reach a maximum 
blood concentration within a short period of time after oral ingestion.119 In addition, BZDs can 
cross the blood brain barrier (BBB) within 20 to 30 minutes of administration and readily 
distributes throughout the brain. Some BZDs can reach high enough concentration in the brain 
within five minutes after iv administration which has made them suitable for treatment of status 
epilepticus.120-122 Unfortunately, the development of tolerance in humans after 3 – 5 days limits 
their use in emergency rooms, as a treatment for epilepsy. BZDs also cause a number of adverse 
effects, as mentioned, such as drowsiness, sedation, ataxia, dependence, withdrawal issues and 
tolerance to the anticonvulsant effects, which further limits their clinical use.104,106,123,124 These 
adverse effects are principally due to the positive modulation (PAM) of  α1β3γ2 GABAA-subunits, 
but some side effects can also be mediated by other Bz receptors including (in the CNS) the α4β3γ2 





Figure 8. Structures of some representative examples of BZDs: diazepam, chlordiazepoxide, the 
triazolobenzodiazepine alprazolam and imidazobenzodiazepine (IBZD) midazolam.  
 
The BZDs such as diazepam or flunitrazepam exhibit high affinity at α1β2/3γ2, α2β2/3γ2, α3β2/3γ2, 
and α5β2/3γ2 subtypes. These sites are termed diazepam sensitive (DS) sites. Other BZDs can also 
interact with α4β2/3γ2 or α6β2/3γ2 receptors, which are termed “diazepam insensitive” (DI) sites. The 
receptors containing γ1 or γ3 are present in very low abundance and their respective in vivo effects 
on benzodiazepine binding sites and on GABA processes is still unclear.13  
The α4 and α6 benzodiazepine binding sites are insensitive to benzodiazepines because in the 
binding site the lipophilic pocket (L3) is too small or nonexistent, consequently, the pendant phenyl 
ring will not fit in the pocket. This is due to the histidine (DS) to arginine switch (DI) in the 
Bz/GABA ion channel subunit.125 
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It is known that compounds of various classes can bind to the BZD binding site of the GABAAR.
104 
When a ligand binds to the BZ site, it can influence the action of GABA to its receptor site  and 
hence can alter the chloride ion flow through the pore.126 A ligand can act as an agonist, antagonist, 
or inverse agonist. The binding of an agonist ligand results in an increase in the frequency of the 
opening of the chloride channel, which results in a net hyperpolarization of the neuron and a 
decrease in neuronal firing. This type of ligand is called a ‘Positive Allosteric Modulator (PAM) 
and illicits anxiolysis, sedation, and anticonvulsant effects. The opposite effect occurs when an 
inverse agonist binds to the BZD site, which decreases the flow of Cl- ions. These are called 
negative allosteric modulators (NAM) or inverse agonists. The NAMs exert an opposite action on 
GABA neurotransmitter actions on the GABAAR, i.e., they exhibit effects that include: anxiogenic, 
proconvulsant, convulsant, enhanced vigilance, as well as increased cognition and learning. There 
is one more type of allosteric modulator that, presumably, stabilizes the BZD antagonist 
conformational state, which does not have a major effect on the chloride ion-flux. As a result, these 
antagonists are nearly functionally silent on their own but can antagonize the effects of agonists or 
inverse agonists at BZD receptors. This type of ligand is termed an ‘antagonists’.104  
The efficacy of these allosteric modulators can be different. Full agonists or full inverse agonists 
exhibit maximum effects on their respective processes. Between these two efficacy extremes, there 
are partial agonists and partial inverse agonists, which elicit the same type of effects as their full 
versions but to a lesser extent. The allosteric efficacy of modulators are distinct at different receptor 
subtypes and as a result, a full agonist or inverse agonist at one receptor may be a partial agonist 
or partial inverse agonist at another. It is also possible for compounds to show efficacy in the 
opposite direction at different receptor subtypes; i.e., a partial agonist at one receptor can be an 
antagonist or inverse agonist (NAM) at another subtype. This illustrates the different spectrum of 
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efficacy of clinically used BZDs. In addition, a number of compounds may have similar affinity 
for an αxβ2/3γ2 subtype but their efficacy is usually different at these receptors, which can affect 
the spectrum of specific anxiolytic, antinociceptive, antidepressant, anticonvulsant, sedative, or 
muscle relaxant activity.104 Illustrated in Figure 6 is a schematic diagram of subunits and ligands 




Figure 9. Diagram of the benzodiazepine-GABA receptor-chloride channel complex (modified from the figure 
in Rallapalli, S.)12  
 
The pharmacological responses vary with the composition of the activated α1-6β1-3γ2-GABAAR. 
As mentioned above, benzodiazepines bind to the interface between the α and the γ subtypes. In 
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the mammalian nervous system there are 6 different α and 3 different γ subunits, which would 
result in 18 such possible sites for BZD binding. It is known that most BZDs are inactive or show 
very weak efficacy at receptors containing γ1 subunits.
127 Furthermore, although BZDs show some 
activity at γ3, the very low abundance of γ3 containing receptors in the mammalian nervous system 
render the contribution from these receptors as insignificant in the overall efficacy of BZDs. 
Consequently, BZDs that are used currently for clinical practice, interact with GABAARs 
containing (DS) α1β2/3γ2, α2β2/3γ2, α3β2/3γ2, and α5β2/3γ2 subunits. The α4 and α6 subunits exhibit 
completely different pharmacology than most of the clinically used BZDs (e.g., diazepam, 
clonazepam, flunitrazepam etc.) because they do not bind or interact at these (DS) BZD receptor 
subtypes.  
The presence of different α subunits plays a major role. Single-point-knock-in mice have been 
used to identify the role of different α subunits located in the brain pioneered by Seeburg, Möhler, 
McKeinan, and Rudolph.128,129 The α1 containing GABAAR receptors have been associated with 
amnesia, motor impairment, sedation, ataxia, addiction, muscle relaxation and dependence, as well 
as anticonvulsant effects.130,131 The positive activation of α2 subunits mediates anxiolytic effects 
and anticonvulsant effects.132,133 On the other hand, activation of α3 subunit effects anxiolysis and 
muscle relaxation at higher concentrations.134,135 The α5 subunits influences cognition and spatial 
memory as well as schizophrenia, depression and asthma.136 The α4 and α6 subunits are diazepam 
insensitive (DI) sites. In the brain the α1 subtype of the GABAAR is the most abundant (40-
50%)135,137,138 followed by α2 and α3 (up to 35% and 14%, respectively)
107. These are mainly 
located in the limbic region. The α5 receptors are the least abundant (~5%) and are present 
principally in the hippocampus139,140 and some in the spinal cord as mentioned.141  
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The two diazepam insensitive subtypes (α4 and α6 subtypes) correspond to a much smaller 
percentage of functional GABAAR than the diazepam sensitive (DS) subtypes. Some known 
imidazobenzodiazepines such as Ro15-4513, and Ro15-1788 (flumazenil) are known to interact 
with α4βγ2 and α6βγ2 subtypes but they also interact with α1βγ2, α2βγ2, α3βγ2, and α5βγ2 subtypes, 
making them non-selective BZD compounds. The α4 ion channels make up 6% of all subtypes
142 
GABAA receptors are also expressed in the peripheral nervous system (PNS).
143,144 There are both 
α4 and α6 subtypes in the CNS and periphery. Although GABAAergic drugs readily cross the BBB, 
the major quantity of administered BDZ drug is found in the periphery where they can cause side 
effects.73 But very very significant amounts of BZDs go through the BBB in 5-30 minutes. This 
makes them terrific anxiolytics. There is potential for using BZDs targeting the GABAARs 
(especially, the DI sites) expressed in the peripheral nervous system especially within the lungs 
(Emala et al.)145-147 and spleen.148,149 The α6β3γ2 subtypes are found largely in the cerebellum.
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Although GABAA receptors are ubiquitously present in the CNS, limited studies have been done 
to find their distribution in the nonneuronal cells. The GABAA channels in the central part of the 
brain control the cholinergic outflow to the lung. Functional GABAA and GABAB receptors inhibit 
cholinergic activity and have been detected in the presynaptic sites of lung prostaglandin 
parasympathetic nerves. The presence of functional GABAB and GABAA receptors in the ASM of 
human and guinea pig was confirmed recently by Emala.151 Emala and Cook et al. also illustrated 
the relaxation of precontracted ASM (substance P or histamine) by selective agonism at the α5β3γ2 
receptor subtype. The overall outcome of their study was the finding that GABAA receptor 
subtypes especially α4 and α5β3γ2 subtypes relax the contraction of airway smooth muscle (ASM) 




Table 1. Action of benzodiazepines at CNS GABAA α1-6β1-3γ2 receptor subtypes. Presented at 
ASPET Annual Meeting at EB 2019152 
 
Subtype Associated Effect 
α1 Sedation, anterograde amnesia, some anticonvulsant action, ataxia, involved 
in development of tolerance, addiction 
α2 Anxiolytic, some anticonvulsant action, antihyperalgesia 
α3 Anxiolytic, antihyperalgesia action, may be some muscle relaxation at higher 
doses  
α4 Diazepam-insensitive site; asthma 
α5 Cognition, temporal and spatial memory, depression, schizophrenia, 
asthma  
α6 Diazepam-insensitive site; migraine, trigeminal orofacial pain, active in a 
model of Tourettes syndrome, PPI model 
Note: Effects in bold are effects found by pharmacologists using ligands from Milwaukee 
 
As found by Emala, Cook et al., airway smooth muscle (ASM) contains a restricted and conserved 
repertoire of α4 and α5-GABAA receptors and allosteric modulators of GABAA receptors enhanced 
the efficacy of GABA, which resulted in electrophysiological changes (effected by these ligands) 
in these two subtypes. Selective GABA agonists also augmented ASM relaxation by isoproterenol, 
as well as spontaneous relaxation of precontracted ASM by various contractile agents due to α4-
GABAA receptor activation.
153 
The α4 and α5 receptor subunits have been identified in airway smooth muscle, airway epithelium, 
and inflammatory cells, and their ligand-mediated activation has been shown to reduce immune 
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response measures and reduce airway hyperresponsiveness (ex vivo and in vivo).151,154-158 In these 
studies, GABA dose-dependently reduced IL-12 and IL-6 production in LPS stimulated 
macrophages.157 GABA and muscimol also inhibited anti-CD3 and antigen specific T cell 
proliferation.159 Honokiol, a GABAAR agonist, reduced cardinal features of the asthma-like 
phenotype including inflammation (reduced airway eosinophilia), mucous cell metaplasia, 
collagen deposition, and airway hyperresponsiveness in acute and chronic ovalbumin-induced 
murine asthma models.160 However, nonselective GABAAR activation is associated with unwanted 
CNS effects161 and increased mucous production.158,162,163 
As mentioned earlier, the classical GABAA receptors with β3γ2 and one subunit of α1, α2, α3, or α5 
represent the diazepam sensitive (DS) sites where benzodiazepines usually bind. On the contrary, 
diazepam does not bind to the receptors corresponding to α4, and α6 subtypes, making these 
diazepam-insensitive (DI) sites of potential use with clinical significance since the sedation, ataxia, 
amnesia and dependence cannot be mediated by these two subunits.  
While, the functions of DS GABAAR are well understood in terms of the effects of classical 
benzodiazepines (Table 1 details) and certain properties can be directly linked to specific receptor 
subtypes such as sedation (α1), anxiolysis (α2), cognition (α5); the functions of the diazepam 
insensitive (DI) sites are still largely not understood. Previous studies in rodents reported, α6-
containing receptors were found in the cerebral membranes and granule cell cultures in a distinct 
anatomical distribution; around 25-30% of brain GABAA receptors in these brain regions. On the 
other hand, α4 containing receptors were less abundant (approximately 5% of the total GABAA 
population) and were primarily located in the hippocampus and thalamus.16  
Several classes of ligands which include imidazobenzodiazepines are known to bind to DI sites 
with moderate to high affinities (see Figure 10 for several examples). But these ligands do not 
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exhibit sufficient selectivity for DI over DS which explains some of their in vivo functions ascribed 
to DI sites. This represents a complexity in clear characterization of their physiological and 
pharmacological functions apart from DS receptors.16 
 
 
Figure 10. Some benzodiazepine receptor ligands for DI GABAA receptors 
Among the numerous ligands that have been investigated to date, imidazo [1,5-a][1,4] benzo-
diazepines are the most extensively studied and exhibited the highest selectivity towards the DI 
sites, as well. It was shown that alteration at the C-3 and C-8 positions of 6-oxo- imidazo [1,5-





2. Aims of this Research 
It is evident from the above discussion that there is a huge unmet demand for better treatments for 
asthma. The current options for treatment of asthma are neither sufficient nor up to the desired 
clinical level in regard to safety and convenience. The adverse CNS side effects, poor patient 
compliance and inconsistent dosage is due to several individual factors; frequent dosage as well as 
expense, improper use of inhalers, ineffective long term treatment, and unavailability of better 
medications are among the shortcomings of the current management of asthma. The aim of the 
current study was to develop a novel strategy for treatment of asthma by targeting the diazepam 
insensitive α4 GABAA receptor sites in the periphery, but to avoid untoward side effects that 
usually occur with some drugs in the CNS. It has been found that receptors in the lung, which is a 
part of peripheral nervous system (PNS), express functional GABAA receptors including the DI 
subtypes (i.e., α4). In addition, it was illustrated that an α4 GABAAR agonist effected relaxation in 
pre-contracted airway smooth muscle (ASM) by different contractile agents both in human and in 
guinea pig tissues.153 Expression of functional α4-GABAAR subunits was also confirmed in mouse 
lungs. The reduction of airway-hyperresponsiveness by α4-selective GABAA agonists or positive 
allosteric modulators (PAM) of the GABAA receptor was reported in mouse model, as well.
15 
Furthermore, part of the immune system plays a key role in airway inflammation during asthmatic 
periods. Interestingly, immune and inflammatory cells (CD4 and T-helper cells) also express 
functional GABAA receptors including those of  the α4β2/3γ2 subtype. The α4-subtype selective 




To summarize, the useful effects of α4β2/3γ2 receptor subtypes as selective GABAAR allosteric 
modulators, which can mediate the efficacy of the functional GABAARs expressed in airway 
smooth muscle, as well as immune/inflammatory cells by removing contraction, reducing 
hyperresponsiveness or reducing and/or preventing inflammation by reducing eosinophilia count 
or mucous hypersecretion is important in regard to treatment strategies. These previously found 
important results provided important insight for a novel treatment of asthma by targeting the α4 
GABAAR receptors in the lung and in the immune cells. By avoiding the central part of the nervous 
system (CNS), this would provide asthma drugs, which would be ideal to avoid any off-target CNS 
side-effects. Since, α4-sites are diazepam insensitive sites activation (PAM) of α4-GABAAR 
subtypes would avoid effects corresponding to diazepam or other benzodiazepine adverse effects.  
By controlling the lipophilicity of the ligands, it should be possible to prevent them from travelling 
across the BBB, while maintaining optimal GABAAR efficacy in the peripheral target organ 
GABAA receptors. The ultimate goal of this research was to optimize the development of an α4-
subtype selective drug for treatment of asthma, using the imidazodiazepine lead ligand (XHE-III-
74), which has elicited α4-subtype selective GABAAR efficacy and showed promising results both 
in ASM and inflammatory cells. These results also indicated further improvement in terms of 
desired drug properties was required. In addition, increasing the in vivo stability (by fortifying 
metabolic sites) for a longer duration of action was needed. By incorporating the following 
properties into a drug candidate for treatment of asthma by targeting α4 (DI) subtype selective 
ligands in the PNS. 




ii. Develop drugs with appropriate lipophilicity which will retard BBB-penetrability, as well as 
will be orally bioavailable 
iii. Develop ligands with a longer duration of action by improving metabolic stability to decrease 
frequency of dosage by the incorporation of deuterium at metabolically labile sites or by 
employing bioisosteric equivalents at the C-3 position to optimize drug properties. 






















3. Chemistry and Results 
3.1 Background 
Earlier in the search of a diazepam insensitive (DI) GABAA receptor ligands (α4β3γ2 and α6β3γ2), a 
series of 3- and 8- substituted 6-oxo-imidazo [1,5a] [1,4]-diazepines were prepared.  After a study 
of their SAR and receptor binding, it was found that CMD-45 and XHE-III-74 (Figure 11) 
exhibited potent binding affinity (with Ki values less than 1nM) and selectivity at DI subtypes 
(Table 2).16 The difference between these two ligands is in the ring size of the D ring. The outcome 
of this study with Emala et al.2 suggested that CMD-45 and XHE-III-74 were potential leads for 
further development in cases where DI ligands might exhibit unique biological activity. 
                                        
Figure 11. Structures of XHe-III-74 and CMD-45 
 
Table 2. In vitro binding affinity at αxβ3γ2 (values in nM)16   
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3.2 The Synthesis of CMD-45 and XHE-III-74  
 
Based on the earlier route of Fryer and Gu,3,16,17 the synthesis of XHE-III-74 7 began with the 
preparation of 5-methoxyanthranilic acid 2 (Scheme 1) from 5-methoxy-2-nitrobenzoic acid 1 by 
catalytic hydrogenation. The resulting anthranilic acid 2 was converted into isatoic anhydride 3 
with triphosgene. (Be very careful in working with triphosgene. After the completion of the 
reaction, be careful to remove and quench the remaining triphosgene or phosgene. To this 
end air or a gas was passed through the reaction flask into a scrubber flask which contained 
a solution of NaOH in water). The anhydride 3 was heated with L-proline in DMSO to generate 
the corresponding benzodiazepine 4. This compound was converted into the imidazodiazepine, 
XHE-III-74 ethyl ester 5. This ester was converted into the tert-butyl analog XHE-III-74 (7) with 
Li rod (small pieces) in tBuOH on multi-gram scale. CMD-45 was synthesized in Dr. Cook’s lab 
by Michael Stephen by using the same synthetic route with replacement of L-azetidine-2-
carboxylic acid for the L-proline in high overall yield.  
The last step of the synthesis of XHE-III-74 (7), i.e. the conversion from ethyl ester to tert-butyl 
ester was deemed problematic for several reasons. The reaction was extremely moisture sensitive 
and as a result a significant amount of the starting ethyl ester became saponified, which resulted 
in yield loss. In addition, reactions often fail to go to completion and the unreacted ethyl ester (if 
any) poses a hindrance to purification of the desired tert-butyl ester. This is because the polarity 
of these two esters are quite similar and often co-elute on chromatography or requires long, tenuous 
separations, which retard the pace of derivatization of XHE-III-74 (7). As an alternative, the 
carboxylic acid of XHE-III-74, which was also an important target ligand, was treated with DMF-
di-tertbutyl acetal in toluene at reflux.18 This resulted in a cleaner reaction to execute in which it 
was easy to isolate the desired product even if the reaction failed to go to completion. This 
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accelerated the process of making novel analogs of XHE-III-74 (7) which are potential drug 
candidates under the current hypothesis. 









3.3 Comparative Biological Evaluation of CMD-45 and XHE-III-74 
To evaluate the effectiveness of these two ligands, their corresponding therapeutic potential, and 
to find out the best one of the two for further development, it was decided to compare their 
effectiveness in relaxing airway smooth muscle (ASM) in the laboratory of Dr. Charles Emala at 
Columbia University. Dr. Emala had recently discovered that α4β3γ2 and α5β3γ2 Bz/GABA(A)ergic 
subtypes were found in tissue from healthy transplantation donor lungs. His results were on the 
healthy part of the lung tissue. The same phenomenon was discovered in rodents including guinea 




3.3.1 Oocyte Efficacy Study of XHE-III-74 and CMD-452  
In oocytes, which expressed each α subunit individually (along with β3 and γ2 subunits; α1-6β3γ2), 
both CMD-45 and XHe-III-74 produced a greater augmentation of GABA [EC3]-induced currents 
in oocytes which contained α4 or α6 subunits compared with the other α subunits at multiple 
concentrations (Figure 2; P < 0.01, n = 3–4). A higher value of the current at EC3 (Y-axis) implies 
better efficacy at that subunit at a particular concentration (X-axis). Illustrated in Figure 12 are 
both CMD-45 and XHE-III-74, which produced better augmentation of GABA-EC3 induced 
currents at α4 and α6 subtypes than others. Ligand XHE-III-74 induced more current at the α4 
subtype than at the α6 receptor up to the highest concentration of 30 μM and induced higher current 
(up to ~300% of the control), as compared to CMD-45. On the other hand, CMD-45 induced higher 
EC3 current at α4 subtypes at 1 μM but at 10 and 30 μM concentrations the current observed was 
greater at α6 than at α4 ion channels.  
Examination of additional studies in oocytes expressing the α4 subunit along with the delta subunit 
(α4β3δ) indicated no XHe-III-74–mediated augmentation of GABA ([EC3])–induced currents, even 
at the highest concentration of XHe-III-74 tested (10 µM; data not shown; n = 4). Similarly, at 10 
µM CMD-45 showed only a modest augmentation of GABA-induced currents (116±3% of current 
induced by a GABA EC3 concentration alone, P < 0.05, n = 4) at δ subtypes. The CMD-45 did not 
significantly augment GABA-induced currents at δ subtypes either at lower concentrations (data 
not shown). These studies demonstrate the selectivity of CMD-45 and XHe-III-74 for α4β3γ2 
subunit–containing receptors, and also demonstrate that they have very little to no activity at 

















Figure 12. Augmentation of GABA-induced currents in oocytes expressing GABAARs of specified subunit 
composition. At multiple concentrations, both CMD-45 and XHe-III-74 led to significantly greater 
augmentation of GABAAR-mediated currents in oocytes expressing α4 or α6 subunits in combination with β3/γ2 
subunits (when each is compared with α1 as a reference in two-way repeated measures ANOVA with Bonferroni 
post test comparisons). Data are presented as a percent of current induced by a 3% maximal effective 
concentration (EC3) of GABA. This demonstrates the subunit selectivity of these novel, positive allosteric 
modulators of the GABAAR (*P < 0.05 for both α4 and α6 as compared with the α1 subtype by Bonferroni post 
hoc analysis; n = 3–4; mean ± SE). Modified from the figure in Yocum, et al.2 
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3.3.2 Mouse Tracheal Ring Organ Bath Studies on XHE-III-74 and CMD-452  
In ex vivo organ bath experiments carried out by Yocum and Emala, CMD-45 and XHE-III-74 
were evaluated for their ability to relax pre-contracted mouse tracheal rings. The treatment of ACh-
contracted WT (wild type) mouse tracheal rings with CMD-45 and XHe-III-74 led to a significant 
relaxation (Figure 13). The tracheal rings from GABAA receptor α4 knock out (KO) mice also 
exhibited a response to CMD-45 and XHe-III-74, which indicated relaxation, but was significantly 
less than in wild type (WT) mice for both ligands at multiple concentrations. This finding further 
confirmed that the α4 subtype GABAAR selectivity of these imidazoles and the mechanistic role 
of the α4 GABAAR activation in the relaxation of ASM. In these experiments too, XHE-III-74 was 
found to be more potent than CMD-45 in relaxation of pre-contracted mouse tracheal rings. This 
is consistent with the electrophysiological data presented previously here, which demonstrated a 
larger GABAAR-mediated current with exposure to XHe-III-74 as compared to that with CMD-45 
at equal concentrations (Figure 11). The prorelaxant effects of both compounds were reversible in 
WT tracheal rings at the highest doses tested (100 µM for CMD-45 and 50 µM for XHe-III-74) 
after repeated buffer changes. This was demonstrated by showing that both XHe-III-74– or CMD-
45–treated rings contracted with equal force to 80 mM KCl treated rings as compared with vehicle-
treated rings after these repeated buffer changes (data not shown). The data from these “wash 





Figure 13. Mouse tracheal ring contraction force in ex vivo organ bath preparations. (A and C) Representative 
muscle force tracings of acetylcholine (ACh)–contracted murine tracheal rings. (B) CMD-45 significantly 
relaxed precontracted wild-type (WT) murine tracheal rings but not rings from Gabra4 knockout (KO) mice, 
at 50 µM (n = 3) and 75 µM (n = 3), consistent with heightened selectivity for the Gabra4 subunit, as 
demonstrated in Figure 12. (D) XHe-III-74 led to significant relaxation of precontracted murine tracheal rings 
as compared with vehicle (0.1% DMSO) in both WT and Gabra4 KO mice at 10 µM (n = 5), 25 µM (n = 5), and 
50 µM (n = 3). At 25 µM XHe-III-74, tracheal rings from WT mice relaxed to a greater extent than rings from 
Gabra4 KO mice, consistent with the heightened Garbra4 selectivity. Contraction force is presented as percent 
of DMSO vehicle control for WT and Gabra4 KO tracheal rings (*P<0.05 in comparison to DMSO control, 
#P<0.05 in comparison to drug-exposed Gabra4 KO; ANOVA with Bonferroni post hoc comparison; mean ± 







3.3.3 Effect of XHE-III-74 and CMD-45 on Human Airway Smooth Muscle2  
To further evaluate the pro relaxant properties of these two ligands, human tracheal airway smooth 
muscle (ASM) strips were used in ex vivo organ bath experiments. This work by Yocum and Emala 
employed healthy human tracheal rings that were part of a surgery resection. Both CMD-45 and 
XHe-III-74 led to a significant reduction in contractile force in ACh-contracted human ASM strips 
at 50 µM (n = 5) and 100 µM (n = 6, Figures 14A and 14B P < 0.05 for both compounds, as 
compared to vehicle control at 50 and 100 µM). In separate experiments low concentrations of 
both CMD-45 and XHe-III-74 (25 µM) potentiated the albuterol induced relaxation of human 
ASM contracted with ACh ex vivo, which led to a full log decrease in the albuterol EC50 (Figure 
14C; albuterol EC50 was 807.0 nM for DMSO, 69.3 nM for the CMD-45 treatment group, and 87.9 
nM for the XHe-III-74 treatment group; n = 4, P < 0.01 for change in albuterol EC50 compared 







Figure 14. Human tracheal airway smooth muscle (ASM) strips in ex vivo organ bath preparations. (A) 
Representative muscle force tracings of the 100 µM CMD-45– and XHe-III-74–induced direct relaxation of 
ACh [EC50]–precontracted human tracheal ASM strips. (B) CMD-45 or XHe-III-74 (50 and 100 µM) induced 
significant relaxation of ACh-precontracted tracheal ASM strips compared with vehicle (0.2% DMSO) controls 
at 30 minutes (n for 0, 10, 25, 50, and 100 µM, respectively: CMD-45, 6, 6, 4, 5, and 6; XHe-III-74, 6, 4, 3, 5, 
and 6. *P<0.05 for both CMD-45 and XHe-III-74 as compared with vehicle control, ANOVA with Bonferroni 
post hoc comparison). (C) CMD-45 (short dashed line) and XHe-III-74 (long dashed line) at low dose (25 µM) 
both induced significant leftward shifts in the dose–response curve for albuterol (β2-adrenoceptor–selective 
agonist)-mediated human ASM relaxation as compared with the DMSO control (solid line). The EC50 
concentration of albuterol with coadministration of CMD-45 was 69.3 nM, and with coadministration of XHe-
III-74 was 87.9 nM as compared with 807.0 nM for DMSO (n = 4 per group; P<0.01 for leftward shift in EC50 
for both ligands compared with vehicle; mean ± SE). Modified from the figure in Yocum, et al.2 
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3.3.4 Effect of XHE-III-74 and CMD-45 on Resistance (in vivo) on the Mouse 
Respiratory System2 
To evaluate the relaxant or respiratory system resistant potential of these ligands, when 
administered as an aerosol, the dose was applied by inhalation to an asthmatic subject (HDM 
sensitized WT-mouse model) before introducing the challenge. The better compound of the two 
ligands in the earlier experiments, XHe-III-74 (25 µl, 10 mM), when administered by inhalation 
10 minutes before a bronchoconstrictive challenge, led to a significant reduction in RRS, as 
measured by the forced oscillation technique (flexiVent) in asthmatic (HDM-sensitized) mice 
(Figure 15; area under the curve analysis, P<0.05, n = 3 for vehicle, 4 for XHe-III-74). This 
demonstrated the potential of this compound to be administered therapeutically by inhalation to 
treat bronchospasms. 
 
Figure 15. In vivo mouse respiratory system resistance (RRS) tests. Inhalation of XHe-III-74 10 minutes before 
a bronchoconstrictive challenge (methacholine) significantly reduced RRS in house dust mite antigen–sensitized 
WT mice (asthma model) as compared with inhaled vehicle control (*P<0.05 for area under the curve analysis; 




3.3.5 Effect of XHE-III-74 and CMD-45 on ASM Calcium Dynamics2  
The pretreatment of human ASM cells with CMD-45 and XHe-III-74 inhibited histamine-induced 
increases in intracellular calcium concentrations in vitro, an effect that was lost when calcium was 
omitted from the extracellular buffer. This phenomenon suggests that inhibition of calcium influx 
due to alterations in plasma membrane potential may play a role in the mechanism of ASM 
relaxation. 
In in vitro studies using a fluorescent intracellular calcium indicator, the removal of calcium from 
the external buffer led to a 29.8% diminution in histamine-mediated increases in intracellular 
calcium in primary cultures of human ASM cells (P < 0.001 comparing 0 [n = 28] to 2 mM [n = 
14] external calcium in DMSO-pretreated and histamine-stimulated cells). In the absence of 
extracellular calcium, the addition of 100 µM CMD-45 (n = 17) or XHe-III-74 (n = 20) did not 
further augment this inhibition of the histamine-induced intracellular calcium response (Figure 
16A; P = not significant). However, in the presence of 2 mM external calcium, CMD-45 and XHe-
III-74 (25 and 50 µM) inhibited the histamine-mediated increase in intracellular calcium in 
cultured primary human ASM cells to an extent similar to removal of external calcium (25.0% and 
30.0% for 50 µM CMD-45 and XHe-III-74, respectively, P<0.05 and P<0.001, respectively; 
Figures 16B and 16C). This suggests that these two ligands lead to ASM relaxation by limiting the 









Figure 16. In vitro primary human ASM cell calcium dynamics. (A) The increase in intracellular calcium 
concentrations ([Ca2+]i) in primary human ASM upon exposure to 10 µM histamine is inhibited 29% (P<0.05; 
n = 28) by the removal of extracellular calcium ([Ca2+]e; 0 mM). The addition of 100 µM XHe-III-74 (n = 20) or 
CMD-45 (n = 17) does not further inhibit histamine-induced increases in [Ca2+]i (P>0.05). (B and C) In contrast, 
in the presence of 2 mM external calcium, pretreatment with 25 or 50 µM CDM-45 or XHe-III-74 significantly 
inhibited subsequent histamine-induced increases in peak [Ca2+]i (n [DMSO, 10, 25, and 50 µM]: [B] (CMD-
45): 12, 9, 11, 9; [C] (XHe-III-74): 16, 10, 14, 14; human ASM cell lines established from three donor patients; 
data are presented as percent of average of simultaneously tested vehicle control wells; n = total plate wells; 
*P< 0.05, **P< 0.01, ***P< 0.001, ANOVA with Bonferroni post hoc comparison; mean ± SE). ∆F/Fo, peak 
change in fluorescence/baseline fluorescence; ns, not significant. Modified from the figure in Yocum, et al.2 
 
In in vitro experiments, CMD-45 and XHE-III-74 blocked the Ca2+ influx and inhibited the 
increase by 25-30% in intracellular [Ca2+]i concentration induced by histamine. However, in the 
absence of extracellular Ca2+ these ligands did not potentiate any inhibition which gave important 
mechanistic insight into the role of [Ca2+]i in regulating ASM tone. The effects of GABAAR 
modulators on ASM are likely via membrane potential since GABAAR is a chloride ion channel. 
In a resting ASM, the internal chloride concentration is higher and the activation of the GABAAR 
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is likely to result in depolarization of the membrane potential. The membrane potential of the ASM 
increases from a resting value (-50 to -60 mV) to a potential of -20 mV, which is predicted to be 
crossing the chloride equilibrium potential. This would result in opening of the chloride channel 
which favors chloride influx and relative hyperpolarization. These conditions may pose an 
inhibition of voltage-sensitive Ca2+ entry mechanisms. This is in agreement with the in vitro data 
of CMD-45 and XHE-III-74, which led to a significant retardant in raising the intracellular [Ca2+]i 
in histamine-exposed ASM. In addition, in the absence of extracellular Ca2+ these compounds do 
not further inhibit calcium intake even at higher concentrations (100 μM) which further reinforces 
the hypothesis of the mechanism of action of these compounds is via inhibition of calcium influx.  
 
3.3.6 The Outcome of the Comparative Studies on CMD-45 and XHE-III-74 
It was demonstrated that the two novel compounds, CMD-45 and XHe-III-74, are positive 
allosteric modulators of the GABAAR and have superior selectivity for receptors containing the 
α4/α6 subunit. Both compounds acutely relaxed ASM from mice and humans. These selective 
compounds offer the potential to treat bronchoconstriction via a novel therapeutic mechanism, 
while reducing or avoiding unwanted CNS side effects. 
Consideration of the inference from the experimental evidence, XHE-III-74 was deemed to be a 
better ligand (better selectivity, higher efficacy and more desirable properties) than CMD-45 and 
it was selected for further development and SAR studies. The logic behind this choice includes: 
1. It is known that human ASM also express α5 subunits of GABAARs.
151 It was also purportedly 
demonstrated that α5-subtype selective PAM’s were responsible for memory impairment
164 and 




In addition, activation of α2 and α5 in human airway epithelium was reported to increase mucus 
production.158 Since CMD-45 exhibited a much higher α5 subtype selectivity in addition to the 
useful α4 selectivity as compared to XHE-III-74, targeting only the α4 (i.e., XHE-III-74) GABAAR 
ion channel would avoid any potential undesired effects associated with α5 receptors. 
2. XHE-III-74 exhibited better properties than CMD-45 in the oocyte electrophysiology studies, 
in ex vivo organ bath studies (both murine and human), as well as in vitro human ASM calcium 
dynamics. 
3. Finally the materials required for the synthesis of CMD-45 were much more expensive, as 
compared to the materials for synthesis of XHE-III-74. This means XHE-III-74 was better suited 
for additional studies.  
The GABAAR plays a prominent role in inhibitory neurotransmission and off target binding of 
ligands to undesired GABAA receptors containing the α1, α2, or α5 subtypes may cause unwanted 
CNS effects, especially if the drug is administered intravenously (iv). To evaluate the potential of 
these compounds in the exhibition of such unwanted side-effects, the Savic group at the University 
of Vienna performed several experiments (see Appendix for details). The basket test was used to 
assess the effect of XHE-III-74 and CMD-45 on motor performance. Both ligands caused 
sensorimotor deficits in C57BL/6 mice at higher doses in Dr. Savic’s laboratory (30 mg/kg, 
Appendix, Table A1). To evaluate the anti-anxiety effects of XHE-III-74 and CMD-45, a step-
down test was performed on trained C57BL/6 mice (Appendix, Table A2). Neither of the ligands 
exhibited any hint of anti-anxiety properties in keeping with their activity at α4 diazepam 
insensitive subtypes. To further evaluate the effects of these two α4-preferring ligands on motor 
performance, the rotarod experiment was undertaken (Appendix, Table A3). Both XHE-III-74 and 
CMD-45 showed ataxia at higher doses [10 mg/kg (XHE-III-74) and 15 mg/kg (CMD-45) i.p. 
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administration]. In addition, locomotor activity was performed separately on adult male and female 
Wistar rats to access the sedative effects of the two ligands in consideration. Both showed 
pronounced sedative effects (Appendix, Table A4) at 10 mg/kg i.p. dose. Furthermore, the plasma 
and brain distribution of XHE-III-74 after iv administration (solution and nanoemulsion) was 
evaluated by pharmacokinetic studies. Significant concentrations of XHE-III-74 were detected in 
both brain and plasma up to 12 hours after iv administration (Appendix, Figure A1).  
 
3.4 Strategies for Further Optimization of the Lead Compound, XHE-III-74 (7) 
From the oocyte efficacy and organ bath experiments, it was clear that XHE-III-74, as mentioned, 
was better suited than CMD-45 for further development for the treatment of asthma by targeting 
the airway smooth muscle in the lung. This was a promising novel strategy for asthma 
management. However, the negative CNS side effects which were found in the evaluation of 
sedative effects by Savic et al. (unpublished result) was likely due to the brain penetration of these 
drugs. Since α1, α2, and α5 subunits are expressed in higher concentrations in the brain, the binding 
to the GABAA receptor containing these subunits would certainly evoke the negative undesired 
effects such as, sedation and ataxia that were observed by Savic et al. (unpublished results). By 
considering the outcome of all the experiments discussed above, the following strategy was taken: 
• Since the expression of the α4 subunit was more pronounced in lungs, which were also 
devoid of other subtypes (except α5) which caused the negative GABAAR-induced effects, 




• To inhibit brain penetration of XHE-III-74, this lead compound should be modified to 
increase polarity (reduced lipophilicity) while retaining α4 selectivity, which would retard 
BBB penetration. This would avoid adverse CNS side-effects exhibited by XHE-III-74 
itself. 
• Potential ligands should be synthesized only after consulting molecular modeling and the 
pharmacophore model to reduce the number of ligands to be synthesized. 
• A library of XHE-III-74 ligands with different substitution at C-3, C-4, and C-8 would be 
of high interest. 
Therefore, XHE-III-74 (7) was selected as the lead compound for further development based on 
the above hypothesis. Consequently, further improvements in this ligand were deemed beneficial 
in the search for better asthma drugs with the novel mechanism of action described above and with 











3.5 Novel XHE-III-74 Analogs Based on the Pharmacophore Model 
3.5.1 Molecular Modeling and the Pharmacophore Model13,14 
 
               
Figure 17. a) The pyrazolo[3,4-c]quinolin-3-one CGS-9896 (dotted line), diazepam (thick line), and planar 
diazadiindole (thin line) fitted to a schematic representation of the inclusive pharmacophore model for the BzR. 
The descriptors H1 and H2 designate hydrogen bond donor sites on the receptor protein while A2 represents a 
hydrogen bond acceptor site necessary for potent inverse agonist activity in vivo. L1, L2, L3, and LDi are four 
lipophilic regions in the binding pharmacophore. Agonist activity requires interaction with H1, H2, L1, L2, 
and/or L3. Receptor descriptors S1, S2, and S3 are regions of negative steric repulsion. Lp=lone pair electrons. 
[Modified from the review published in 2007 (Clayton et al)]13,14 b) A simplified representation of the interaction 
of XHE-III-74 inside the pharmacophore pocket according to the homology model.  
 
Molecular modeling is necessary to decrease the number of potential ligands to be synthesized. 
This strategy provides a list of potential ligands that fit the target receptor and should show higher 
binding affinity. The group in Milwaukee developed a unified and comprehensive pharmacophore 
model for benzodiazepine receptor site employing about 30 rigid planar ligands to map out the 
protein repulsive regions (S1, S2, S3). In Figure 16, this two-dimensional representation of the 
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pharmacophore model contains lipophilic pockets (designated L), steric regions of protein-ligand 
repulsion (designated S), and hydrogen bond donor sites (designated H) and acceptor sites 
(designated A). This model was employed to design new ligands. 
The substituents of varying lipophilicity or size at position C-8 could have a profound effect on 
receptor subtype selectivity since groups at this position can interact with the lipophilic pocket L2.  
The alkyl group of the esters at position C-3 were proposed to interact with the lipophilic pocket 
LDi in the pharmacophore model. Thus, variation of the alkyl substituents on this position could be 
profound in terms of efficacy and subtype selectivity, as well as effects on metabolism. 
The chiral center at C-4 was significant in the determination of affinity. The different 
stereochemistry at this position both 4(S) and 4(R) along with various ring sizes (4-6 membered 
rings) interact differently with the lipophilic pocket LDi thus resulting in very different effects on 
affinity.  
Consequently, analysis of the pharmacophore model revealed that these three positions are 
preferred for further variations to achieve a better α4 GABAAR agonist to treat asthma. The 
















3.6 Synthesis of Novel XHE-III-74 (7) Analogs 
3.6.1 Synthesis of Analogs at the C(3) Position of XHE-III-74 (7) 
The ethyl ester 5 was saponified to give the acid 9 and this was treated with thionyl chloride to 
make the corresponding acid chloride. The acid chloride was converted into the amides, esters and 
thioesters (11-19) by treating the acylchloride with suitable nucleophiles in the presence of 
triethylamine to scavenge the HCl which formed. The methyl ester 10 was formed by trans 
esterification in the presence of NaOMe in methanol. 
The chiral esters (20 and 21) were prepared via trans-esterification of the ethyl ester with (R) and 
(S)-2-butanol. The cyclopropyl ester 22 was prepared from the carboxylic acid 9 with cyclopropyl 
bromide and Cs2CO3 in DMF. The deuterated ethyl ester 23 was prepared from deuterated ethyl 

















3.6.2 Synthesis of the Analogs of XHE-III-74 (7) at C(4) Position 
When the known16 isatoic anhydride 3 was heated with D-proline in DMSO, the corresponding 
benzodiazepine 4′ was obtained. This was converted into the imidazodiazepine following the 
reported procedure to provide the (R) enantiomer of XHE-III-74 ethyl ester 5ʹ. This material was 
converted into the (R) enantiomer of the tert-butyl analog of XHE-III-74 7ʹ with a Li rod in tBuOH 
on multi-gram scale. 















3.6.3 Synthesis of Analog at the C(8) Position of XHE-III-74 (7) 
To optimize compounds for therapeutic use in patients, it is planned to increase metabolic stability 
in vivo and druggability. In addition, it is critical to understand the rate and mechanism of the 
overall clearance of the molecule. It is certainly more complex when the drug is metabolized by 
more than one metabolic pathway. As a result, it necessitates the knowledge of the extent of each 
metabolic pathway involved in the overall metabolism of the molecule. In addition, one would like 
to know the mechanism of the metabolic enzymes, and whether there should be a kinetic isotopic 
effect (KIE) in the rate of metabolism and clearance.166 Incorporation of deuterium into a molecule 
which exhibits low-to moderate clearance would increase both systemic exposure and 
bioavailability (half-life). In contrast, introduction of deuterium into a metabolically fragile 
molecule would only increase their systemic exposure but not the half-life.166 The carbon-
deuterium (C-D) bond is approximately 9 times stronger than carbon-hydrogen (C-H) bond.167 As 
a result, the metabolic stability of compounds which contain the C-D bond at a key metabolic 
position would be expected to be greater than that of compounds which contain a C-H bonds.166 
This does not hold true in every case, for sometimes blocking the metabolism with the C-D 
substituents leads to a different metabolic pathway and a toxic metabolite. The OCH3 group at C-
8 is susceptible to metabolic action; cleavage of the C-H bond would give the more polar phenolic 
(OH) ligand, which in turn could be excreted from the body via conjugation to the glucuronide on 
second pass metabolism and excretion.  Thus, replacing the OCH3 group with an OCD3 group 





     
Figure 20. Retrosynthesis of C-8 deuterated analogs via demethylation followed by deutero methyl-alkylation 
 
In the case of the C-8 OCD3 analogs of XHE-III-74, it was felt it was more practical to incorporate 
the deuterated methoxy function into ring-A at the end of the synthetic route instead of carrying 
the OCD3 substituent through the entire route because of the expense of CD3I. Instead, the OCH3 
version was felt to be more appropriate if a facile method of conversion of the 8-methoxy group 
into a phenolic function was available. The methoxy function would be easily substituted for by 
the deuterated methoxy function simply by de-methylation of XHE-III-74 to give the phenol, 
followed by re-methylation of the phenol with CD3I (Figure 10). Although an aryl-methoxy 
function is a robust protecting group for phenols, numerous deprotection methods have been 
reported.168-170  
A number of methods were available and screened to find a suitable reagent for this essential 
transformation (Scheme 5). Surprisingly, most of the known reagents that have been reported as 
facile for this transformation either did not furnish the phenol or furnished it in trace amounts 
and/or accompanied by decomposition of the starting material.  
The lithium chloride-dimethylformamide combination (Krapcho conditions) has been used as a 
mild method for the demethylation of aryl-alkyl ethers.169,171-174 When the desired demethylation 
was attempted using LiCl in DMF under thermal and microwave irradiation, no product was 
detected. Introduction of additives such as NMP and p-TSA were not successful as well.  
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Boron tribromide (BBr3)-mediated demethylation of an aromatic methoxy function is the most 
common and popular method.175-177 Besides, BBr3 mediated demethylation is a milder condition 
and can be carried out in the presence of sensitive functional groups.169 This method has been 
employed in the total synthesis of a number of natural products.178-184  Consequently, BBr3 was 
employed to perform the desired transformation. It was realized, after numerous trials with BBr3 
under many different conditions that the OCH3 function in XHE-III-74 was surprisingly resistant 
to BBr3-mediated cleavage and this lead ligand failed to undergo the desired transformation. 
Scheme 5. Attempted demethylation of the C-8 OCH3 functional group under different 
conditions 
 




Demethylation of aryl methyl ethers using Lewis acids such as AlCl3 to furnish phenols have been 
well studied and reported.185-189 A number of phenolic natural products have been accessed 
employing this method of demethylation.189-191 Consequently, the desired transformation was 
attempted using aluminum chloride at low temperature and this was followed by heating to 
elevated temperature. Upon repeated attempts in refluxing toluene for longer times, the 
demethylation process failed to furnish any demethylated product. Only the starting methyl ether 
was recovered.  
Methyl magnesium iodide192-194 has been successfully employed in the total synthesis of several 
phenolic natural products for cleavage of aryl methyl ethers in high yields. Upon heating the aryl 
methyl ether starting material in the presence of MeMgI at 160 oC, this process failed to perform 
the desired transformation.  
Strong acids such as HI and HBr have been reported for the dealkylation of aryl alkyl 
ethers.169,170,195,196 Although such harsh conditions are not generally desired for most substrates 
these have been successfully employed in many cases.197 Using strong hydrogen halide acid such 
as HI may result in decomposition of most heterocyclic organic compounds. To avoid exposure of 
the substrate to a high concentration of HI, reagents that slowly release HI upon heating could be 
a useful way around problems with decomposition.195 Iodoalkanes are able to release HI slowly 
via an elimination process upon heating, which has been used to perform the desired demethylation 
in high yields in several cases.198-201 Iodocyclohexane in DMF under reflux conditions was 
reported to generate HI in situ and performed demethylation or aryl methyl ethers in high yield.195 
Consequently, the aryl methyl ether was heated in the presence of iodocyclohexane in DMF but 
this method failed to facilitate the desired transformation, as well. On the contrary, treatment with 
an excess of aqueous HBr195,202 both in the presence or absence of KI or NaI as an additive did 
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cleave the desired methyl ether but also cleaved the ester function, as well. This process was further 
complicated by the decomposition of the material since only trace amounts of demethylated 
phenolic carboxylic acid were isolated.  
Sodium ethanethiolate in aprotic solvents such as DMF has been reported to be an efficient 
dealkylating reagent for aryl alkyl ethers.169,203,204 Upon treatment of the methyl ether starting 
material with ethanethiol and sodium hydride in DMF at 0-100 oC. This process resulted in 
cleavage of the ether function, accompanied by the cleavage of the ester function. In addition, only 
a small amount of product could be isolated which turned out impractical for the synthesis of the 
desired phenol, as well.  
The combination of a hard acid with a soft nucleophile has been reported to be successful in an 
efficient deprotection of aryl methyl ethers.190,196,205-208 Aluminum chloride in the presence of 
ethanethiol is such a combination. If desired, the stench associated with low molecular weight 
thiols could be avoided by using long chain thiols such as 1-dodecanethiol.206 
Gratifyingly, at last, the mixture of aluminum chloride and ethanethiol was found to be the only 
effective method among the methods and reagents screened for this transformation on this 
particular substrate, to date. The mixture of AlCl3, EtSH in DCM at rt furnished the desired 
phenolic compound in >70% isolated yield (>85% based on recovered SM). 
After the successful demethylation of the aryl-methyl ether, re-alkylation with CD3I under standard 
conditions failed to furnish the 8-CD3 substituted analog 5a. For example, methylation of phenols 
with CH3I in the presence of K2CO3 or Cs2CO3 in DMF is well known. But in this case the reaction 
process with Cs2CO3 and CD3I in DMF provided only a trace amount of the analog, while K2CO3 
in DMF furnished the 8-OCD3 ligand only in a mediocre yield of 43% (Scheme 6). Other bases; 
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e.g., NaH, tBuOK and solvents e.g., DCM, THF, acetone were also attempted (Table 3). 
Gratifyingly, Cs2CO3 in DCM was found to be the best combination, which furnished the desired 
deuterated analog in a clean 84% yield ending a long-standing deadlock for the synthesis of this 
important 8-OCD3 ethyl ester target 5a. It was felt this deuterated analog 5a would have more 
desirable metabolic properties required for a better drug candidate for asthma. This was based on 
the long-standing research on the metabolism of aryl methoxy groups to phenols for later 
conjugation and excretion. 
 




Table 3. Alkylation of the C-8 phenolic function of 8-hydroxy ethyl ester 6 under different 
conditions 




The ester 5a was converted into its tert-butyl analog 7a via trans esterification (Li rod in tBuOH) 
in good yield. Additionally, the corresponding methyl ester 10a was readily available in excellent 
yield by reacting 5a with NaOMe in methanol. The carboxylic acid 9a was also prepared from 5a 
by saponification and this was followed by acidification in excellent yield. The deuterated acid 9a 
was employed as the starting point for the synthesis of the corresponding deuterated versions (11a-
19a) of 11-19 employing the same procedure as described in Scheme 3 (Scheme 7). 
In addition, phenol 6 was also converted into its tert-butyl analog 8 via trans-esterification with 



































3.7 Biological Evaluation of Analogs of XHE-III-74 Derivatives 
Earlier, Forkuo et al illustrated in ex vivo organ bath experiment that XHE-III-74 7 was capable of 
inducing relaxation in precontracted ASM in mice. In addition, in vivo aerosol administration of 
XHE-III-74 7 could reduce lung resistance in a house dust mite (HDM) mice model of asthma.2,15 
These encouraging results lead to further evaluation of XHE-III-74 7 including evaluation of in 
vitro and in vivo metabolic stability and ability in vivo to relax ASM in the lung.  
 
3.7.1 In vitro Microsomal Stability of XHE-III-74 (7) and XHE-III-74EE (5), 
and XHE-III-74A (9)15 
The metabolic stability of XHE-III-74 7 was investigated in vitro prior to the evaluation of its 
effectiveness in the reduction of methacholine-induced resistance in mouse lungs. The XHE-III-
74 7 and two related compounds XHE-EE 5, and XHE-acid 9 were incubated for 1 h with human 
liver microsomes (HLM) and mouse liver microsomes (MLM), the metabolism of which was 
monitored by mass spectroscopy on a LCMS. The metabolism of XHE-III-74 7 was much faster 
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in MLM, as you would expect, than HLM, which had 24.1% and 92.1% remaining after 1 hour, 
respectively. This corresponds to the half-life of XHE-III-74 7 in MLM to be less than 24 min. 
The ethyl ester version of XHE-III-74 (XHE-EE) 5 was much more stable than XHE-III-74 7 itself 
both in HLM (99.2% remaining after 1 h) and MLM (86.3%), as well as in the respective S9 liver 
fractions (95.6% and 98.4% in MLM and HLM S9, respectively). This corresponded to a predicted 
half-life of several hours (Table 4). The metabolite of XHE-III-74 was identified by mass 
spectroscopy as the corresponding carboxylic acid 9. Consequently, the carboxylic acid derivative 
XHE-III-74A 9 was also evaluated for microsomal stability against both HLM and MLM and their 
corresponding S9 liver fractions. Just like the parent ligand, in the case of XHE-III-74A 9 too 
species-specific metabolism was not observed and acid 9 was found to be metabolized faster than 
ester 5 both in HLM and MLM with the % remaining, after 1h of 56.1 ± 0.6 % and 51.3 ± 0.4 %, 
respectively (Table 4). The half-lives of acid 9 and ester 5 were 80.1 ± 10.1 min and 73.4 ± 6.5 
min in HLM and MLM, respectively. Similar metabolic stability was also observed in the 
corresponding S9 fractions. Interestingly, the acid 9 was metabolized faster than XHE-III-74 7 in 
HLM but in MLM the acid was twice as stable than XHE-III-74 7 (Table 4). Both ester 5 and acid 
9 were stable in blood plasma for at least one hour. To further confirm the metabolic stability of 
XHE-III-74EE in vivo, a single dose (5 mg/kg i.p. administration) pharmacokinetics study was 













3.7.2 Pharmacokinetic Profiles of XHE-III-74EE (5), and XHE-III-74A (9)15 
The ester 5 was rapidly absorbed and distributed in blood and lung with a Tmax of 10 and 3 min, 
respectively with a higher concentration in the blood [Cmax (blood)/Cmax (lung) > 2]; 
AUC(lung)/AUC(blood) = 0.6 (Figure 21A). These results confirm good absorption and distribution 
of ester 5 into the target organ for potential treatment of asthma (lungs). In addition, ester 5 was 
rapidly metabolized in lung as indicated by the half-life of only 17.6 min. Besides, there was a 
significant concentration of XHE-III-74EE 5 observed in brain [AUC(brain)/AUC(blood) = 0.79] with 
a longer half-life (36.7 min). This indicated that ester 5 was able to penetrate the BBB and exhibits 
higher relative stability in the brain. In order to distinguish between clearance (via conjugation) 
and metabolism of XHE-III-74EE in blood, lung, and brain, the metabolic product XHE-III-74A 
was quantified (Figure 21B). Interestingly, a quantifiable amount of XHE-III-74A 9 was present 
only in the blood AUC (74A)/AUC (74EE) = 0.75, which indicated that the rate of metabolism of 
65 
 
XHE-III-74EE 5 in blood is much faster than the rate of excretion of XHE-III-74A 9. Since, XHE-
III-74EE 5 is stable in blood plasma, the metabolism is likely to occur in the liver much like the 
anxiolytic ethyl ester XHE-III-053, as observed by BMS in human patients. On the other hand, 
since XHE-III-74A 9 was not found in a quantifiable amount in brain and lung, there may not be 
any metabolism of XHE-III-74EE 5 taking place in these organs. When a similar pharmacokinetic 
study (5 mg/kg) was performed on XHE-III-74A 9, it underwent a rapid absorption and distribution 
similar to XHE-III-74EE (Tmax 10 min, Figure 21C). Comparable AUC values of XHE-III-74A 9 
in blood and lung were observed, which indicated excellent distribution of XHE-III-74A 9 in lung 
tissue. In this case as well, the half-lives in lung and blood were 11.0 and 13.1 min, respectively, 
which indicates rapid clearance of XHE-III-74A 9 from both lung and blood. Unlike, XHE-III-
74EE 5, XHE-III-74A 9 was present at a very low concentration in the brain which indicated that 
XHE-III-74A 9 had poor BBB penetration. This negates potential CNS side effects. The high 
levels of XHE-III-74A 9 were detected in urine, as compared to the brain, upon quantification after 
30 min of administration (Figure 21D) as expected. A high concentration of XHE-III-74A 9 in the 
kidneys supports the hypothesis that most of acid 9 is excreted from the body chemically unaltered. 
On the other hand, the concentration of acid 9 in the liver was much lower (4% of blood conc.) 

















Figure 21. Pharmacokinetic profile of XHE-III-74 EE and XHE-III-74A in mice brain, lung, and blood (N = 3). 
(A) Time-dependent distribution of XHE-III-74EE (5 mg/kg, i.p.). (B) Time-dependent distribution of 
metabolite XHE-III-74A given as XHE-III-74EE (5 mg/kg, i.p.). (C) Time dependent distribution of XHE-III-
74A (5 mg/kg, i.p.). (D) Distribution of XHE-III-74A (5 mg/kg, i.p.) at 30 min in different tissue and fluids (N 
=1). Modified from the figure in Gloria, et al.15 
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3.7.3 Oocyte Efficacies of XHE-III-74EE 5 and XHE-III-74A 915 
 
Ligand ester 5 is known as an α4β3γ2 subtype selective GABAAR allosteric modulator with weak 
activity at the α6β3γ2 GABAAR at >1 μM concentration.
209 The efficacy of acid 9 was evaluated in 
oocytes individually expressing single α (α1-5) subunits in combination with β3 and γ2 subunits in 
comparison with XHE-III-74EE (Figure 22). Gratifyingly XHE-III-74A 9 showed significant 
positive modulatory effects only at the α4 and α5 GABAARs and was mostly inactive at the α1, α2, 
and α3 sites. XHE-III-74A showed selectivity biased to α4β3γ2 at a concentration of 3 μM, while it 
reached a plateau at α5β3γ2.  
 
 
Figure 22. GABAA receptor subtype selectivity. Dose-dependent modulation of GABA (EC3−5 concentration) 
elicited currents by XHE-III-74A (A) and XHE-III-74EE (EE) on Xenopus oocytes expressing GABAA receptor 
subtypes α1β3γ2, α2β3γ2, α3β3γ2, α4β3γ2, and α5β3γ2. Data points represent means ± SEM from 2−8 oocytes from 
two batches, normalized to control currents (100%) in the absence of compound. XHE-III-74EE modulation of 
a set of GABAAR subtypes has been published previously,27 and only α4β3γ2 and α5β3γ2 are shown here for 
comparison. XHE-III-74EE modulation of α5β3γ2 GABAAR was measured at GABA EC20. Modified from the 
figure in Gloria, et al.15 
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3.7.4 Sensorimotor Effects of XHE-III-74EE (5) and XHE-III-74A (9)15 
A rotarod experiment was performed to evaluate the possible CNS side-effects of XHE-III-74EE 
5 which results from its ability to cross the BBB (Figure 23). The XHE-III-74EE 5 did not show 
any motor sensory impairment at 20 mg/kg while the positive control diazepam induced significant 
impairment at 5 mg/kg. However, XHE-III-74EE 5 did exhibit motor impairing effects at 40 
mg/kg. On the other hand, XHE-III-74A 9 did not exhibit any sensory motor impairment at 20 
mg/kg, as expected, which confirms its inability to travel across the blood brain barrier. There was 
no loss of righting response as well. 
 
Figure 23. Effect of XHE-III-74EE and XHE-III-74A on sensorimotor coordination. The Balb/c mice were 
tested on a rotarod at 15 rpm for 3 min. Mice received a single i.p. injection of test compound or control 
compound. A fail was assigned to a mouse that fell from the rotarod prior to 3 min. The % success rate is 
expressed as mean ± SEM (N = 8). ∗∗, ∗∗∗ indicates p < 0.01, p < 0.001 significance compared to vehicle-treated 
mice. Modified from the figure in Gloria, et al.15  
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3.7.5 Effect of XHE-III-74EE (5) and XHE-III-74A (9) on Airway Hyperres-
ponsiveness15 
Based on the results from the previous experiments, the ligands 5 and 9 were evaluated for their 
effectiveness in the ovalbumin sensitized mouse asthma model. In this model of asthma, the mice 
are first sensitized by Ova to establish airway inflammation by i.p. administration, and this was 
followed by an intranasal challenge, which generated airway hyper-responsiveness (AHR), mucus 
hypersecretion, and airway inflammation. Both XHE-III-74EE 5 or XHE-III-74A 9 were 
administered i.p. to primed mice during the Ova challenge phase (chronic repeated dosing) or 40 
min (acute) before measuring AHR (Figure 24).  
The asthmatic mice exhibited a reduction in methacholine-induced airway hyper-responsiveness 
after 5 days treatment with XHE-III-74EE (twice daily) of 20 mg/kg doses (Figure 24A). A single 
dose (10 or 20 mg/kg), however did not reduce AHR (Figure 24B, 24C). Since it was known from 
previous experiments that XHE-III-74EE 5 is metabolized fast and XHE-III-74A 9 is cleared 
rapidly, a minipump was implanted surgically to administer the dose over 7 days which results in 
a steady blood concentration of 27.2 ± 2.7 ng/g on the day of AHR measurement. The pump 
delivery of XHE-III-74EE 5 was effective in reducing AHR for methacholine concentration up to 
6.25 mg/mL. However, at higher doses, no significant AHR reduction was observed (Figure 24D). 
A similar trend was also observed for the positive control and known anti-inflammatory drug 
dexamethasone (24E). In addition, acute (20 mg/kg, i.p. 40 min prior to measurement) 









Figure 24. Effect of XHE-III-74EE (EE) and XHE-III-74A (A) on airway hyperresponsiveness. Specific airway 
resistance (sRaw) to increasing doses of methacholine measured by DSI’s Buxco FinePointe noninvasive airway 
mechanics instrument. Balb/c mice were administered (A) XHE-III-74EE, two 20 mg/kg i.p. injections daily for 
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5 days; (B) XHE-III-74EE, single i.p. injection 10 mg/kg 40 min prior to analysis; (C) XHE-III-74EE, single i.p. 
injection 20 mg/kg 40 min prior to analysis; (D) XHE-III-74EE via osmotic pump, 20 mg/kg daily for 7 days; 
(E) DEX, single 4 mg/kg i.p. injection daily for 8 days; and (F) XHE-III-74A, single i.p. injection 20 mg/kg 40 
min prior to analysis. Data represent mean ± SEM from 4−7 mice in each group. ∗, ∗∗, and ∗∗∗ indicate p < 
0.05, p < 0.01, or p < 0.001 significance, respectively, compared to vehicle treated Ova S/C Balb/c mice. Modified 
from the figure in Gloria, et al.15 
 
3.7.6 Effects of ligands 5 and 9 on Mucus Hypersecretion15 
To evaluate and compare mucus hypersecretion in treated and untreated Ova sensitized mice, lung 
sections were stained with PAFS stain (Figure 25). A significant increase in mucus production was 
observed in Ova S/C mice. An 8-day treatment with dexamethasone (4 mg/kg, i.p. daily) 
significantly decreased mucous metaplasia in Ova S/C mice compared to vehicle treated mice 
whereas, XHE-III-74EE 5 and XHE-III-74A 9 did not induce a noticeable reduction in mucin 









Figure 25. Effect of XHE-III-74EE (EE) and XHE-III-74A on mucin production. (A) Morphometric 
quantification of mucin volume density and (B) representative images of mucin (red) in the airway epithelium 
(green) with periodic acid fluorescent Schiff’s stain. Balb/c mice were administered once daily 4 mg/kg i.p. DEX 
(dexamethasone) injections for 8 days, a single 20 mg/kg i.p. injection of XHE-III-74EE 40 min prior to analysis, 
two XHE-III-74 EE 20 mg/kg i.p. injections daily for 5 days, 20 mg/kg XHE-III-74EE for 7 days via osmotic 
pump, XHE-III-74 EE single 20 mg/kg i.p. injection 40 min prior to analysis, or two XHE-III-74A 20 mg/kg i.p. 
injection daily for 5 days. Data represent % normalized mucin volume density relative to CTL and Ova S/C 
Balb/c mice from 5−7 mice in each group. ∗∗ indicates p < 0.01 significance compared to vehicle treated Ova 
S/C Balb/c mice. Scale bar represents 100 μm. Modified from the figure in Gloria, et al.15 
 
3.7.7 Effect of XHE-III-74EE (5) and XHE-III-74A (9) on Airway Eosino-
philia15 
Additionally, the immune response in the lungs of Ova S/C mice was quantified by collecting the 










Figure 26. Effect of XHE-III-74EE (EE) and XHE-III-74A (A) on airway eosinophilia. (A) Quantification of 
airway eosinophilia and (B) representative images of Wright Giemsa stained slides. Balb/c mice were 
administered single 4 mg/kg i.p. DEX injection daily for 8 days, XHE-III-74 EE single 20 mg/kg i.p. injection 
40 min prior to analysis, two XHE-III-74 EE 20 mg/kg i.p. injections daily for 5 days, 20 mg/kg XHE-III-74 EE 
via osmotic pump for 7 days, XHE-III-74 EE single 20 mg/kg i.p. injection 40 min prior to analysis, and two 
XHE-III-74A 20 mg/kg i.p. injections daily for 5 days. Data represent % normalized eosinophils relative to 
CTL (negative control) and Ova S/C Balb/c mice (positive control) from 5−7 mice in each group. ∗ and ∗∗∗ 
indicate p < 0.05 and p < 0.001 significance compared to vehicle treated Ova S/C Balb/c mice. Modified from 






It is known that the Ova asthma model demonstrates mainly eosinophil driven inflammation in the 
lung.210 Treatment with the anti-inflammatory agent dexamethasone significantly decreased 
airway eosinophilia.211 However, treatment with XHE-III-74EE 5 did not effect any change in 
airway eosinophilia. In contrast, significant reduction in airway eosinophilia was observed in acute 
(40 min, i.p., 20 mg/kg) treatment with XHE-III-74A 9. Although, acid 9 is a metabolite of XHE-
III-74EE 5, the absence of any such effect in the case of acute treatment with XHE-III-74EE 5 was 
not observed probably because XHE-III-74EE 5 is metabolized in the blood but not in the lung. 
 
3.7.8 Modulation of Immune Response by XHE-III-74EE (5) and XHE-III-74A 
(9)15 
To further investigate the direct effect of XHE-III-74EE 5 and its metabolite XHE-III-74A 9 on 
immune cells, the effects on human Jurkat T-cells was investigated in vitro. The stimulation by 
phytohemagglutinin (PHA) and phorbol myristate acetate (PMA) resulted in a sudden increase in 
intracellular [Ca2+]i and a significant amount of IL-2 production, which can be used for measuring 
cell activation.212,213 The natural ligand of the GABAAR is known to depolarize Jurkat cell plasma 
membranes where different α-subunits which contain GABAARs (including α4) are expressed. The 
direct effect of GABA is the release of IL-2 in PMA and PHA stimulated Jurkat cells (Figure 27A). 
The GABA did decrease IL-2 production at 100 nM but was not effective at 1 nM concentration. 
The XHE-III-74A did reduce IL-2 secretion at 100 pM concentration while XHE-III-74EE did not 











Figure 27. Modulation of immune response. GABAAR ligands inhibit intracellular calcium spike and increased 
IL-2 production in PMA/PHA stimulated Jurkat cells. (A) IL-2 in the presence of different concentrations of 
GABA, XHE-74EE, and XHE-74A. (B, C, D) Decrease of [Ca2+]I concentration in Jurkat cells measured with 
a cell-permeable fluorescence probe Fluo-4 in the presence of different concentrations GABA, XHE-III-74A, 
and XHE-III-74EE. (E) Patch-clamped change of Jurkat current response in the presence of GABA. (F) Patch-
clamped change of Jurkat current response in the presence of 300 nM GABA and XHE-III-74A and XHE-III-
74EE. ∗∗∗ indicates p < 0.001 significance compared to vehicle treated activated Jurkat cells. Modified from 
the figure in Gloria, et al.15 
 
The increment in intracellular Ca2+ concentration by GABA and GABAergic ligands in response 
to PMA and PHA; the Ca2+ concentration peaked at 50 s after this PMA/PHA treatment. The 
GABA did decrease the [Ca2+]i in a dose-dependent manner and fully suppressed it at 150 mM 
GABA IC50 = 74 ± 3 mM (Figure 27B). In contrast, XHE-III-74A 9 significantly reduced 
PMA/PHA-induced [Ca2+]i increase at much lower concentrations, IC50 = 210 ± 122 nM (Figure 
27C). XHE-III-74EE, on the other hand, caused only partial inhibition of the PMA/PHA induced 
increase in [Ca2+]i, IC50 = 24.3 ± 9.8 nM (Figure 27D).  
GABA has been reported to depolarize human jurkat T-cells at 100 μM concentration. The GABA 
level showed a dose-dependent effect on jurkat cell membrane current with EC50 = 3.1 μM (Figure 
27E). In the presence of GABA (EC3 conc.) and the positive modulator XHE-III-74EE 5, a 
significant dose-dependent change of current was observed. A GABA-induced current potentiation 
of 734% and 808% was observed with XHE-III-74EE 5 (EC50 = 2.5 μM) and XHE-III-74A 9 (EC50 
= 0.7 μM, Figure 27F), respectively. 
3.7.9 Relaxation of Pre-Contracted Guinea Pig ASM by XHE-III-74 (7), XHE-
III-74EE (5), and XHE-III-74A (9)15 
In ex vivo organ bath experiments on pre-contracted (by substance P) guinea pig tracheal rings 





Figure 28. Muscle force measurements in guinea pig tracheal rings. (A) Time-dependent change of muscle 
contraction in the presence of substance P and GABAergic compounds. (B) Force remaining 30 min after drug 
addition is shown. Tracheal rings were contracted with 1 μM substance P and at the peak of muscle contraction 
100 μM (in 0.1% DMSO) was added and the percent of remaining force was measured at 30 min. ∗∗∗ p < 0.001, 






3.7.10 In vitro Liver Microsomal Stability of Deuterated and Non-Deuterated 
XHE-III-74 Analogs3 
In addition, a liver microsomal stability of HLM and MLM was investigated to identify 
metabolically labile compounds and deuterated compounds which should be more stable than their 
nondeuterated counterparts. The results of this study are summarized in Table 5. The parent 
compound XHE-III-74 (7) was metabolized rapidly by mouse liver microsomes with 16.2% 
remaining after 1 h (Table 5, Entry 4). The corresponding half-life was less than 24 minutes. 
However, ligand 7 was stable in the presence of human liver microsomes, similar to the majority 
of compounds investigated. Less than 80% of the parent compound was observed after 1 h for acid 
9; esters 11, 11a, 12a; and cyclopropyl amide 19 (Table 5, Entries 7, 11, 12, 14 and 27). For acid 
9 and amide 19, stability of the deuterated analogs (9a and 19a) was significantly increased (Table 
5, Entries 7, 8, 27, and 28). A smaller number of compounds were stable in the presence of mouse 
liver microsomes for 1 h. The most stable compounds (as judged by less than 20% loss at 1 h on 
microsomes) were esters 5, 5a; phenol 6, deuterated acid 9a, deuterated methyl ester 10a; amides 
16, 16a, 17a, 19, and 19a (Table 5, Entries 1, 2, 3, 8, 10, 21, 22, 24, 27, and 28). All compounds 
that exhibited good stability in mouse liver microsomes were also stable in the presence of human 
liver microsomes. Importantly, different metabolic rates for deuterated and non-deuterated 
compounds in the presence of mouse liver microsomes were observed for acid 9, esters 10, 11, and 

















% remaining after 
1 hour 
1 5 99.1 ± 0.1 85.4 ± 0.3 
2 5a 92.8 ± 0.3 85.5 ± 0.3 
3 6 91.7 ± 0.2 91.1 ± 0.1 
4 7 92.1 ±  1.0 16.2 ± 0.2 
5 7a 91.9 ± 0.4 17.6 ± 0.2 
6 8 90.6 ± 0.2 46.6 ± 0.3 
7 9 56.1 ± 0.5 52.9 ± 0.5 
8 9a 84.6 ± 0.3 84.6 ± 0.2 
9 10 89.7 ± 0.2 70.3 ±  0.2 
10 10a 92.9 ± 0.2 85.9 ± 0.2 
11 11 77.8 ± 0.2 13.4 ± 0.9 
12 11a 78.7 ± 0.2 22.4 ± 0.3 
13 12 -a -a 
14 12a 77.1 ± 0.2 62.5 ± 0.3 
15 13 -a -a 
16 13a -a -a 
17 14 -a -a 
18 14a -a -a 
19 15 93.8 ± 0.3 54.3 ± 0.2 
20 15a 94.9 ± 0.2 56.8 ± 0.3 
21 16 92.4 ± 0.2 82.5 ± 0.3 
22 16a 96.3 ± 0.3 83.1 ± 0.2 
23 17 90.7 ± 0.3 50.1 ± 0.2 
24 17a 93.5 ± 0.2 94.8 ± 0.2 
25 18 92.8 ± 0.5 4.2 ± 0.2 
26 18a 95.6 ± 0.2 9.4 ± 0.4 
27 19 79.9 ± 0.2 91.3 ± 0.2 
28 19a 88.1 ± 0.2 94.1 ± 0.2 
 
a Compound was not soluble at 10 mM in PBS with 1% DMSO. Data were acquired by two 





3.7.11 Cytotoxicity Evaluation of XHE-III-74 Analogs3 
Further characterization of these compounds included the determination of their cytotoxicity using 
three different cell lines; HEK293 kidney cells, HepG2 liver cells, and BEAS2B lung epithelial 
cells (Table 6).  
Table 6. In vitro cytotoxicity of XHE-III-74 analogs3 
 









BEAS 2B (Lung) 
LD50 (µM)
 a 
1 5 >400 >400 >400 
2 5a >400 >400 >400 
3 6 >400 >400 >400 
4 7 >100 >400 >200 
5 7a >100 >400 >200 
6 8 >400 >400 >400 
7 9 >400 >400 >400 
8 9a >400 >400 >400 
9 10 >400 >400 >400 
10 10a >400 >400 >400 
11 11 >100 >200 >200 
12 11a >100 >200 >200 
13 12 >200 >400 >400 
14 12a >200 >400 >400 
15 13 >100 >100 >100 
16 13a >100 >100 >100 
17 14 18.8 ± 2.4 >100 >100 
18 14a 16.8 ± 2.0 >100 >100 
19 15 >100 >400 >400 
20 15a >100 >400 >400 
21 16 >400 >400 >400 
22 16a >400 >400 >400 
23 17 >400 >400 >400 
24 17a >400 >400 >400 
25 18 >200 >400 >400 
26 18a >200 >400 >400 
27 19 >200 >400 >400 




a Compounds were incubated at different concentrations with specified cells for 48 h, followed by 
detection of viability using Cell-Titer Glo (Promega). The results were normalized using DMSO 
(negative) and 3-dibutylamino-1-(4-hexyl-phenyl)-propan-1-one (150 mM in DMSO final 
concentration, positive). Data were acquired by three independent experiments carried out in 
quadruplet. 
 
Most of the compounds exhibited no major cytotoxicity at the concentrations tested. The 
compounds with the most pronounced cytotoxicity were thioesters 13, 13a, 14, and 14a (Table 6, 
Entries 15-18). Among the compounds identified as stable in human and mouse liver microsomes, 
only cyclopropyl amide 19 and 19a showed any toxicity in HEK293 cells (Table 6, Entries 27 and 
28) and it was at a concentration much higher than a therapeutic dose.  
3.7.12 Sensorimotor Effects of Analogs of XHE-III-74 (7)3 
In addition, possible adverse CNS sensorimotor effects were evaluated using a rotarod apparatus 
(Figure 29).  
The Swiss Webster mice were injected i.p. with 40 mg/kg of the indicated compound. The 
sensorimotor test was carried out after 10, 30 and 60 min. All compounds, including the diazepam 
positive control, showed the greatest impairment of sensorimotor steadiness at 10 min, followed 
by 30 and 60 min. The compounds that caused the most severe motor impairment were esters 10a, 
11a; amides 15 and 18a. In addition, some of the esters and thioesters 11, 12, 12a, 13, 13a, 14 and 
14a were not soluble in the vehicle (50% PBS, 40% propylene glycol, 10% DMSO) and could not 
be tested. Similar rotarod data were published previously for ester 5 and acid 9, which indicated 
that ester 5 weakly induced sensorimotor impairment whereas acid 9 did not, this is likely due to 
the inability of the acid to penetrate the blood brain barrier.15 The lead 7 (XHE-III-74) induced 
sensorimotor impairment in rats at 15 mg/kg (unpublished results). Taken together, compounds in 
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this series that are stable in the presence of human and mouse liver microsomes and exhibited 
neither cytotoxicity nor sensorimotor impairment are phenol 6, acid 9a, amides 16, 16a, and 17a. 
 
Figure 29. Effect of compounds on sensorimotor coordination. Swiss Webster mice were tested on a rotarod at 
15 rpm for 3 min at 10, 30, and 60 min following compound exposure. Mice (N ¼ 10) received a single i.p. 
injection of test compound (40 mg/kg), diazepam (5 mg/kg), or vehicle (50% PBS, 40% propylene glycol, 10% 
DMSO). The time of fall was recorded if it occurred prior to 3 min. Data are expressed as mean ± SEM (N ¼ 
10). ** (p < 0.01) or *** (p < 0.001) significance compared to vehicle-treated mice. Compounds 11, 12, 12a, 13, 
13a, 14, 14a did not dissolve in the vehicle. Modified from the figure in Jahan, et al.3 
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From the above data dimethyl amide 16/16a showed the most promising performance of the 
nondeuterated/deuterated pairs of compounds.  
3.8 Further Evaluation of the Most Promising Analog, Dimethyl Amide 163 
The α4β3γ2 GABAAR subtype selectivity of 16 was confirmed by comparison of its GABA induced 
current potentiation with the α1β3γ2 GABAAR (Figure A2).  
At a concentration of 1 mM of amide 16, 161% potentiation was observed for the α1β3γ2 GABAAR 
in contrast to 319% potentiation for the α4β3γ2 GABAAR in the presence of a GABA EC20 
concentration. To investigate if amide 16, like other analogs of XHE-III-74, exhibited the ability 
to relax airway smooth muscle, an ex vivo assay, which employed tracheal rings precontracted 
with substance P (Figure 30), was carried out. 
Examination of the results indicated that amide 16 reduced the contractile force of substance P in 
guinea pig tracheal rings over a period of 1 hour. The greatest significance was observed after 30 
min with a p < 0.001. Consequently, amide 16 was able to relax airway smooth muscle consistent 
with other analogs of XHE-III-74.3,15 
In addition, it was investigated if amide 16 could reduce airway hyperresponsiveness in a mouse 
asthma model. To establish an asthma-like disease, model male BALB/c mice were sensitized with 
three i.p. injections of ovalbumin (2 mg/kg/d emulsified in 2 mg of alum on days 0, 7 and 14, in a 
total volume of 100 µL). This was followed by intra-nasal challenge (1.6 mg/kg/d ovalbumin for 
5 days on days 23-27). The control mice were sensitized with ovalbumin but challenged with 
saline.15 The separate groups of ovalbumin induced (S/C) BALB/c mice received a single 40 mg/kg 
i.p. dose of 16 at 40 minutes before the measurement or twice daily 40 mg/kg of 16 i.p. for a 
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Figure 30. Airway smooth muscle contractile force in guinea pig tracheal rings. Tracheal rings were contracted 
with 1 µM substance P and then treated with 50 µM of 16 (or the vehicle control 0.1% DMSO). The percent of 
remaining contractile force was measured at various time points and expressed as a percent of the initial 
substance P induced contractile force. N and p-values are given for each condition. Modified from the figure in 






Figure 31. Effect of amide 16 on airway hyperresponsiveness: Specific airway resistance (sRAW) to increasing 
doses of methacholine measured by DSI's Buxco® FinePointe non-invasive airway mechanics instrument. (A) 
Balb/c mice were administered 40 mg/kg of 16 single i.p. injection 40 min prior to analysis; (B) administration 
of 16 at 40 mg/kg i.p. injections daily for 5 days. Data represent mean ± SEM from 4 to 7 mice in each group. * 




For animals treated with a single dose of ligand 16, no statistical significant specific airway 
resistance (sRAW) differences in comparison to the vehicle-treated group were observed at any of 
the methacholine concentrations tested. Importantly, significant reduction in sRAW (p < 0.05) was 
observed at the 12.5 mg/mL methacholine challenge for animals given amide 16 over a 5 day 
treatment course. 
In light of the observed partial in vivo efficacy of 16 in reducing airway hyperresponsiveness, a 






Figure 32. Pharmacokinetic analysis. A) Concentration changes of compound 16 in mouse brain, lung, and 
blood over time when given as a 5 mg/kg, i.p. injection. B) Quantification of metabolite 15 in mouse blood at 
indicated time points. Modified from the figure in Jahan, et al.3 
 
The concentrations following an i.p. dose of 5 mg/kg, amide 16 were quantified in blood, brain, 
and lung at different time points (Figure 32A). the ligand 16 reached a maximum absorption within 
minutes (tmax = 3 min) but also was cleared very rapidly, with a half-life of 8.8 min. The overall 
exposure of amide 16 (AUC = 6205 ng*min/ml) was not very high. A markedly decreased 
distribution of  dimethyl amide 16 was observed in brain and lung. The amide 16 did penetrate the 
blood brain barrier but reached only a very low Cmax of 123 ng/g. The distribution in the lung was 
even less pronounced with an AUC of 764 ng*min/ml in comparison to an AUC = 6205 ng*min/ml 
in blood. The presence of two likely metabolites of dimethyl amide 16, principally methyl amide 
15 (formed by N-demethylation) and acid 9 (formed by peptidase-mediated hydrolysis or by 
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hydrolases) were then investigated. The metabolite 15 was observed in substantial amounts in 
blood after only 3 min after injection (Figure 32B). The peak blood concentration was higher than 
the parent compound and occurred later, as expected for a metabolite. Overall, the distribution of 
methyl amid 15 was superior to dimethyl amide 16 with an AUC of 64675 ng*min/ml. Acid 9 
however, which was shown previously to reduce airway hyperresponsiveness, was not detected in 
any blood samples.15 
 
3.9 Biological Evaluation of the XHE-III-74 Ethyl Ester with the Phenolic 
Hydroxyl Function at the C-8 Position (Ligand 6)4 
It has been shown previously that XHE-III-743 7 and XHE-III-74EE 5,15 can cross the blood−brain 
barrier (BBB) and induce CNS effects at higher concentrations. To reduce the compounds ability 
to travel across the BBB it was decided to reduce the lipophilicity of XHE-III-74EE and related 
derivatives. The C-8 methoxy substituted compounds XHE-III-74 7, XHE-III-74-EE 5, and XHE-
III-74A 9 could relax airway smooth muscle but all of them exhibited a poor pharmacokinetic 
profile. The analog XHE-III-74A 9 was devoid any CNS side-effects, while XHE-III-74 7 and its 
EE derivative 5 exhibited undesired CNS effects. More importantly, XHe-III-74 and XHe-III-
74EE reduced airway hyper-responsiveness but acid 9 did not show any AHR reduction. On the 
other hand, XHe-III-74A could reduce inflammation while XHe-III-74 and XHe-III-74EE did not 
exhibit any reduction of inflammation.15 This led to a further search for a GABAAR ligand which 
would show all of the desired properties: better microsomal stability, a good PK profile, no 
CNS effects, relaxation of ASM, reduction of AHR, and reduction of inflammation. The C-8 
phenol variant of XHE-III-74EE 6, which is in fact an intermediate for the synthesis of other 
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investigated derivatives above, might potentially have the desired properties. Consequently, 
phenol 6 was evaluated for the above-mentioned properties. 
3.9.1 Relaxation of Airway Smooth Muscle by Phenol 6 Analog4 
The airway smooth muscle relaxation capability of phenol 6 was investigated using two different 
ex vivo models (Figure 33). One of the models utilized substance P-induced guinea pig tracheal 
muscle constriction, which was mediated by Gq-coupled neurokinin receptors. The other one 
utilized the application of acetylcholine to human tracheal airway smooth muscle strips that affect 
the muscarine acetylcholine receptors (Gi and Gq-proteins).  
In the guinea pig ASM, phenol 6 effected significant attenuation of the substance P-induced 
contraction at 15, 30, 45, and 60 minutes (Figure 33A). Although, substance P-induced contractile 
force spontaneously decreased over a period of 1 h, ligand 6 exhibited significant reduction of the 





Figure 33. Smooth muscle contractile force measurement in the presence of phenol 6 (compound 1). (A, B) 
Airway smooth muscle contractile force in guinea pig tracheal rings. Tracheal rings were contracted with 1 μM 
substance P and then treated with (A) 50 μM of 6 (or the vehicle control 0.1% DMSO). The percent of remaining 
contractile force was measured at various time points and expressed as a percent of the initial substance P 
induced contractile force (N = 4). (B) Tracheal rings were contracted with 1 μM substance P and then treated 
with 6 at different concentrations. The percent of remaining contractile force was measured at 30 min and 
expressed as a percent of the initial substance P induced contractile force as a percent of control (N = 3). 
Modified from the figure in Gloria, et al.4  
 
3.9.2 Distribution of Phenol 6 in Different Organs After Oral Administration in 
Mice4 
To ensure the delivery of the drug molecule 6 to the target organ or tissue at a pharmacologically 
active concentration, a pharmacokinetic profile was investigated. This would permit manipulation 
and further dose optimization to achieve the desired pharmacological effects. The pharmacokinetic 




Figure 34. Time dependent pharmacokinetic distribution of phenol 6 in mice blood, lungs, and brain (25 mg/kg 
via oral gavage). Modified from the figure in Gloria, et al.4 
 
The ligand 6 was absorbed within one hour after a 25 mg/kg oral dose. Excellent distribution in 
blood and lung (Tmax = 60 min, AUC = 2270.2 μg.min/g) was observed, as well. The ligand 6 was 
present in the blood at a higher concentration (Cmax 10.23 μg/g) than in the lung. The half-life of 
phenol 6 was higher in the lung (238 min) than in the blood and was detected in the lung even after 
8 hours (Figure 35). More importantly, the level of phenol 6 was rather insignificant in the brain. 
In addition, to evaluate any undesired CNS effects induced by a higher dose, 6 was administered 
orally at a 100 mg/kg dose. Ligand 6 did not induce any motor sensory impairment which was 
clear from the rotarod assay (Figure A3). In addition, phenol 6 exhibited low efficacy toward the 
α1β3γ2 GABAAR, which would mediate sedation and tolerance (Figure A4). 
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3.9.3 Anti-Inflammatory Properties of Phenol 64 
To evaluate the effect of ligand 6 on inflammatory cells, ova s/c BALB/c mice were treated with 
twice a day dose of 100 mg/kg for 5 days and the subsequent changes of inflammatory cells in 
bronchoalveolar lavage fluid was quantified using flow cytometry (Figure 35A-F). Ova s/c mice 
that usually exhibit asthma-like inflammation contained a significantly high amount of white blood 
cells in BALF. The 5-day oral treatment with phenol 6 showed an anti-inflammatory effect which 
was demonstrated by the reduced number of leukocytes in BALF (Figure 35A). To further confirm 
the anti-inflammatory properties of phenol 6, eosinophilia in BALF was quantified in ova s/c mice 
using Wright Geimsa stain (Figure 35B). A five-days b.i.d. treatment with ligand 6 showed 
significant reduction in eosinophil counts in mouse BALF. Similar studies were also performed on 
CCR3+, GR1+, CD4+, and CD11b+ immune cells. In all these cases ligand 6-treated mice exhibited 
a lower cell count compared to the untreated ova s/c mice (Figure 35C-F). In addition, the change 
in transmembrane current in the presence of phenol 6 in isolated CD4+ T cells (from the spleen of 
ova s/c mice) was determined using patch clamp. There was a dose-dependent increment in current 
caused by phenol 6 (Figure 35G). Overall, ligand 6 exhibited more pronounced electro-





Figure 35. Effect of compounds 1 (phenol 6) and 2 (MIDD-0301, structure not shown) on inflammatory cells. 
Groups of 10 ova s/c BALB/c mice were administered dexamethasone i.p., 4 mg/kg daily for 8 days; compound 
1 via oral gavage, 100 mg/kg twice daily for 5 days, and compound 2 via oral gavage, 100 mg/kg twice daily for 
5 days. BALF was harvested from each animal and used for (A) quantification of total inflammatory cells. Cells 
were stained with mouse CD45 APC antibody, and samples were analyzed with BD FACS Calibur on high flow 
rate (60 μL/min) for 180 s. The gated positive events in the fourth channel (FL4) were used to calculate the total 
inflammatory cell count as cells/mL. (B) Quantification of Wright Giemsa stained airway eosinophils. Data 
represent % normalized eosinophil count relative to CTL (negative control) and ova s/c mice (positive control). 
(C−F) Quantification of specific leukocyte population. (C) CCR3+, (D) GR1+, (E) CD4+, and (F) CD11b+ cell 
populations were stained with specific antibodies and detected by flow cytometry. Data represent mean ± SEM 
from 10 mice in each group. *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001 significance, respectively, 
compared to vehicle treated ova s/c BALB/c mice. (G) Current recordings in the presence of 600 nM GABA 
and increasing concentration of compound 1 applied together for 3 s using CD4+ T-cells isolated from ova s/c 
BALB/c mice spleen. (H) Current recordings in the presence of 600 nM GABA and increasing concentrations 
of compound 2 applied together for 3 s using CD4+ T-cells isolated from ova s/c BALB/c mice spleen. (I) 
Concentration-dependent current responses of CD4+ T-cells from ova s/c BALB/c mice spleen in the presence 
of 600 nM GABA and increasing concentration of compound 1 or 2. Current readings were normalized to 600 
nM GABA response set as 100% (n = 16). Modified from the figure in Gloria, et al.4  
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3.9.4 Alleviation of Airway Hyperresponsiveness by Phenol 64 
      
Figure 36. Effect of 6 on airway hyperresponsiveness. Specific airway resistance (sRaw) was measured at 
increasing dosages of methacholine by a DSI’s Buxco FinePointe noninvasive airway mechanics instrument. 
Ova s/c BALB/c mice were administered 6 via oral gavage, 100 mg/kg twice daily for 5 days. Data represent 
mean ± SEM from 10 mice in each group. *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001 significance, 
respectively, compared to vehicle treated ova s/c BALB/c mice. Modified from the figure in Gloria, et al.4 
 
Airway hyperresponsiveness is characterized by the physiologic agitation of cholinergic agonists 
and is a primary aspect of the symptoms of asthma.214 The specific airway resistance (sRaw) in 
ova s/c mice was measured in the presence of an increasing amount of aerosolized methacholine 
to investigate the pharmacodynamic properties of phenol 6 after oral administration (Figure 36). 
Significant AHR was observed for methacholine at 6.25 and 12.5 mg/mL. After a 5-day treatment 
with ligand 6 (100 mg/kg, b.i.d. and 30 min before the measurement), this resulted in a significant 
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reduction in sRaw values for Cmethacoline = 3.13 and 6.25 mg/mL (Figure 26) which was in 
agreement with a previous report.15 In addition, ligand 6 did not cause significant mucous 
metaplasia after oral administration (Figure A5). 
In summary, phenol 6 demonstrated for the first time, the potential of this novel oral drug strategy 
for asthma by relaxing ASM, and alleviating AHR without mucous metaplasia. This novel asthma 
drug candidate will be further optimized for even better properties to combat AHR and airway 
inflammation which are responsible for the symptoms of asthma and perhaps COPD. In part, the 
method of administration might be the most important aspect of future research on phenol 6. 
 
3.10 The Synthesis of Heterocyclic Bioisosteres of XHe-III-74 at the C-3 Ester 
Position  
Isostere, as a concept, was first contemplated by Moir in 1909, which was later refined by Grimm 
and experimentally established by Langmuir.215-218 It was initially based on the octet theory of 
valence electrons. According to Langmuir, if two compounds or chemical species existed with the 
same number of atoms and electrons, they would arrange themselves in a similar manner and 
would exert similar properties.218 As predicted based on this concept, diazomethane would have 
physical properties similar to ketene. Bioisosteres, on the other hand, are structurally distinct 
compounds that have similar biological properties or are recognized similarly by biological 
systems. This concept was developed by Erlenmeyer and Landsteiner in the 1930s.217,219  Although 
the term “bioisostere” did not appear until 1950, when Friedman defined and distinguished 
between isosteres and bioisoteres.220 Isostereic compounds are not necessarily bioisosteric, and 
vice versa.217 Bioisosteres are generally not structural mimetics but biochemical mimetics. In the 
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design of bioisosteres factors that play key roles in molecular recognition and mimicry include 
size, shape, electronic distribution, lipophilicity, dipole moment, pKa, etc.217 In current medicinal 
chemistry and modern drug discovery strategies, bioisosteres have become a fundamental tactic in 
the design and development of drugs.215-217,221-223 The application of this strategy encompasses 
improving potency, increasing selectivity, reducing or altering metabolism, and acquiring 
intellectual property of the drug candidate.217 Although established initially for a medicinal 
chemistry context, this concept has found useful and productive applications in optimization and 
development of organocatalysts.224  
Classical bioisosteres can be as simple as the replacement of a hydrogen with a deuterium or 
fluorine atoms, an amine function with a hydroxyl function, etc. On the other hand, non-classical 
bioisosteres can range from a subtle to a sophisticated alteration of the molecule which may be 
completely different in terms of functionality, structure, and topology.217 For example, a 
benzothiazole225 moiety can be a bioisostere for a phenol function, a tetrazole function can be a 
carboxylic acid bioisostere,217,226 an oxadiazole for  an ester, a trifluoromethylamine function for 
an amide function, etc.217  
3.10.1 Synthesis of Bioisosteres of Ligands 24-26, 28, 29 and 31 
The ester function at C-3 was converted into a series of heterocyclic bioisosteres; 1,2,4-oxadiazoles 
with an alkyl substituent (Me, Et, iPr) at the C-3 position of the heterocycle.  
For the 1,2,4-oxadiazoles, oximes with appropriate alkyl substituents were first stirred with NaH 
in THF before the introduction of the ethyl ester 5 and the reaction mixture, which resulted, was 
stirred at room temperature until completion (usually 2 hours), as indicated on analysis by TLC 
(silica gel) to furnish the 3-alkyl-1,2,4-oxidiazoles (Scheme 9) in excellent yields.9 
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Figure 37. ORTEP representation of oxadiazole 25 
 
 
Figure 38. ORTEP representation of oxadiazole 26 
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The oximes required for these transformations were prepared earlier by the reaction of 
hydroxylamine with the corresponding alkyl nitriles in aqueous methanol at elevated temperature 
(Scheme 10).9 
Scheme 10. Synthesis of the oximes9 
 
These three bioisosteres were analyzed for their potential cytotoxicity on HEK293, HEP2 and 
BEAS 2B lung cells (Appendix, Table A5, unpublished results). These bioisosteres were not 
cytotoxic at any concentration related to a therapeutic concentration of 24, 25, and 26 required for 
treatment of asthma. Moreover, importantly there was no cytotoxicity in lung cells.  
In addition to the 1,2,4-oxadiazoles, a 1,3-oxazole, which is not a usual bioisosteric replacement 
for an ester but has been used before,144 was also prepared as a bioisostere of the ester. The five-
membered heterocyclic ring in a 1,3-oxazole is comparable to a methyl ester in size but 
electronically more related to the oxadiazoles. It does have two sites of electron density (O, N) 
which can interact with the protein in similar fashion to the oxygen atoms of an ester function. 
The reaction of aldehyde 27 with TosMIC in the presence of potassium carbonate in methanol227 
furnished the oxazole KRM-II-68 28 in good yield, while the required aldehyde 27 was prepared 
from the ethyl ester 5 by reduction with DIBAL-H at -78 oC (Scheme 11). The synthesis of 
aldehyde 27 was further improved by using SDBBA (Figure 38).228,229 The SDBBA was prepared 
(Scheme 12) and used in situ from sodium tert-butoxide and DIBAL-H in excellent yield.228 The 
SDBBA mediated reduction of the ester was more facile because the reaction was carried out at 
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room temperature (not in –78 oC). In this process the aldehyde was formed quickly from the 
hindered hydride reagent and the reaction was stopped before the aldehyde could be reduced to the 
alcohol byproduct.  
Scheme 11. Synthesis of the aldehyde 27 and this was followed by conversion into the 1,3 












Figure 40. ORTEP representation of oxazole 28 
Scheme 12. Improved synthesis of the aldehyde 27 at the C-3 position from ester 5 with in 




The 1,3-oxazole 28 did not show any cytotoxicity at a concentration up to 400 µM in the three 
different cell lines; HEK293 kidney cells, HEP2 liver cells and BEAS2B lung epithelial cells (see 
Appendix, Table A6, unpublished results).  
In pre-contracted (with 1 mM substance P) guinea pig tracheal rings, oxazole 28 reduced the 
constriction of airway smooth muscle after 15 minutes for a period of at least 60 minutes 
(comparable with XHE-III-74; Appendix, Figure A6, unpublished results). The effect of oxazole 
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28 on sensorimotor gating at 40mg/kg was performed and it showed profound motor impairment 
beginning at 10 minutes all the way through 60 minutes on the rotorod (Appendix, Figure A7, 
unpublished results). 
Although 1,3-oxazole 28 was not cytotoxic and it exhibited the desired relaxation of ASM, it 
passed through the BBB which led to CNS side effects. Consequently, the more polar variant, the 
C-8 phenolic C-3 oxazole 29 (RJ-03-30) was prepared via the previously mentioned ethanethiol 
and ALCl3 mediated demethylation of oxazole 28 in excellent yield (Scheme 13). 
Scheme 13. Synthesis of C-8 phenolic C-3 oxazole 29229 
 
 
The phenolic, C-3 substituted oxazole 29 was very stable on both human and mouse liver 
microsomes (see Appendix, Table A7). The oxazole 29 did not show cytotoxicity at a 
concentration of 400 µM in HEK293 kidney cells and HEPG2 liver cells, as well (Appendix, Table 
A8). In addition, it was found to exhibit relaxation of guinea pig airway smooth muscle which 
began at 15 minutes, which was very promising (Appendix, Figure A8). As expected, ligand 29 
did not show any sensory motor impairment at 100 mg/kg in the rotarod assay, which indicated 
the lack of distribution in the brain because of the more polar nature, which, presumably,  
prevented it from traveling across the BBB (Appendix, Figure A9). Although oxazole 29 did not 
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show alleviation of airway hyper-responsiveness (Appendix, Figure A10), and did not modulate 
inflammatory cells in the preliminary experiments (Appendix, Figure A11), it evoked a very 
pronounced GABA induced current in electrophysiological measurement of CD4+ T lymphocytes 
(Appendix, Figure A12).229 Consequently, it is still a promising candidate for further development 
because of its desirable properties in other criteria. It is important that further biology be carried 
out on this molecule. 
It is known that 1,2,3,4-tetrazoles are excellent bioisosteres for carboxylic acids. The synthesis of 
tetrazole 31 (RJ-03-57) began from the XHE-III-74 ethyl ester 5 already in hand. The ethyl ester 
5 was first converted into the aldehyde 27 using SDBBA, and this was followed by conversion 
into the corresponding nitrile 30 by reaction of 27 with I2 in aqueous ammonia in excellent yield 
with no chromatography required for purification.228 Subsequently, the nitrile 30 was treated with 
sodium azide in the presence of zinc bromide at elevated temperature (refluxing THF) to furnish 











Scheme 14. Synthesis of 1,2,3,4-tetrazole 31 from ester 5228-230 
 
Tetrazole 31 was much more stable than the acid 9 in the microsomal enzyme stability assay 
(Appendix, Table A7). In human liver microsomes 98.5 ± 0.2% of tetrazole 31 remained (acid 9 
was 56.1 ± 0.5%) after 1 hour, while in mouse liver microsomes 94.3 ± 0.1% remained (acid 9 was 
52.9 ± 0.5%) of 31 after 1 hour. It did not show cytotoxicity at a concentration of 400 µM in 
HEK293 kidney cells and HEPG2 liver cells at a therapeutic dose, as well (Appendix, Table A8).229 
As expected, tetrazole 31 did not show any sensorimotor impairments on the rotarod assay when 
dosed at 40 mg/kg (Appendix, Figure A9). But this compound could not reduce the constriction of 
guinea pig airway smooth muscle after 15 minutes for a period of at least 60 minutes (Appendix, 
Figure A8). Unfortunately, it also was not able to alleviate airway hyperresponsiveness (AHR) 
(Appendix, Figure A10). The pharmacokinetic profile of tetrazole 31 in mice blood, lungs, and 
brain, when administered at 25 mg/kg via oral gavage, indicated a moderate absorption and fast 
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clearance had occurred (Appendix, Figure A13).229 This was not suitable for treatment of asthma, 
it was felt.  
Subsequently, the phenolic ethyl ester 6 was saponified and this was followed by acidification to 
furnish the phenolic acid (RJ-03-90) 32, as shown in Scheme 15 below. 




The phenolic acid 32 did not show any sedative effects on the rotarod at 100 mg/kg on oral dosing 
(Appendix, Figure A9). When the effect on inflammatory cells was performed, acid 32 did not 
modulate the numbers of inflammatory cells when ova s/c BALB/c mice were administered 32 at 
100 mg/kg twice daily for 5 days (Appendix, Figure A11).229 However, this is only preliminary 
data. It is hoped that this compound will be rescreened for AHR and anti-inflammatory 





Scheme 16. Synthesis of amides 33 and 34 from acid 9229 
 
 





Additionally, the carboxylic acid at C-3 was converted into methoxyamide 33 and cyanamide 34 
in cooperation with Dr. Michael Stephen. The carboxylic acid 9 was converted to corresponding 
acyl chloride by reaction with thionyl chloride and this was followed by the treatment of 
methoxylamine and cyanimide in the presence of triethylamine to furnish amides 33 and 34, 
respectively (Scheme 16). Furthermore, the phenolic function at C-8 of ester 6 was converted to 
alkyl ethers 35-39 for additional C-8 ether derivatives. The phenol function was alkylated by 
reaction with alkyl halides in the presence of cesium carbonate in DCM to convert them into their 
corresponding ethers (individually). The ester function was saponified subsequently to furnish the 
C-8 alkyl ether containing carboxylic acids 35-39 in good to excellent yield (Scheme 17).   
The biological evaluation of these promising α4-subtype selective GABAAR agonists is yet to 















There are only a limited number of options available for the long-term management of chronic 
asthma. The beta 2 adrenergic receptor (β2AR) agonists and inhaled anti-inflammatory 
corticosteroids have been the mainstays in ameliorating asthmatic symptoms in moderate to severe 
incessant asthma.4,231,232 In this case administration of the drugs through inhalation offers a more 
direct approach since it promises targeted delivery of the drug to the lung in high dosages, while 
avoiding undesirable adverse effects from systemic exposure. Despite this apparent advantage, 
prolonged use of corticosteroids may result in drug adherence and compliance issues.233,234 In 
addition, asthma therapeutics that offer the inhaler route may not be economically viable in many 
circumstances and have to be carried-with always.4,233 It is a considerable encumbrance for 
children and elderly asthma patients since improper technique of the inhaler use often causes 
incorrect dosage and poor efficacy of the drug. This ultimately contributes to the poor management 
of asthma and increased asthma related morbidity and mortality.4,233,234 On the contrary, 
administration through the oral route is widely accepted and can be supervised by relatives and 
caregivers. In addition, if the oral drug can be formulated into a slow-release form, it would ensure 
a long-lasting exposure of the drug and consequently, it will ensure pharmacological benefits 
around-the-clock. 
Esters and amides are common functional groups in many FDA approved drugs, although a 
number of such compounds are prodrugs that rely on endogenous enzymes such as peptidases to 
be activated. The lead XHE-III-74 7, has a tert-butyl ester function which was shown to be labile 
in the presence of mouse liver microsomes, while relatively stable in vitro in human liver 
microsomes. Nevertheless, XHE-III-74 7 reduces airway hyperresponsiveness when given by 
aerosol delivery in mice.2 Consequently, the stability of XHE-III-74 7 was sufficient in mice when 
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administered directly to the target organ. Other compounds with limited half-lives in the presence 
of mouse liver microsomes are 18 and 18a bearing a tert-butyl amide, 8 bearing a tert-butyl ester, 
and 11, 11a bearing a isobutyl ester.3 Therefore, it was found that esters and amides with longer 
and more branched carbon chains are metabolically less stable than their shorter carbon chain 
analogs. Another aspect of the SAR determined herein was the comparison of deuterated and non-
deuterated compounds. Overall, a trend, that deuterated compounds are equally or more stable than 
their corresponding non-deuterated analogs was found. This effect was very pronounced for acids 
9 and 9a, probably because a hydrolysable carboxylic ester or amide group inherent to other 
analogs in this series was missing.3 Thus, for 9 and 9a, oxidation of the methoxy group (deuterated 
or non-deuterated) to the corresponding hemiacetal followed by hydrolysis might be the rate-
determining step of metabolism. This specific route of metabolism can be species dependent. For 
instance, ethyl amides 17 and 17a had similar stability on human liver microsomes; however, in 
the presence of mouse liver microsomes the non-deuterated amide 17 was notably less stable.3 
Therefore, it was confirmed that small molecule metabolism was highly species dependent and 
involved many different metabolic reactions that are structure dependent. The cytotoxicity of 
XHE-III-74 analogs was not very pronounced. The analysis showed that 50% of all compounds 
have LD50 values greater than 400 µM for the sensitive HEK293 kidney cells. For the BEAS2B 
lung cells, 71% of the compounds were not toxic. The compounds with the highest toxicity were 
thioesters 14 and 14a.3 Interestingly, the deuterium protecting effect was less pronounced for 
cytotoxicity, although small differences were observed (Appendix, Figure A11). This is as 
expected, for if a molecule is cytotoxic as is, increasing the duration may well not decrease toxicity. 
The only way to affect cytotoxicity is to block metabolism to a toxic metabolite. Sensorimotor 
impairment is another important screen for unwanted side effects in a possible asthma drug. 
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Among the different GABAAR in the CNS, the α1β3γ2 GABAAR’s subtype is known to mediate 
sedation, which in turn compromises sensorimotor skills.3,235 Therefore, compounds with high 
efficacy toward this receptor subtype are expected to induce sedation in vivo, as seen for 
diazepam.209 However, due to the unique scaffold of XHE-III-74 and its analogs, low efficacy 
towards α1β3γ2 GABAAR and high efficacy towards α4β3γ2 GABAAR was shown, e.g. XHE-III-74 
7,2 XHE-III-74EE 5,209 and XHE-III-74A 9.15 Only a few of the compounds described herein 
induced sensorimotor effects comparable to diazepam; however, at concentrations that were eight 
times greater. At 40 mg/kg the deuterated analogs, in comparison to non-deuterated parents are 
more likely to impair sensorimotor abilities. This effect correlated with their better metabolic 
stability. For instance, 30% of methyl ester 10 was metabolically converted into the acid after 1 h, 
whereas only 15% of deuterated ester 10a was converted into the acid during the same time. 
Accordingly, ester 10 did not induce any sensorimotor impairment in contrast to deuterated ester 
10a. Thus, increasing the half-life of a drug candidate using deuterium substitution in the present 
case amplified not only the therapeutic effect but also potentiated possible side effects.3 The only 
compounds investigated herein that were stable in mouse and human liver microsomes and did not 
induce sensorimotor impairment were phenol 6, acid 9a, as well as amides 16, 16a, and 17a. Amide 
16, like other compounds in this series e.g. esters 5, 7, and acid 9,15 significantly reduced airway 
muscle constriction caused by substance P. Airway smooth muscle relaxation is an important 
hallmark of an efficacious asthma treatment and amide 16 mediated this effect within 15 min. In 
vivo, using ovalbumin S/C mice, ligand 16 reduced airway hyperresponsiveness at high 
methacholine challenge when given chronically.3 Similar effects were reported for ethyl ester 5 
when given repeatedly over five days.15 Both ligands (5 and 16) are metabolically stable in vitro 
and non-toxic, however, their effect was less pronounced in vivo probably due to sub-
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pharmacological concentrations. Ethyl ester 5 was shown to be absorbed and cleared slower with 
a t1/2 of 16.3 minutes instead of 8.8 minutes in comparison to dimethyl amide 16. Using the same 
dose, the AUC for lung exposure decreased from 4516 ng*min/ml for ester 5-to 764 ng*min/ml 
for amide 16.3 Finally, it was shown that ester 5 metabolized to acid 9 probably by mouse esterases 
and acid 9 decreased airway eosinophilia.15 In contrast, dimethyl amide 16 metabolized to methyl 
amide 15 (demethylation) but no hydrolysis took place to yield acid 9 was detected. Thus, the 
incremental weaker pharmacodynamic effects of amide 16, presumably is due in part by its short 
half-life and the inability to form the anti-inflammatory acid 9.3  
 
The common GABAAR positive allosteric modulators (PAMs) suffer from significant distribution 
in the brain which elicits undesirable side effects. In contrast, phenol 6, a novel PAM for GABAAR, 
demonstrated pharmacological effects to treat asthma, while maintaining an extremely low brain 
concentration. No detectable murine sensorimotor impairment at high doses in the rotarod assay 
confirmed the low brain exposure and no corresponding CNS adverse effects (Appendix, Figure 
A12).4 The active key chemical composition was realized by incorporating a hydrophilic function 
such as phenolic hydroxyl group attached to a well-established imidazobenzodiazepine scaffold 
(phenol 6) into the molecule. The improvement in hydrophilicity (pKa) resulted in reduction in 
brain distribution almost entirely. In addition, phenol 6 exhibited excellent pharmacokinetic 
properties with very high concentrations in blood and lung, as well as a longer in vivo half-life 
which would facilitate the management of asthma.4 It was demonstrated that a five day long oral 
b.i.d administration of ligand 6 during an ovalbumin challenge (following ovalbumin sensitization) 
could significantly diminish airway hyperresponsiveness (AHR) at low concentrations of 
methacholine. This observation was in accord with the results from a prior investigation with α4 
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subtype selective GABAAR PAM XHE-III-74EE 5.
15 The in vivo effects of phenol 6 on ASM 
were similar to its positive effect on ex vivo ASM relaxation. In organ bath experiments on guinea 
pig tracheal smooth muscle (ex vivo), phenol 6 significantly relaxed substance P induced 
contraction.4 Other useful pharmacological properties of ligand 6 include the anti-mucogenic 
property for treatment of asthmatics.4 
To formulate a single compound that can mitigate both AHR and airway inflammation, GABAAR 
proteins expressed on immune/inflammatory cells were targeted, which would respond similarly 
to the effects of GABA on GABAARs expressed in the brain. It has been demonstrated that CD4
+ 
T lymphocytes responded proportionately to phenol 6 in the presence of GABA. The lung 
eosinophilic inflammation due to ovalbumin allergen was attenuated, as well. Ligand 6 
demonstrated a significant decrease in CD4+ T cells in BALF and changed transmembrane current 
in a dose dependent manner, although the exact mechanism of transmembrane current mediated 
reduction in T-cell population is yet to be elucidated.4 
The 3-alkyl-1,2,4-oxadiazoles 24-26 were designed as bioisosteric replacements of the C-3 ester 
function since such alteration often results in superior drug properties which include longer in vivo 
duration of drug-action. These compounds showed promising results in a cytotoxicity assay on 
several cell-lines where none of them were cytotoxic anywhere near therapeutic dose for asthma. 
Gratifyingly, cytotoxicity was not observed in lung cells. The 1,3-oxazole 28, which is a non-
conventional ester bioisostere, did not exhibit any cytotoxicity up to 400 µM in three different cell 
lines. Although oxazole 28 showed significant sensorimotor impairment in a rotorod assay at high 
concentrations, it showed pronounced relaxation in pre-contracted guinea pig tracheal rings, which 
was comparable with XHE-III-74 7. As indicated by the CNS side effects, oxazole 28 could travel 
across the BBB. As inferred from this observation, a more polar derivative (i.e., higher 
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hydrophilicity) was designed. The C-8 phenolic C-3 1,3-oxazole 29 showed superior microsomal 
stability both on human and murine liver microsomes. The phenolic oxazole 29 was also not 
cytotoxic up to 400 µM in kidney and liver cells. As desired, oxazole 29 did not show any 
sensorimotor impairment in rotorod assay at a dose as high as 100 mg/kg, obviously due to low 
brain distribution, while showing promising relaxation in guinea pig ASM. Although in initial 
experiments, oxazole 29 did not show desired promise in alleviating AHR and modulating 
inflammatory cells, it evoked very strong GABA induced current in CD4+ T lymphocytes in 
electrophysiological measurements.229 It is hoped that oxazole 29 could be an excellent lead 
for further developments because of its promising properties in other useful criteria.  
Tetrazole 31 was designed as a carboxylic acid bioisostere. The tetrazole exhibited much better 
stability as compared to the parent carboxylic acid 9 both in human and mouse liver microsomes. 
It did not show any cytotoxicity in several cell lines and did not exhibit CNS side effects in the 
rotorod assay. Unfortunately, tetrazole 31 failed to show promising pharmacokinetic properties 















Classical benzodiazepines have demonstrated many useful clinical applications as evidenced by 
their presence in the market for the last five decades lacking a better replacement. Over the years, 
numerous promising candidates to treat asthma have appeared, but failed due to poor 
pharmacokinetic properties and adverse CNS effects. The primary goal of this research was to 
further develop the promising α4-subtype selective GABAAR ligand, lead compound XHE-III-74, 
for better subtype selectivity, efficacy, in vivo stability, as well as superior modulation of airway 
hyper-responsiveness, and effective and rapid relaxation of ASM constriction. All the while 
avoiding brain exposure to prevent CNS related adverse effects consequently, work toward 
development of novel asthma drug with an innovative mechanism of action. Specifically to find a 
new drug candidate for the treatment of asthma by targeting the GABAARs expressed in the lung 
airway smooth muscle (ASM) and inflammatory cells of the peripheral nervous system. This is a 
novel mechanism of action and has now shown promising developments toward a novel treatment 
to manage asthma. This approach should not only be economically more viable but would be a 
direct and sustainable approach.  
 
The relaxation of ASM and reduction of AHR by XHE-III-74 7 has been confirmed but it did not 
show any reduction in airway inflammation. In addition, poor microsomal stability and an inferior 
pharmacokinetic profile, as well as CNS side effects indicated the requirement for further 
modification and optimization of this drug candidate. Subsequently, the ethyl ester analog 5 (XHE-
III-74EE) elicited better microsomal stability, ASM relaxation, AHR reduction, and reduction of 
inflammation. However, it suffered from poor pharmacokinetic properties and CNS adverse 
effects. Fortunately, further modification at the same position (C-3) gave another good candidate, 
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the dimethyl amide 16 which did not show any CNS activity but also suffered from a poor PK 
profile and inability in mitigating airway inflammation. In continuation of the development 
process, the carboxylic acid derivative XHE-III-74A 9, while showing promise in microsomal 
stability, ASM relaxation, avoiding CNS exposure and reduction in inflammation, suffered from 
lack of AHR reduction and inferior PK properties. This led to the development of phenolic ethyl 
ester derivative of XHE-III-74 6, which has shown desirable properties in all the criteria for 
treatment of asthma since it has exhibited good metabolic stability, better pharmacokinetic 
properties, and no CNS activity. Furthermore, phenol 6 exhibited ASM relaxation, AHR mitigation 
properties, as well as reduction of airway inflammation. However, despite the fundamental 
successes with 6 and 3 other analogs to treat asthma modifications built on the results obtained 
thus far, may provide even better ligands to treat asthmatic patients.  
In addition, a number of other derivatives were prepared which include different C-8 alkyl 
substituents and ester as well as carboxylic acid bioisosteric moieties at C-3 still await their 
complete biological evaluation. It is hoped that those experiments would result in GABAAR 
ligands with superior drug properties in all aspects, or at the least, will provide important leads for 
further development of next generation asthma drug candidates using the current strategy. 
In conclusion, the goal of this research was not only to understand the chemical aspects of the 
GABAARs and the effects of subtype selective ligands on the GABAAR, but also to apply current 
knowledge in this area to design novel GABAAR ligands to address unmet clinical demands to 
treat asthmatic patients young and old. In terms of outcome, the purpose was to provide aid and a 
better treatment option to the individuals who live with asthmatic symptoms. It is felt some of the 
ligands developed here can do just that. It is expected that the framework of this research will lead 





Indomethacin, acetylcholine, N-vanillylnonanamide, histamine, and pyrilamine (Sigma; St. Louis, 
MO, USA); MK501 (Tocris Bioscience; Ellisville, MO, USA); tetrodotoxin (Calbiochem; San 
Diego, CA, USA); test compounds CMD-45 and XHe-III-74 (designed and synthesized by Dr. 
James Cook’s laboratory in the Department of Chemistry and Biochemistry, University of 
Wisconsin-Milwaukee); purified house dust mite (HDM) antigen (Greer Laboratories; Lenoir, NC, 
USA). 
Experimental Animals2 
All studies were approved by the Columbia University Institutional Animal Care and Use 
Committee. The 8 to 10 week old male mice with a global genetic deletion of the GABAAR α4 
subunit (gabra4 KO; originally a gift of Dr. Gregg Homanics, University of Pittsburgh)236 and/or 
their corresponding background wild type C57/Bl6 mice (WT) were utilized for all mouse studies. 
Prior to tissue harvests, all animals were euthanized with an overdose of intraperitoneal (i.p.) 
phenobarbital (100 mg/kg). For in vivo airway resistance testing, wild type C57/Bl6 mice 
underwent house dust mite (HDM) antigen sensitization to induce an asthmatic phenotype. Briefly, 
all mice were exposed to 30 Eg of intranasal purified HDM or vehicle (PBS) during isoflurane 
anesthesia daily for 3 weeks prior to airway resistance testing. 
Human Tissue2 
Human trachea and bronchi samples were collected from healthy donor lungs at the time of lung 
transplant surgery (surgical discards). All experiments using these tissues were deemed non-
human subjects research after review by Columbia University’s Institutional Review Board. 
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6.1 Oocyte Electrophysiological Studies (Dr. Margot Earnst at the Medical University of 
Vienna)2 
To generate the respective mRNAs, cDNAs of rat GABAA receptor subunits (each α subunit with 
β3 and γ2, or α4 with β3 and δ) were used, which were then injected into Xenopus laevis oocytes 
(Nasco, Fort Atkinson, WI, USA) as described previously.209 For electrophysiological recordings, 
oocytes were placed on a nylon-grid in a bath of Xenopus Ringer solution (XR, containing (in 
mM): 90 NaCl, 5 HEPES-NaOH (pH 7.4), 1 MgCl2, 1 KCl and 1 CaCl2). The oocytes were impaled 
with two microelectrodes (2-3 mʊ, filled with 2 mM KCl) for current measurements. The oocytes 
were constantly washed by a flow of 6 ml/min XR, which could be switched to XR containing 
GABA and/or ligands (CMD-45 or XHe-III-74). Both ligands were diluted into XR from DMSO-
solutions which resulted in a final concentration of 0.1% DMSO. The ligands, CMD-45 and XHe-
III-74 were pre-applied for 30 sec prior to the addition of GABA, which was co-applied with the 
drugs until a peak response was observed. As identical peak responses were observed after pre- 
applied ligand compared to co-applied ligand, the datasets were completed by co-application of 
GABA at EC3 with the ligand. To ensure full recovery from desensitization, between two 
applications, oocytes were washed in XR for up to 15 minutes. All recordings were performed at 
room temperature at a holding potential of -60 mV using a Dagan TEV-200A two electrode voltage 
clamp or a Dagan CA-1B Oocyte Clamp (Dagan Corporation, Minneapolis, MN). Data were 
digitized and recorded using a Digidata 1322A data acquisition system (Axon Instruments, Union 




6.2 Mouse Tracheal Ring Organ Bath Experiments (Dr. Charles Emala at Columbia 
University)1,2 
Mouse tracheas were removed from WT and gabra4 KO mice and placed in modified Krebs- 
Henseleit (KH) buffer of the following composition in mM: 115 NaCl, 2.5 KCl, 1.91 CaCl2, 2.46 
MgSO4, 1.38 NaH2PO4, 25 NaHCO3, and 5.56 D-glucose at pH 7.4. The tracheas were then 
mounted on wire pins in a myograph system (DMT, Ann Arbor, MI) and held at a resting tension 
of 5 mN for one hour in buffer that was continuously bubbled with 95% O2/5% CO2 (buffer was 
exchanged every 15 minutes) at 37°C. By following this equilibration period, three acetylcholine 
(ACh) dose-response curves were constructed (100 nM-1 mM) with extensive buffer exchanges 
and a resetting of resting tension to 5 mN between dose-response challenges. After determining 
the ACh EC50 for each tracheal ring, the rings were contracted with their respective EC50 
concentration of ACh, their contraction force was allowed to plateau, and the rings were exposed 
to concentration ranges of CMD-45 (25 to 100 μM), XHe-III-74 (10 to 50 μM) or DMSO (0.2%; 
vehicle). The amount of residual contractile force was measured after 30 minutes and compared to 
the initial contractile force to determine the percent of relaxation. Each ring was only exposed to 
a single concentration of CMD-45, XHe-III-74, or DMSO once (multiple concentrations and/or 
compounds were not tested on the same ring). 
6.3 Human Airway Smooth Muscle Strip Organ Bath Experiments (Dr. Charles Emala at 
Columbia University)2 
Human ASM strips were dissected from trachea and mainstem bronchi samples and the epithelium 
was removed. Strips were suspended at 1.5 g resting tension in KH buffer with 10 EM 
indomethacin (to block endogenous release of prostanoids), as previously described (5-7). Briefly, 
strips were suspended in a water-jacketed, 2 ml glass organ baths at 37° C (Radnoti Glass 
119 
 
Technology, Inc., Monrovia, CA, USA) and attached to Grass FT03 force transducers (Grass 
Telefactor, West Warwick, RI) coupled to a computer using BioPac hardware and Acqknowledge 
7.3.3 software (Biopac Systems, Inc., Goleta, CA, USA). The KH buffer was continuously bubbled 
with 95% O2/5% CO2 and tissues were allowed to equilibrate at 1.5 g isotonic force for 1 hour with 
fresh KH buffer changes every 15 min.  
The ACh EC50 was calculated for each strip (based on three cycles of exposure to 100 nM-100 EM 
ACh). Tetrodotoxin (1 EM; antagonist of endogenous neuronal-mediated effects), pyrilamine (10 
EM; H1 histamine receptor antagonist), and MK571 (10 EM; leukotriene D4 antagonist) were then 
added to the buffer to eliminate potentially confounding effects of endogenous contractile 
mediators. Each strip was then contracted with its EC50 concentration of ACh. After the 
contractile force reached steady state, the strips were exposed to concentration ranges (10-100 μM) 
of CMD-45, XHe-III-74, or 0.2% DMSO. The amount of residual contractile force was measured 
after 30 minutes and compared to the initial contractile force to determine the percent of relaxation. 
Each strip was only exposed to CMD-45, XHe-III- 74, or DMSO once (multiple concentrations 
and/or compounds were not tested on the same strip). 
Separate human ASM organ bath experiments were conducted to determine if CMD-45 or XHe-
III-74 potentiated the relaxation induced by the β2-agonist albuterol (first-line asthma rescue 
therapy). In these studies, human ASM was contracted to a stable plateau of force with an EC50 
concentration of acetylcholine and then increasing concentrations of albuterol were added to each 
organ bath at 7 minute intervals (half-log increments 100 pM – 10 μM). Concurrent with the 500 
pM albuterol addition, a single exposure of CMD-45, XHe-III-74 (25 μM each) or vehicle (0.2% 




6.4 In Vivo Mouse Respiratory System Resistances Testing (Dr. Charles Emala at Columbia 
University)2 
In vivo airway resistances were assessed using a flexiVent FX1 module with an in-line nebulizer 
(SciReq, Montreal, QC, Canada), as described previously,1,237 using HDM-sensitized WT mice. 
Briefly, the mice were anesthetized with pentobarbital (i.p., 50 mg/kg), paralyzed with 
succinylcholine (i.p., 10 mg/kg), and mechanically ventilated via a tracheostomy (tidal volume 
10mg/kg, 150 breaths/min). Mice were nebulized by XHe-III-74 (25 μl, 10 mM) or vehicle (25% 
ethanol in PBS) 10 minutes prior to measuring respiratory system resistances (RRS) by the forced 
oscillatory technique during a graded, nebulized methacholine challenge (0-50 mg/ml). 
Throughout the experiment EKG and temperature monitoring were performed. Lung resistance 
values for each mouse at each methacholine dose represent an average of three measurements. 
 
6.5 In Vitro Human Airway Smooth Muscle Cell Calcium Dynamics (Dr. Charles Emala at 
Columbia University)2 
Primary human airway smooth muscle cells (collected from healthy lung transplantation donor 
tissue)238 were grown to 80% confluence as monolayers in phenol red-free 50%/50% DMEM/F12 
media containing 10% FBS and 1X antibiotics/antimycotics on clear-bottomed, black-walled 96 
well plates. The cells were incubated in serum-free basal media for 48 hours, prior to each 
experiment. The cells were then washed with Hank’s balanced salt solution (HBSS) containing the 
following in mM: NaCl 138, KCl 5.3, CaCl2 2.5, MgSO4 0.4, MgCl2 0.49, Na2HPO4 0.34, NaHCO3 
4.2, KH2PO4 0.44, dextrose 5.5, hepes 20, pH 7.4. Cells were then incubated in HBSS containing 
the calcium indicator Fura‐2 AM (5 μM; Life Technologies, Grand Island, NY, USA) for 45 
minutes at 37°C. Following the dye loading, cells were washed with HBSS three times, pretreated 
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with concentration ranges (10-50 μM) of CMD-45, XHe-III-74, or DMSO (0.1%), and allowed to 
rest 15 minutes at 37°C. The cells were then continuously excited (alternatively at 340 and 380 
nm) every 4 seconds and the resultant emission at 510 nM was recorded using a FlexStation3 
microplate reader (Molecular Devices, Sunnyvale, CA) at 37°C during the addition of 10 μM 
histamine using the injection feature of the FlexStation3. In separate experiments, after dye 
loading, the cells were washed with Hank’s balanced salt solution containing no calcium. The cells 
remained in this buffer during pretreated with 100 μM CMD-45, XHe-III-74, or DMSO (0.1%) 
and during fluorescent recording with histamine exposure. 
Experimental animals3 
The 5-10 week old male BALB/c and Swiss Webster mice (Charles River Laboratory, WIL, MA) 
and adult (425-450 g) male Hartley guinea pigs (Charles River Laboratory, WIL, MA) were used 
for the experiments. The animals were housed under specific pathogen free conditions, under 
standard conditions of humidity, temperature and a controlled 12 h light and dark cycle and had 
free access to food and water. All animal experiments were in compliance with the University of 
Wisconsin, Milwaukee or Columbia University Institutional Animal Care and Use Committees 
(IACUC). 
6.6 Microsomal Stability Assay Procedure (Revathi Kodali at UWM)3 
The 4 μL of 1 mM test compound at a final concentration of 10 μM in DMSO were preincubated 
at 37°C for 5 minutes on a digital heating shaking dry bath (Fischer Scientific, Pittsburgh, PA) in 
a mixture containing 282 μL of water, 80 μL of phosphate buffer (0.5 M, pH 7.4) 20 μL of NADPH 
Regenerating System Solution A (BD Bioscience, San Jose, CA) and 4 μL of NADPH 
Regenerating System Solution B (BD Bioscience, San Jose, CA) in a total volume of 391.2 μL. 
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Following preincubation, the reaction was initiated by addition of 8.8 μL of either human liver 
microsomes (BD Gentest, San Jose, CA) or mouse liver microsomes (Life technologies, Rockford, 
IL) at a protein concentration of 0.5 mg/mL. Aliquots of 50 μL were taken at time intervals of 0 
(without microsomes), 10, 20, 30, 40, 50 and 60 minutes. Each aliquot was added to 100 μL of 
cold acetonitrile solution containing 1 μM of verapamil HCl as an internal standard. This was 
followed by sonication for 10 seconds and centrifugation at 10,000 rpm for 5 minutes. Then 100 
μL of the supernatant was transferred into Spin-X HPLC filter tubes (Corning Incorporated, NY) 
and centrifuged at 13,000 rpm for 5 minutes. The filtrate was diluted 100 fold and subsequently 
analyzed by LC-MS/MS with a Shimadzu LCMS 8040, (Shimadzu Scientific Instruments, 
Columbia, MD). The ratio of the peak areas of the internal standard and the test compound was 
calculated for every time point and the natural log of the ratio was  plotted against time to determine 
the linear slope (k). The metabolic rate (k*C0/C), half-life (0.693/k), and internal clearance (V*k) 
were calculated, where k is the slope, C0 is the initial concentration of test compound, C is the 
concentration of microsomes, and V is the volume of incubation in μL per microsomal protein in 
mg. All experiments were repeated three times in duplicates. 
6.7 Cytotoxicity Assay (Dr. Michael Stephen and Dr. Gloria Forkuo at UWM)3 
Human liver hepatocellular carcinoma (HEPG2), human embryonic kidney 293T (HEK293T) and 
human bronchial epithelial (BEAS 2B) cell lines were purchased (ATCC) and cultured in 75 cm2 
flasks (CellStar). Cells were grown in DMEM/High Glucose (Hyclone, #SH3024301) media to 
which non-essential amino acids (Hyclone, #SH30238.01), 10 mM HEPES (Hyclone, 
#SH302237.01), 5 x 106 units of penicillin and streptomycin (Hyclone, #SV30010), and 10% of 
heat inactivated fetal bovine serum (Gibco, #10082147) were added. Cells were harvested using 
0.05% Trypsin (Hyclone, #SH3023601), washed with PBS, and dispensed into sterile white, 
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optical bottom 384-well plates (NUNC, #142762). After three hours, small molecule solutions 
were transferred with a Tecan Freedom EVO liquid handling system equipped with a 100 nL pin 
tool (V&P Scientific). The controls were 3-dibutylamino-1-(4-hexyl-phenyl)-propan-1-one (25 
mM in DMSO, positive control) and DMSO (negative control). The cells were incubated for 48 
hours followed by the addition of CellTiter-Glo™, a luminescence-based cell viability assay 
(Promega, Madison, WI). All luminescence readings were performed on a Tecan Infinite M1000 
plate reader. The assay was carried out in quadruplet with three independent runs. The data was 
normalized to the controls and analyzed by nonlinear regression (GraphPad Prism). 
6.8 Rotarod Assay (Nicholas Zahn at UWM)3 
The swiss Webster mice were trained to maintain balance at a constant speed of 15 rpm on the 
rotarod apparatus (Omnitech Electronics Inc. Nova Scotia, Canada) until mice could perform for 
3 min at three consecutive time points. Separate groups of mice received intraperitoneal (i.p.) 
injections of vehicle (10% DMSO, 40% propylene glycol and 50% PBS) or test compounds. 
Diazepam was used as a positive control compound (5 mg/kg) in an approximate volume of 100 
ml. Ten minutes after each injection, mice were placed on the rotarod for 3 min. A fail was assigned 
for each mouse 
that fell from the rotarod prior to 3 min. Mice were rested two to three days before administration 






6.9 Guinea Pig Airway Smooth Muscle Organ Bath (Dr. Charles Emala at Columbia 
University)3 
Guinea pigs were anesthetized with intraperitoneal pentobarbital (100 mg/kg). Their tracheas were 
then surgically removed and transected into cross-sectional sections containing two cartilaginous 
rings as described previously.15 The epithelium was removed with cotton swabs and the rings were 
suspended by two silk threads in 4 mL jacketed organ baths (Radnoti Glass Technology). One 
thread was attached to a Grass FT03 force transducer (Grass- Telefactor) coupled via Biopac 
hardware to a computer with Acknowledge 7.3.3 software (Biopac Systems) for continuous digital 
recording of muscle tension. The rings were bathed in 4 mL of KH buffer solution (composition 
in mM: 118 NaCl, 5.6 KCl, 0.5 CaCl2, 0.2 MgSO4, 25 NaHCO3, 1.3 NaH2PO4, 5.6 D-glucose) 
with 10 mM indomethacin (DMSO vehicle final concentration of 0.01%), which was continuously 
bubbled with 95% O2 and 5% CO2 at pH 7.4, at 37 
OC. The rings were equilibrated at 1 g of 
isotonic tension for 1 h with new KH buffer added every 15 min. All rings were precontracted with 
10 mM N-vanillylnonanamide (capsaicin analog) and then two cycles of cumulatively increasing 
concentrations of acetylcholine (0.1-100 µM) with extensive buffer washes between and after 
those two cycles with resetting of the resting tension to 1.0 g. To eliminate the confounding effects 
of airway nerves and histamine receptors, tetrodotoxin (1 µM) and pyrilamine (10 µM) were added 
to the buffer. After a stable baseline tension of 1.0 g was established, tracheal rings were contracted 
with 1 µM substance P. After the peak contraction was reached, 50 µM of compound 16 (or the 
vehicle control 0.1% DMSO) was added to each bath. The percentage of initial contraction 





6.10 Human Airway Smooth Muscle Organ Bath (Dr. Charles Emala at Columbia 
University)4 
The human trachea were obtained from healthy donor lungs incidental to lung transplantations and 
airway smooth muscle strips were dissected from them. All the studies were reviewed by the 
Columbia University IRB and deemed not to be human subject research. The strips were suspended 
as above in organ baths in oxygenated KH buffer at 37 °C at 1.5g of resting tension. This was 
followed by equilibration for 1h with buffer exchanges every 15 min, after which the strips were 
contracted with 3 cycles of increasing concentrations of acetylcholine (100 nM - 1 mM) with 
extensive buffer exchanges between and after these pre-contractile challenges. Before each strip 
was contracted to its individually calculated EC50 concentration of acetylcholine MK571 (10 μM), 
pyrilamine (10 μM) and tetrodotoxin (1 μM) were added to the buffer. When a plateau in the 
increase in contractile force was achieved (typically 15 min), 100 μM of test compound or its 
vehicle (0.2% ethanol) was added to the buffer and the maintenance of contractile force was 
continuously measured over 1h. The remaining contractile force at 15, 30, 45 and 60 min was 
expressed as a percentage of the initial acetylcholine-induced contractile force. 
6.11 Assessment of Airway Hyper-Responsiveness (Dr. Gloria Forkuo at UWM)3 
Airway hyper-responsiveness to methacholine in conscious, spontaneously breathing animals was 
measured by DSI's Buxco® FinePointe Non-Invasive Airway Mechanics (NAM) instrument.15 
Before measurements were taken, mice were acclimated to the chamber for 15 min daily for 5 
days. The chambers were also calibrated each time before data collection. Briefly, the nasal 
chamber in combination with the thoracic chamber permits computation of Specific Airway 
Resistance (sRaw). The FinePointe software computes sRaw with all other ventilatory parameters 
derived by the NAM analyzer. Mice were exposed to aerosolized PBS (for the baseline 
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measurement) or methacholine (1.56-12.5 mg/mL) for 1 min and readings were taken and averaged 
for 3 min after each nebulization. Data obtained were presented as sRaw versus aerosolized 
methacholine concentration (mg/ml). Data analysis was carried out using 2way ANOVA repeated 
measures with Bonferroni post-test. Overall p-value was 0.0937 and F = 1.763. The Bonferroni 
post-test gave significance for 12.5 mg methacholine as indicated in Figure 30. 
 
6.12 Pharmacokinetic Study (Revathi Kodali at UWM)3 
The female Swiss Webster mice received i.p. injections of vehicle or each ligand formulated in 
DMSO/ propylene glycol/ PBS, 10:40:50, v/v/v) and injected at a dose of 5 mg/kg. At different 
time points, the blood (collected into heparinized tubes, 50 μL of 1 mg/mL heparin), lungs, and 
brain were harvested and the samples were stored in liquid nitrogen until analysis. 
Blood samples were thawed on ice, vortexed for 10 seconds, and a 100 μL aliquot was taken and 
added to 400 μL cold acetonitrile containing [20 nM] internal standard 1 (Hz166). Samples were 
vortexed for 30 seconds and centrifuged at 13,000 RPM for 3 minutes. The supernatant layer was 
then transferred to clean tubes and evaporated overnight. The residue was reconstituted with 300 
μL of mobile phase and spin-filtered through 0.22 μm nylon centrifugal filter units (Costar). After 
reconstitution, verapamil (internal standard 2) was added and 5 μL of the sample was injected into 
the LC–MS/MS. 
The brain and lung tissue samples were stored in liquid nitrogen prior to homogenization and 
extraction. The whole organs were thawed over ice, weighed, and homogenized directly into 500 
μL of ACN containing internal standard 1 (HZ166) using a Benchmark Scientific BeadBug 
Homogenizer with three 3.2mm stainless steel beads. Samples were homogenized for 30 seconds, 
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and centrifuged for 3 minutes at 13,000 RPM. This process was repeated for a total of three 
extractions. 
The supernatants were combined and prepared in the same manner as the blood samples for LC-
MS/MS analysis. 
High performance liquid chromatography (HPLC) was performed with Shimadzu Nexera X2 
LC30AD series pumps (Shimadzu, Kyoto, Japan) that include a 20A5R degassing unit, SIL 30AC 
autosampler and a 20A column oven. Analytes were separated by a Restek Ultra Biphenyl II 
column (2.1 mm × 50 mm, 5 um particle size, Restek, California, US) under gradient elution at a 
flow rate of 0.6 mL/min. The mobile phase was acetonitrile and water (both containing 0.1% 
formic acid). Time program: 10% B → 99% B (3 min), hold at 99% B (3.75 min), return to 10% 
B (4 min), hold (4.5 min). Column Temperature: 50°C. 
Analytes were monitored under positive mode on a Shimadzu 8040 triple quadrupole mass 
analyzer (Shimadzu, Kyoto, Japan) electrospray (ESI) and atmospheric pressure ionization (APCI) 
run in dual (DUIS) mode. The following transitions were monitored in multiple reaction 
monitoring (MRM) mode. Ion transition pairs for 17 are 340.85 > 296.00, 340.85 > 277.95, 340.85 
> 268.10 and 340.85 > 227.15. Transition pairs for HZ-166 are m/z 356.90 > m/z 311.15, m/z 
356.90 > m/z 283.15, and m/z 356.90 > m/z 282.15. Transition pairs for verapamil (internal 
standard) are 454.70 > 165.15, 454.70 > 150.20, and 454.70 > 303.30. Collision energy was 
optimized for each transition to obtain optimal sensitivity. The mass spectrometer was operated 
with the heat block temperature of 400°C, drying gas flow of 15 L/min, desolvation line 
temperature of  250 °C, nebulizing gas flow of 1.5 L/min, and both needle and interface voltages 
of 4.5 kV. The response acquisition was performed using LabSolutions software. 
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The sample preparation of calibration standards and quality control for LC–MS/MS: HZ-166 was 
chosen as an internal standard (I.S.) because it has a similar chemical structure as that of 17 and 
was therefore used to account for sample dilution, evaporation, and matrix effects. Verapamil was 
also used as a second standard to monitor instrumental variations. The stock solutions of all were 
prepared at a concentration of 2 mg/mL separately in ACN and stored in a −20 °C freezer, with 
the exception of the acid which was prepared in 80:20 ACN:water. The intermediate working 
solutions of each were prepared by serial dilution with mobile phase (80:20, ACN:water with 0.1% 
formic acid). Calibration curve cocktails were prepared at concentrations of 1, 5, 10, 15, 25, 50, 
75, 100, and 150 nM. 
The intra-run/within-run validation was performed at concentrations of 10, 25 and 75 nM with 
three replicates for each concentration. For separate validations, separate standard curves were 
freshly prepared. The standard curves were fitted by a linear regression and the validation samples 
were calculated back by the calibration curve of that day. The mean and the coefficient of variance 
(CV) were calculated accordingly. Accuracy was calculated by comparing calculated 
concentrations to corresponding nominal. 
Pharmacokinetic parameters were calculated with PK solutions software 2.0 and fitted to the 
following equation: c = A•e-at + B•e-bt. Due to the rapid absorption two phases could be identified 







6.13 Patch clamp assay (Amanda Neiman at UWM)3  
HEK293T stably expressing α1β3γ2 GABAAR or α4β3γ2 were maintained RPMI 1640 medium with 
L-glutamine supplemented with 10% (v/v) fetal bovine serum and 1% penicillin/streptomycin. 
Automated patch-clamp studies were conducted as described previously.15 Briefly, the IonFlux 
plate layout consists of units of 12 wells: two wells contain intracellular solution (ICS containing 
140 mM CsCl, 1 mM CaCl2, 1 mM MgCl2, 11 mM EGTA, 10 mM HEPES, pH 7.2 with CsOH), 
one contains cells diluted in extracellular solution (ECS containing 140 mM NaCl, 5.4 mM KCl, 
1 mM CaCl2, 10 mM D-glucose monohydrate, and 10 mM HEPES, pH 7.4 with NaOH), eight 
contain different concentration of amide 16 in the presence of GABA at 0.1% DMSO. Well 1 is 
for waste collection. The cells are captured from suspension by applying suction to microscopic 
channels in ensemble recording arrays. Once the array is fully occupied, the applied suction breaks 
the membranes of captured cells, which establishes the whole cell voltage clamp. For compound 
applications, pressure is applied to the appropriate compound wells, which introduces the 
compound into the extracellular solution rapidly flowing over the cells. For recording GABAAR 
induced currents, cell arrays were voltage clamped at a hyperpolarizing holding potential of −80 
mV. Prior to use on the automated patch clamp, cells were centrifuged at 380g for 5 minutes and 
resuspended gently in ECS. This was repeated two more times before the cells were dispensed into 








7. Experimental  
7.1 5-Methoxyanthranilic acid (2) 
A solution of 2-nitro-5-methoxybenzoic acid 1 (60.3 g, 306 mmol) in EtOAc (1.5 L) was degassed 
under reduced pressure and refilled with argon (repeated 3 times). Palladium (10% w/w on carbon, 
3.9g, 1.2 mol%) was added to the above solution. The reaction flask was evacuated under reduced 
pressure and refilled with H2 from a balloon (repeated 3-4 times to make sure that the solution was 
saturated with H2). The reaction mixture was stirred at rt for 6 h. After the completion of the 
reaction (TLC, silica gel), the solution was filtered over a bed of celite to remove the Pd. The solids 
were washed with ethyl acetate. The solvent was removed under reduced pressure to yield acid 2 
as a yellow solid in 97% (49.7 g) yield: M.p = 147-149 ˚C; 1H NMR (300 MHz, CDCl3) δ 3.66 (s, 
3H), 6.71 (d, 1H, J = 9.0 Hz), 6.94 (dd, 1H, J = 9.0 Hz, 3.0 Hz), 7.19 (d, 1H, J = 3.0 Hz), 8.40 (bs, 
2H). The spectral data matched the reported values16. This material was employed directly in the 
next step. 
7.2 5-Methoxyisatoic anhydride (3) 
The 5-methoxyanthranilic acid 2 (30 g, 179 mmol) was dissolved in a mixture of H2O (1.2 L) and 
conc HCl (15 mL), and this was followed by the addition of triphosgene (63.8 g, 215 mmol). The 
contents were stirred at rt for 3-4 h until the completion of the reaction (TLC, silica gel).  A white 
solid precipitated from the solution after completion. The solids were collected by filtration and 
washed with H2O (4 L). The solids were dried under vacuum to give pure anhydride 3 in 89% 
(30.7 g) yield: M.p = 237-239 ˚C; 1H NMR (300 MHz, CDCl3) δ 3.65 (s, 3H), 7.11 (d, 1H, J = 8.9 
Hz), 7.35 (dd, 1H, J = 8.9 Hz, 2.7 Hz), 7.19 (d, 1H, J = 2.7 Hz), 11.61 (bs, 1H). The spectral data 
were identical with the reported values16. This material was employed directly in the next step. 
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Triphosgene reacts to give toxic phosgene; care must be exercised. The phosgene itself smells 
like new mown hay. Do not breath it. 
7.3 (S)-2,3-Dihydro-7-methoxy-1H-pyrrolo[2,1-c][1,4]benzodiazepine-5,11(10H,11aH)-dio-
ne (4)  
A mixture of 5-methoxyisotoic anhydride 3 (30.7 g, 158.9 mmol) and L-proline (20.2 g, 174.8 
mmol) in dry DMSO (300 mL) was heated with stirring at 160 ̊ C for 2 h. The white turbid reaction 
mixture, which resulted, became a clear brown solution as the temperature was increased to above 
80 ˚C. After the completion of the reaction, on examination by TLC (silica gel), the solution was 
cooled to rt. The mixture was poured into 250 mL of ice water to yield benzodiazepine 4 as a white 
solid. The solids were collected by vacuum filtration and washed with ice cold water (2 X 50 mL). 
The filtrate was extracted with ethyl acetate and the solvent was removed under reduced pressure 
to yield solid diazepine 4.  The combined solids were dried in a vacuum oven at 80 ˚C for 4 h. The 
yield of 4 was 96% (37.9 g): M.p = 214-216 ˚C; [α]D
25= +444.40 (c 1%, in CH2Cl2); 
1H NMR (300 
MHz, CDCl3) δ 1.82-2.01 (m, 3H), 2.50-2.51 (m, 1H), 3.40-3.49 (m, 1H), 3.56-3.63 (m, 1H), 3.78 
(s, 3H), 4.07-4.10 (m, 1H), 7.07 (d, 1H, J = 8.7 Hz), 7.13 (dd, 1H, J = 8.7 Hz, 3.0 Hz), 7.26 (d, 
1H, J = 3.0 Hz), 10.30 (bs, 1H). The spectral data were identical to the reported values16. This 
material was employed directly in the next step. 
7.4 (S)-Ethyl-7-methoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]pyrrolo-
[1,2-a][1,4]diazepine-1-carboxylate (5)  
A well dried reaction flask was evacuated completely and flushed with argon. The flask was then 
charged with diazepine 4 (37 g, 150.2 mmol) in dry THF (800 mL). The turbid solution was cooled 
to -20 ˚C. Potassium tert-butoxide (good material, 33.7 g, 300.4 mmol) was added to the flask and 
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the solution was stirred at rt for 1 h. Good diethyl chlorophosphate (43.4 mL, 300.4 mmol) was 
then slowly added to the reaction mixture at -20 ˚C and it was allowed to stir at rt over a period of 
2-3 h. The cloudy reaction mixture became a clear golden-brown solution. After complete 
consumption of the starting material 4 (TLC, silica gel), the reaction was cooled to -20 ˚C, after 
which ethyl isocyanoacetate (32.8 mL, 300.4 mmol) and potassium tert-butoxide (33.7 g, 300.4 
mmol) were added. The reaction mixture was stirred at rt for 8 h. The reaction was quenched with 
a saturated aq solution of NaHCO3 (80 mL). The THF was removed under reduced pressure and 
the aq layer was extracted with CH2Cl2 (300 mL X 3). The combined organic layer was separated 
and washed with brine (400 mL) and dried (Na2SO4). The CH2Cl2 was removed under reduced 
pressure and the dark brown pasty liquid residue, which resulted, was washed with ether to yield 
the crude ethyl ester 5. This crude solid was recrystallized from CH2Cl2 to yield ethyl ester 5 as a 
pure white solid in 60% (30.85 g) yield: M.p = 195-197 ˚C; (Lit. report: 175-176 ˚C)16; [α]D
25= 
+18.00 (c 0.5%, in CH2Cl2); 
1H NMR (300 MHz, CDCl3) δ 1.44 (t, 3H, J = 7.2 Hz),  2.15-2.31 (m, 
3H), 3.49-3.61 (m, 2H), 3.75-3.85 (m, 1H), 3.91 (s, 3H), 4.41 (q, 2H, J = 7.2 Hz), 4.75 (d, 1H, J = 
6.9 Hz), 7.15 (dd, 1H, J = 8.9 Hz, 3.0 Hz), 7.32 (d, 1H, J = 8.9 Hz), 7.59 (d, 1H, J = 3.0 Hz), 7.82 
(s, 1H); 13C NMR (75 MHz, CDCl3) δ 14.3, 24.3, 28.4, 46.6, 53.4, 55.8, 61.2, 114.5, 119.7, 124.6, 
126.0, 127.3, 130.6, 135.8, 137.6, 159.4, 162.6, 163.7; HRMS (ESI) (M+Na)+, calcd. for 
C18H19N3O4Na 364.1273; Found 364.1279. The spectral data were identical to the reported 
values16. This material was employed directly in the next step. 
7.5 (S)-Ethyl-7-hydroxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]pyrrolo-
[1,2-a][1,4]diazepine-1-carboxylate (6)  
In an oven dried round bottom flask, dry CH2Cl2 (50 ml) was added and it was cooled to 0 ˚C.  
Then AlCl3 (3 g, 22.8 mmol) and good ethanethiol (4.5 ml, 60.8 mmol) were added to the above 
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flask slowly at 0 ˚C. The ice bath was removed and the reaction was allowed to warm to rt. After 
the AlCl3 dissolved completely, ester 5 (2.6 g, 7.62 mmol) was added to the mixture at rt and the 
mixture was stirred for 24 h under Ar. The reaction time will vary with the scale of the reaction. 
After completion of the reaction (TLC, silica gel), the solution was poured onto ice and was 
acidified using an aq 2N HCl solution. The solution was extracted 7 times with CH2Cl2 and 4 times 
with EtOAc, separately. Since the product was soluble in water, the extraction procedure was 
carried out until there was no more product observed in the aq layer (TLC, silica gel). The 
combined organic layer was washed with brine and dried (Na2SO4). The solvent was removed 
under reduced pressure and the residue was purified by flash column chromatography on [silica 
gel, 4% MeOH in CH2Cl2] to furnish the phenolic ethyl ester 6 as a solid (2.1 g) in 84% yield: M.p 
= >260 ˚C (decomp.); 1H NMR (300 MHz, CDCl3) δ 1.44 (t, 3H, J = 7.1 Hz),  2.19-2.42 (m, 3H), 
3.55-3.64 (m, 2H), 3.81-3.89 (m, 1H), 4.42 (q, 2H, J = 7.1 Hz), 4.82 (d, 1H, J = 7.3 Hz), 7.13 (dd, 
1H, J = 8.7 Hz, 2.6 Hz), 7.27-7.31 (m, 1H), 7.85 (s, 1H), 7.91 (d, 1H, J = 2.6 Hz), 9.22 (s, 1H); 
13C NMR (75 MHz, CDCl3) δ 14.3, 24.4, 28.4, 46.9, 53.8, 61.2, 117.5, 120.8, 124.9, 125.2, 127.7, 




To a solution of phenol 6 (1.5 g, 4.6 mmol) in CH2Cl2 (30 mL), Cs2CO3 (3 g, 9.2 mmol) was added 
and the mixture stirred at rt for 30 min. Then CD3I (2.3 ml, 36.8 mmol) was added slowly and the 
reaction mixture was stirred at rt for 24 h. After completion of the reaction (TLC, silica gel), the 
mixture was quenched with cold water and extracted with CH2Cl2. The combined organic layer 
was washed with brine and dried (Na2SO4). The solvent was removed under reduced pressure and 
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the residue was purified by flash column chromatography [silica gel, 2% CH3OH in CH2Cl2] to 
furnish ester 5a as a solid (1.36 g) in 86% yield: M.p = 195-196 ˚C; [α]D
25= +20.00 (c 0.5%, in 
CH2Cl2); 
1H NMR (300 MHz, CDCl3) δ 1.46 (t, 3H, J = 7.1 Hz),  2.17-2.36 (m, 3H), 3.54-3.63 
(m, 2H), 3.77-3.84 (m, 1H), 4.43 (q, 2H, J = 7.1 Hz), 4.77 (d, 1H, J = 7.3 Hz), 7.16 (dd, 1H, J = 
8.8 Hz, 2.8 Hz), 7.33 (d, 1H, J = 8.8 Hz), 7.60 (d, 1H, J = 2.8 Hz), 7.82 (s, 1H); 13C NMR (75 
MHz, CDCl3) δ 14.3, 24.3, 28.3, 46.5, 53.4, 61.1, 114.4, 119.7, 124.5, 126.0, 127.6, 130.5, 135.8, 
137.6, 159.3, 162.8, 163.7; HRMS (ESI) (M+H)+, calcd. for C18H17
2H3N3O4 345.1637; Found 
345.1635. The 13C-D signal was not observed due to the long relaxation time, line broadening, 
reduced NOE effect, and spin-spin coupling.  
7.7 (S)-tert-Butyl-7-methoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]py-
rolo[1,2-a][1,4]diazepine-1-carboxylate (7) 
A flame dried round bottom flask was charged with dry THF (30 mL) and lithium rod (excess, cut 
into small pieces) was added.  Dry tert-butanol (2.6 mL, 27.1 mmol) was added to the above flask 
at rt and the mixture which resulted was heated to 45-50 ˚C under Ar until the tert-butanol reacted 
completely. This freshly prepared lithium tert-butoxide solution was transferred carefully with a 
cannula to another flame dried round bottom flask charged with ester 5 (1.0 g, 2.71 mmol) and 
stirred at 50 ˚C under Ar for 30 min. After the completion of the reaction (TLC, silica gel), the 
flask was cooled to rt and the THF removed under reduced pressure. Ice water (10 mL) was added 
to the residue and it was then extracted with EtOAc. The organic layer was washed with water (2 
X 10 mL) and brine (15 mL). The solvent was removed under reduced pressure and the residue 
was purified by flash column chromatography [silica gel, EtOAc/hexane (7:3)] to yield tert-butyl 
ester (XHE-III-74) 7 as a solid ( 0.72 g) in 67% yield: M.p = 115-117 ˚C (119-121 ˚C)16; [α]D
25= 
+36.00 (c 0.5%, in CH2Cl2); 
1H NMR (300 MHz, CDCl3) δ 1.63 (s, 9H),  2.14-2.28 (m, 3H), 3.47-
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3.61(m, 2H), 3.74-3.81 (m, 1H), 3.90 (s, 3H), 4.73 (d, 1H, J = 6.9 Hz), 7.14 (dd, 1H, J = 8.8 Hz, 
3.0 Hz), 7.30 (d, 1H, J = 8.8 Hz), 7.57 (d, 1H, J = 3.0 Hz), 7.83 (s, 1H); 13C NMR (75 MHz, CDCl3) 
δ 24.3, 28.2, 28.3, 46.7, 53.4, 55.9, 81.9, 114.5, 119.7, 124.6, 126.1, 128.9, 130.5, 135.6, 136.5, 
159.4, 162.2, 163.8; HRMS (ESI) (M+Na)+, calcd. for C20H23N3O4Na 392.1586; Found 392.1574. 
The spectral data were identical to the reported values.17 
Alternative Synthesis: The acid 9a (0.1 g, 0.32 mmol) was suspended in dry toluene (15 ml) in 
an oven dried round bottom flask and the mixture which resulted, was heated to reflux. N,N-
dimethylformamaide di-tert-butyl acetal (0.3 ml, 1.28 mmol) was added dropwise to the above 
refluxing mixture. The mixture was refluxed until the reaction was complete (30 mins, confirmed 
by TLC, silica gel). After that, the reaction mixture was cooled to rt, and then quenched with an 
ice cold aq NaHCO3 solution followed by extraction with EtOAc (2x 10 mL). The combined 
organic layer was washed with brine and dried (Na2SO4). The solvent was then removed under 
reduced pressure and the residue was purified by flash column chromatography [silica gel, 
EtOAc/hexane (7:3)] to yield tert-butyl ester (XHE-III-74) 7 as a solid (0.07 g) in 60% yield. 
7.8 (S)-tert-Butyl-7-(2H3)-methoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-
c]pyrolo[1,2-a][1,4]diazepine-1-carboxylate (7a) 
The tert-butyl ester 7a was prepared from ethyl ester 5a by following the same procedure 
employed for preparation of tert-butyl ester 7 in 67% yield: M.p = 114-115 ˚C; 1H NMR (300 
MHz, CDCl3) δ 1.65 (s, 9H),  2.15-2.34 (m, 3H), 3.50-3.63 (m, 2H), 3.77-3.84 (m, 1H), 4.75 (d, 
1H, J = 7.2 Hz), 7.15 (dd, 1H, J = 8.8 Hz, 2.8 Hz), 7.27-7.32 (m, 1H), 7.59 (d, 1H, J = 2.8 Hz), 
7.79 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 24.4, 28.2, 28.4, 46.7, 53.5, 81.8, 114.4, 119.8, 124.6, 
126.3, 129.3, 130.6, 135.7, 136.5, 159.3, 162.6, 163.8; HRMS (ESI) (M+H)+, calcd. for 
C20H21





 The tert-butyl ester 8 was prepared from phenolic ethyl ester 6 following the same procedure 
employed for the preparation of tert-butyl ester 7 in 65% yield:  M.p = 174-175 °C; 1H NMR (300 
MHz, CDCl3) δ 1.63 (s, 9H),  2.09-2.34 (m, 3H), 3.50-3.62 (m, 2H), 3.77-3.85 (m, 1H), 4.79 (d, 
1H, J = 7.1 Hz), 7.10 (dd, 1H, J = 8.6 Hz, 2.2 Hz), 7.23-7.28 (m, 1H), 7.77 (bs, 1H), 7.85 (s, 1H), 
9.75 (bs, 1H); 13C NMR (75 MHz, CDCl3) δ 24.4, 28.2, 28.3, 46.9, 53.7, 82.0, 117.4, 120.7, 124.9, 
125.1, 129.1, 129.6, 135.8, 136.2, 157.7, 162.3, 164.6; HRMS (ESI) (M+H)+, calcd. for 
C19H22N3O4 356.1605; Found 356.1615. 
7.10 (S)-7-Methoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]pyrrolo[1,2-
a][1,4]diazepine-1-carboxylic acid (9) 
The ester 5 (2.12 g, 6.21 mmol) was dissolved in a mixture of EtOH (4 mL) and H2O (3 mL), after 
which solid NaOH (1.2 g, 31.0 mmol) was added to the solution. This reaction mixture was heated 
to 50 ̊ C for 15 min and the EtOH was removed under reduced pressure. The remaining aq solution 
was stirred at 0 ˚C for 10 min and then conc HCl was added dropwise to the solution until the pH 
was 3-4 (pH paper). A pale yellow precipitate which formed was left in the solution and the mixture 
was allowed to stir at rt for 2 h. The precipitate was collected by filtration, washed with cold water 
(2 X 5 mL), and the aq layer also was allowed to stand at rt for 10 h to obtain additional solid 9. 
The combined solids were dried in a vacuum oven at 80 ˚C for 7 h to get pure acid 9 in 80 % yield: 
M.p = 210-211 ˚C; [α]D
25= +8.00 (c 0.25%, in CH3OH); 
1H NMR (300 MHz, DMSO) δ 2.03-2.16 
(m, 3H),  3.50-3.63 (m, 3H), 3.87 (s, 3H), 4.84 (d, 1H, J = 7.5 Hz), 7.31 (dd, 1H, J = 8.9 Hz, 3.0 
Hz), 7.41 (d, 1H, J = 3.0 Hz), 7.63 (d, 1H, J = 8.9 Hz), 8.21 (s, 1H); 13C NMR (75 MHz, DMSO) 
δ 24.9, 28.7, 47.3, 53.6, 56.8, 115.3, 119.9, 126.7, 127.0, 128.6, 131.0, 137.4, 137.5, 159.5, 164.0, 
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165.3; HRMS (ESI) (M+H)+, calcd. for C16H16N3O4 314.1141; Found 314.1141. The spectral data 
were identical to the reported values16. This material was employed directly in the next step. 
7.11 (S)-11,12,13,13a-Tetrahydro-7-(2H3)-methoxy-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-c]-
[1,4]benzodiazepine-1-carboxylic acid (9a)  
The acid 9a was prepared from ester 5a following the procedure employed for the preparation of 
acid 9 in 82% yield: M.p = 210-212 ˚C; [α]D
25= +8.00 (c 0.25%, in CH3OH); 
1H NMR (300 MHz, 
CDCl3) δ 2.17-2.34 (m, 3H), 3.48-3.83 (m, 3H), 4.72 (d, 1H, J = 7.1 Hz), 7.17 (dd, 1H, J = 8.7 Hz, 
2.3 Hz), 7.31-7.35 (m, 1H), 7.60 (d, 1H, J = 2.3 Hz), 7.82 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 
24.4, 28.5, 46.7, 53.2, 114.7, 119.8, 124.5, 125.7, 126.7, 130.8, 134.8, 137.5, 159.7, 161.5, 163.6; 
HRMS (ESI) (M+H)+, calcd. for C16H13
2H3N3O4 317.1324; Found 317.1328. This material was 
employed directly in a later step. 
7.12 (S)-Methyl-7-methoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]pyro-
lo[1,2-a][1,4]diazepine-1-carboxylate (10)  
To an oven dried two neck round bottom flask, ethyl ester 5 (0.30 g, 0.87 mmol) was added in dry 
methanol (10 mL) and then NaOMe (0.2g, 3.48 mmol) was added to the solution. The mixture was 
heated to reflux until the reaction was complete (~1h, confirmed by TLC, silica gel). Then the 
reaction mixture was quenched with an ice cold aq NaHCO3 solution. The solvent was removed 
under reduced pressure and the residue was dissolved in water and extracted with EtOAc (2x 20 
mL). The combined organic layer was then washed with brine and dried (Na2SO4). The solvent 
was removed under reduced pressure and the residue was purified by flash column 
chromatography [silica gel, EtOAc/hexane (1:1)] to yield pure methyl ester 10 as a solid (0.286 g) 
in 93% yield: M.p = 180-182 ̊ C; [α]D
25= +8.00 (c 0.25%, in CH2Cl2); 
1H NMR (300 MHz, CDCl3) 
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δ 2.16-2.35 (m, 3H), 3.52-3.61 (m, 2H), 3.75-3.81 (m, 1H), 3.91 (s, 3H), 3.94 (s, 3H), 4.75 (d, 1H, 
J = 6.9 Hz), 7.16 (dd, 1H, J = 8.7 Hz, 2.7 Hz), 7.34 (d, 1H, J = 8.7 Hz), 7.59 (d, 1H, J = 2.7 Hz), 
7.88 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 24.4, 28.4, 46.6, 52.2, 53.4, 55.9, 114.5, 119.8, 124.7, 
125.9, 126.9, 130.6, 135.9, 137.9, 159.5, 162.9, 163.7. HRMS (ESI) (M+Na)+, calcd. for 
C17H17N3O4Na 350.1117; Found 350.1125. 
7.13 (S)-Methyl-7-(2H3)-methoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]-
pyrolo-[1,2-a][1,4]diazepine-1-carboxylate (10a)  
The methyl ester 10a was prepared from acid 5a following the procedure employed for preparation 
of methyl ester 10 in 97% yield: M.p = 182-183 ˚C; 1H NMR (300 MHz, CDCl3) δ 2.17-2.37 (m, 
3H), 3.50-3.63 (m, 2H), 3.75-3.83 (m, 1H), 3.95 (s, 3H), 4.76 (d, 1H, J = 7.0 Hz), 7.17 (dd, 1H, J 
= 8.8 Hz, 2.9 Hz), 7.34 (d, 1H, J= 8.8 Hz), 7.60 (d, 1H, J = 2.9 Hz), 7.82 (s, 1H); 13C NMR (75 
MHz, CDCl3) δ 24.4, 28.4, 46.6, 52.2, 53.5, 114.5, 119.8, 124.6, 126.0, 127.3, 130.6, 135.9, 137.9, 
159.4, 163.2, 163.7. HRMS (ESI) (M+H)+, calcd. for C17H15
2H3N3O4 331.1480; Found 331.1486. 
7.14 General method for the synthesis of esters and amides (11, 11a- 19, and 19a) 
A mixture of acid (9 or 9a, 0.32 mmol) individually, thionyl chloride (5.12 mmol) and dry CH2Cl2 
(8 mL) was added to an oven dried round bottomed flask under argon. This suspension was allowed 
to reflux at 52 ˚C (the outside oil bath temperature was at 60 ˚C) for 1 h under an atmosphere of 
argon. The solution became a clear yellow color. The absence of the starting material was 
confirmed by the examination by TLC (silica gel). The organic solvent and excess thionyl chloride 
were removed under reduced pressure. This evaporation was repeated a couple of times with dry 
CH2Cl2 (5 mL) to remove excess thionyl chloride and any HCl. The yellow residue, which was 
obtained, was dissolved in dry CH2Cl2 (10 mL) and cooled to 0 ˚C for 10 min under argon. The 
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appropriate nucleophile (alcohol/thiol/amine, 3.2 mmol), followed by Et3N (1.6 mmol) was added 
to the reaction mixture at 0˚C and the mixture was then allowed to warm to rt and stirred for 2-7 
h. After the completion of the reaction (TLC, silica gel), the solvent was removed under reduced 
pressure. The residue was quenched with ice cold water (5 mL) and extracted with CH2Cl2 (8 mL 
X 2). The combined organic layer was washed with brine (5 mL). The solvent was removed under 
reduced pressure and the residue was purified by flash column chromatography (silica gel) to yield 
the corresponding pure esters, thioesters and amides whose properties are depicted below. Note: 
We observed in a control experiment that the mixture of dichloromethane plus thionyl 
chloride boils at 52 ˚C. 
7.15 (S)-Isobutyl-7-methoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]pyro-
lo[1,2-a][1,4]diazepine-1-carboxylate (11) 
The isobutyl ester 11 was prepared from acid 9 following the general procedure with dry isobutanol 
as the nucleophile. The crude residue was purified by flash column chromatography [silica gel, 
EtoAc/hexane (7:3)] to yield pure isobutyl ester 11 as a solid in 70% yield: M.p = 126-127 ˚C 
(104-106 ˚C)16;  1H NMR (300 MHz, CDCl3) δ 1.04 (d, 6H, J = 6.7 Hz), 2.13-2.37 (m, 4H), 3.49-
3.63 (m, 2H), 3.76-3.84 (m, 1H), 3.92 (s, 3H), 4.14 (d, 2H, J = 6.9 Hz), 4.76 (d, 1H, J = 6.9 Hz), 
7.17 (dd, 1H, J= 8.8 Hz, 2.9 Hz), 7.33 (d, 1H, J = 8.8 Hz), 7.60 (d, 1H, J = 2.9 Hz), 7.82 (s, 1H); 
13C NMR (75 MHz, CDCl3) δ 19.3, 24.4, 27.8, 28.4, 46.6, 53.5, 55.9, 71.2, 114.5, 119.8, 124.6, 
126.2, 127.8, 130.6, 135.9, 137.6, 159.4, 163.1, 163.8. HRMS (ESI) (M+Na)+, calcd. for 






c]py-rrol-o[1,2-a][1,4]diazepine-1-carboxylate (11a)  
The isobutyl ester 11a was prepared from acid 9a following the general procedure with dry 
isobutanol as the nucleophile. The crude residue was purified by flash column chromatography 
[silica gel, EtOAc/hexane (7:3)] to yield pure isobutyl ester 11a as a solid in 61% yield: M.p = 
125-127 ˚C; 1H NMR (300 MHz, CDCl3) δ 1.03 (d, 6H, J = 6.7 Hz), 2.12-2.31 (m, 4H), 3.51-3.62 
(m, 2H), 3.76-3.82 (m, 1H), 4.14 (d, 2H, J = 6.9 Hz), 4.76 (d, 1H, J = 6.9 Hz), 7.16 (dd, 1H, J = 
8.8 Hz, 2.9 Hz), 7.32 (d, 1H, J = 8.8 Hz), 7.59 (d, 1H, J = 2.9 Hz), 7.81 (s, 1H); 13C NMR (75 
MHz, CDCl3) δ 19.1, 24.2, 27.6, 28.2, 46.4, 53.3, 71.0, 114.3, 119.5, 124.5, 125.9, 127.5, 130.4, 




benzo[e]-imidazo[5,1-c]pyrrolo[1,2-a][1,4]diazepine-1-carboxylate (12)  
The hexafluoro isopropyl ester 12 was prepared from acid 9 following the general procedure with 
dry 1,1,1,3,3,3-hexafluoropropan-2-ol as the nucleophile. The crude residue was purified by flash 
column chromatography [silica gel, EtOAc/hexane (1:1)] to yield pure ester 12 as a solid in 95% 
yield: M.p = 204-205 ˚C; [α]D
25= +16.67 (c 0.3%, in CH2Cl2); 
1H NMR (300 MHz, CDCl3) δ 2.16-
2.29 (m, 3H), 3.38-3.40 (m, 1H), 3.52-3.62 (m, 1H), 3.79-3.85 (m, 1H), 3.92 (s, 3H), 4.77 (d, 1H, 
J = 7.3 Hz), 5.98-6.08 (m, 1H), 7.18 (dd, 1H, J = 8.8 Hz, 2.8 Hz), 7.33 (d, 1H, J = 8.8 Hz), 7.61 
(d, 1H, J = 2.8 Hz), 7.87 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 24.3, 28.3, 46.6, 53.4, 55.9, 66.7 
(sep, J = 34.5 Hz), 114.7, 119.9, 120.6 (q, J = 279 Hz), 124.3, 124.6, 125.6, 130.6, 136.8, 140.6, 





9H-benzo[e]imidazo[5,1-c]pyrrolo[1,2-a][1,4]diazepine-1-carboxylate (12a)  
The hexafluoro isopropyl ester 12a was prepared from acid 9a following the general procedure 
with dry 1,1,1,3,3,3-hexafluoropropan-2-ol as the nucleophile. The crude residue was purified by 
column chromatography [silica gel, EtOAc/hexane (7:3)] to yield pure ester 12a as a solid in 97% 
yield: M.p = 204-206 ˚C; 1H NMR (300 MHz, CDCl3) δ 2.15-2.34 (m, 3H), 3.38-3.42 (m, 1H), 
3.53-3.63 (m, 1H), 3.80-3.86 (m, 1H), 4.79 (d, 1H, J = 7.3 Hz), 5.98-6.10 (sep, 1H, J = 6.1 Hz), 
7.19 (dd, 1H, J = 8.8 Hz, 2.9 Hz), 7.34 (d, 1H, J = 8.8 Hz), 7.62 (d, 1H, J = 2.9 Hz), 7.89 (s, 1H); 
13C NMR (75 MHz, CDCl3) δ 24.3, 28.3, 46.6, 53.4, 66.7 (sep, J = 34.5 Hz), 114.6, 119.9, 120.6 
(q, J =  = 279 Hz), 124.3, 124.6, 125.6, 130.6, 136.8, 140.6, 159.5, 159.7, 163.6; HRMS (ESI) 
(M+Na)+, calcd. for C19H13
2H3F6N3O4 467.1228; Found 467.1230.  
7.19 (S)-S-Ethyl-7-methoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]pyrr-
olo[1,2-a][1,4]diazepine-1-carbothioate (13) 
The thio ethyl ester 13 was prepared from acid 9 following the general procedure with dry 
ethanethiol as the nucleophile. The crude residue was purified by flash column chromatography 
[silica gel, EtOAc/hexane (8:2)] to yield pure thio ester 13 as a solid in 70% yield: M.p = 228-230 
˚C; [α]D
25= -14.29 (c 0.28%, in CH2Cl2); 
1H NMR (300 MHz, CDCl3) δ 1.35 (t, 3H, J = 7.4 Hz), 
2.14-2.25 (m, 3H), 3.00 (q, 2H, J = 7.4 Hz), 3.42-3.60 (m, 2H), 3.74-3.82 (m, 1H), 3.91 (s, 3H), 
4.71 (d, 1H, J = 7.2 Hz), 7.15 (dd, 1H, J = 8.8 Hz, 2.8 Hz), 7.31 (d, 1H, J = 8.8 Hz), 7.59 (d, 1H, 
J = 2.8 Hz), 7.79 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 14.6, 23.1, 24.4, 28.6, 46.5, 53.3, 55.9, 
114.5, 119.8, 124.5, 125.9, 130.6, 132.5, 134.6, 135.5, 159.5, 163.6, 188.1. HRMS (ESI) (M+Na)+, 





The thio ethyl ester 13a was prepared from 9a following the general procedure with dry ethanethiol 
as the nucleophile. The crude residue was purified by flash column chromatography [silica gel, 
EtOAc/hexane (8:2)] to yield pure thio ester 13a as a solid in 80% yield: M.p = 229-231 ˚C; 1H 
NMR (300 MHz, CDCl3) δ 1.36 (t, 3H, J = 7.4 Hz), 2.18-2.26 (m, 3H), 3.02 (q, 2H, J = 7.4 Hz), 
3.44-3.61 (m, 2H), 3.76-3.83 (m, 1H), 4.73 (d, 1H, J = 6.9 Hz), 7.17 (dd, 1H, J = 8.8 Hz, 2.9 Hz), 
7.33 (d, 1H, J = 8.8 Hz), 7.60 (d, 1H, J = 2.9 Hz), 7.81 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 14.6, 
23.1, 24.4, 28.6, 46.5, 53.4, 114.6, 119.8, 124.5, 125.9, 130.7, 133.6, 134.6, 135.5, 159.5, 163.6, 
188.1. HRMS (ESI) (M+H)+, calcd. for C18H17
2H3N3O3S 361.1408; Found 361.1405. 
7.21 (S)-S-tert-Butyl-7-methoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]-
pyrolo[1,2-a][1,4]diazepine-1-carbothioate (14)  
The thio tert-butyl ester 14 was prepared from acid 9 following the general procedure with dry 
tert-butyl mercaptan as the nucleophile. The crude residue was purified by flash column 
chromatography [silica gel, EtOAc/hexane (8:2)] to yield pure thio ester 14 as a solid in 82% yield: 
M.p = 130-132 ˚C; [α]D
27= -23.54 (c 0.17% in CH2Cl2); 
1H NMR (300 MHz, CDCl3) δ 1.57 (s, 
9H),  2.18-2.20 (m, 3H), 3.41-3.59 (m, 2H), 3.74-3.80 (m, 1H), 3.90 (s, 3H), 4.69 (d, 1H, J = 7.2 
Hz), 7.14 (dd, 1H, J = 8.9 Hz, 3.0 Hz), 7.29 (d, 1H, J = 8.9 Hz ), 7.58 (d, 1H, J = 3.0 Hz), 7.74 (s, 
1H); 13C NMR (75 MHz, CDCl3) δ 24.3, 28.5, 29.7, 46.4, 47.1, 53.3, 55.8, 114.4, 119.6, 124.5, 
125.9, 130.5, 134.2, 135.1, 159.3, 163.5, 188.7 ; HRMS (ESI) (M+H)+, calcd. for C20H24N3O3S 




[5,1-c]pyrrolo[1,2-a][1,4]diazepine-1-carbothioate (14a)  
The thio tert-butyl ester 14a was prepared from 9a following the general procedure with dry tert-
butyl mercaptan as the nucleophile. The crude residue was purified by flash column 
chromatography [silica gel, EtOAc/hexane (1:1)] to yield pure thio ester 14a as a solid in 89% 
yield: M.p = 129-131 ˚C; 1H NMR (300 MHz, CDCl3) δ 1.52 (s, 9H),  2.11-2.20 (m, 3H), 3.31-
3.53 (m, 2H), 3.69-3.75 (m, 1H), 4.67 (d, 1H, J = 5.9 Hz), 7.08-7.13 (m, 1H), 7.26-7.30 (m, 1H), 
7.52 (d, 1H, J = 2.0 Hz), 7.72 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 24.4, 28.6, 29.8, 46.5, 47.1, 
53.4, 114.5, 119.7, 124.6, 126.0, 130.6, 134.3, 134.4, 135.2, 159.4, 163.6, 188.8 ; HRMS (ESI) 
(M+H)+, calcd. for C20H21
2H3N3O3S 389.1721; Found 389.1725.  
7.23 (S)-7-Methoxy-N-methyl-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]-
pyrolo[1,2-a][1,4]diazepine-1-carboxamide (15) 
The N-methyl amide 15 was prepared from acid 9 following the general procedure with a solution 
of methylamine (33 wt % in absolute ethanol, 3 mL) as the nucleophile. The crude residue was 
purified by flash column chromatography [neutral alumina, 1% MeOH in CH2Cl2] to yield pure 
amide 15 as a solid in 75% yield: M.p = 180-182 ˚C; [α]D
25= +3.70 (c 0.5%, in CH2Cl2); 
1H NMR 
(300 MHz, CDCl3) δ 2.12-2.25 (m, 2H), 2.30-2.41 (m, 1H), 2.98 (d, 1H, J = 4.6 Hz), 3.50-3.62 
(m, 1H), 3.73-3.89 (m, 2H), 3.91 (s, 3H), 4.73 (d, 1H, J = 7.8 Hz), 7.16 (dd, 1H, J = 8.6 Hz, 2.3 
Hz), 7.32 (d, 1H, J = 8.6 Hz), 7.59 (d, 1H, J = 2.3 Hz), 7.72 (brs, 1H), 7.91 (s, 1H); 13C NMR (75 
MHz, CDCl3) δ 24.5, 26.2, 28.7, 46.8, 53.5, 55.9, 114.7, 119.8, 124.7, 125.6, 128.5, 130.9, 134.2, 






The N-methyl amide 15a was prepared from acid 9a following the general procedure with a 
solution of methylamine (33 wt % in absolute ethanol, 3 mL) as the nucleophile. The crude residue 
was purified by flash column chromatography [neutral alumina, 1% MeOH in CH2Cl2] to yield 
pure amide 15a as a solid in 92 % yield: M.p = 180-182 ˚C; 1H NMR (300 MHz, CDCl3) δ 2.12-
2.25 (m, 2H), 2.30-2.42 (m, 1H), 2.97 (d, 1H, J = 5.0 Hz), 3.50-3.60 (m, 1H), 3.74-3.91 (m, 2H), 
4.73 (d, 1H, J = 7.6 Hz), 7.14 (dd, 1H, J = 8.8 Hz, 2.9 Hz), 7.29 (d, 1H, J = 8.8 Hz), 7.48-7.54 
(bm, 1H), 7.58 (d, 1H, J = 2.9 Hz), 7.70 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 24.5, 25.8, 28.6, 
46.5, 53.4, 114.3, 119.4, 124.4, 126.2, 130.2, 130.6, 134.5, 134.9, 159.1, 162.8, 163.7. HRMS 
(ESI) (M+H)+, calcd. for C17H16
2H3N4O3 330.1640; Found 330.1637. 
7.25 (S)-7-Methoxy-N,N-dimethyl-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-
c]pyrrolo[1,2-a][1,4]diazepine-1-carboxamide (16) 
 The N, N-dimethyl amide 16 was prepared from acid 9 following the general procedure with a 
solution of  N,N-dimethylamine (11% in ethanol, 5 mL) as the nucleophile. The crude residue was 
purified by flash column chromatography [neutral alumina, 5% MeOH in CH2Cl2] to yield pure 
dimethyl amide 16 as a solid in 70% yield: M.p = 186-188 ˚C; [α]D
25= +52.00 (c 0.25%, in 
CH2Cl2); 
1H NMR (300 MHz, CDCl3) δ 2.01-2.08 (m, 2H), 2.25-2.38 (m, 1H), 2.89-2.94 (m, 1H), 
3.08 (s, 3H), 3.14 (s, 3H), 3.63-3.82 (m, 2H), 3.91 (s, 3H), 4.73 (dd, 1H, J = 8.4, 3.0  Hz), 7.15 
(dd, 1H, J = 8.9 Hz, 2.9 Hz), 7.34 (d, 1H, J = 8.9 Hz), 7.57 (d, 1H, J = 2.9 Hz), 7.97 (s, 1H); 13C 
NMR (75 MHz, CDCl3) δ 23.9, 27.8, 35.3, 39.1, 47.2, 52.3, 55.8, 114.9, 119.7, 124.2, 126.1, 130.1, 
131.0, 132.0, 134.8, 159.1, 164.2, 165.7. HRMS (ESI) (M+Na)+, calcd. for C18H20N4O3Na 




zo[5,1-c]pyrrolo[1,2-a][1,4]diazepine-1-carboxamide (16a)  
The N, N-dimethyl amide 16a was prepared from acid 9a following the general procedure with a 
solution of  N,N-dimethylamine (11% in ethanol, 5 mL) as the nucleophile. The crude residue was 
purified by flash column chromatography [neutral alumina, 5% MeOH in CH2Cl2] to yield pure 
amide 16a as a solid in 88% yield: M.p = 185-186 ˚C; 1H NMR (300 MHz, CDCl3) δ 2.01-2.10 
(m, 2H), 2.24-2.37 (m, 1H), 2.89-2.98 (m, 1H), 3.07 (s, 3H), 3.14 (s, 3H), 3.63-3.82 (m, 2H), 4.72 
(dd, 1H, J = 8.3 Hz, 2.9  Hz), 7.13 (dd, 1H, J = 8.7 Hz, 2.9 Hz), 7.29 (d, 1H, J = 8.7 Hz), 7.56 (d, 
1H, J = 2.9 Hz), 7.77 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 23.9, 27.9, 35.3, 39.1, 47.2, 52.3, 
114.9, 119.7, 124.2, 126.3, 130.1, 131.4, 132.0, 134.9, 159.0, 164.3, 166.1. HRMS (ESI) (M+H)+, 
calcd. for C18H18
2H3N4O3 344.1796; Found 344.1798. 
7.27 (S)-N-Ethyl-7-methoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]pyro-
lo[1,2-a][1,4]diazepine-1-carboxamide (17)  
The N-ethyl amide 17 was prepared from acid 9 following the general procedure with a solution 
of ethylamine (2.0 M in THF, 1 mL) as the nucleophile. The crude residue was purified by flash 
column chromatography [neutral alumina, EtOAc/hexane (8:2)] to yield pure ethyl amide 17 as a 
solid in 75% yield: M.p = 175-177 ˚C; [α]D
27=+8.33 (c 0.12%, in CH2Cl2); 
1H NMR (300 MHz, 
CDCl3) δ 1.25 (t, 3H, J = 7.3 Hz),  2.13-2.41 (m, 3H), 3.40-3.59 (m, 3H), 3.74-3.87 (m, 2H), 3.90 
(s, 3H), 4.72 (d, 1H, J = 7.8 Hz), 7.14 (dd, 1H, J = 8.7 Hz, 3.0 Hz), 7.28 (d, 1H, J = 8.7 Hz), 7.48-
7.50 (bm, 1H), 7.58 (d, 1H, J = 2.7 Hz), 7.69 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 14.9, 24.6, 
28.8, 34.0, 46.7, 53.6, 55.8, 114.4, 119.6, 124.5, 126.3,  130.3, 130.7, 134.5, 135.2, 159.3, 162.0, 





The N-ethyl amide 17a was prepared from 9a following the general procedure with a solution of 
ethylamine (2.0 M in THF, 1 mL) as the nucleophile. The crude residue was purified by flash 
column chromatography [neutral alumina, EtOAc/hexane (8:2)] to yield pure amide 17a as a solid 
in 96 % yield: M.p = 176-177 ˚C; 1H NMR (300 MHz, CDCl3) δ 1.25 (t, 3H, J = 7.3 Hz),  2.12-
2.24 (m, 2H), 2.30-2.42 (m, 1H), 3.40-3.60 (m, 3H), 3.74-3.91 (m, 2H), 4.72 (d, 1H, J = 7.7 Hz), 
7.14 (dd, 1H, J = 8.8 Hz, 2.9 Hz), 7.29 (d, 1H, J = 8.8 Hz), 7.47-7.53 (bm, 1H), 7.58 (d, 1H, J = 
2.9 Hz), 7.70 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 14.9, 24.6, 28.8, 34.0, 46.7, 53.6, 114.4, 119.6, 
124.5, 126.4, 130.4, 130.7, 134.6, 135.2, 159.3, 162.1, 163.8; HRMS (ESI) (M+H)+, calcd. for 
C18H18
2H3N4O3 344.1796; Found 344.1797.  
7.29 (S)-N-(tert-Butyl)-7-methoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-
c]pyrrolo[1,2-a][1,4]diazepine-1-carboxamide (18)  
The N-tert-butyl amide 18 was prepared from acid 9 following the general procedure with tert-
butyl amine as the nucleophile. The crude residue was purified by flash column chromatography  
[neutral alumina, EtOAc/hexane (8:2)] to yield pure amide 18 as a solid in 80 % yield: M.p = 152-
154 ˚C; [α]D
27= +170.00 (c 0.10%, in CH2Cl2); 
1H NMR (300 MHz, CDCl3) δ 1.47 (s, 9H),  2.11-
2.37 (m, 3H), 3.50-3.60 (m, 1H), 3.74-3.86 (m, 2H), 3.91 (s, 3H), 4.71 (d, 1H, J = 7.8 Hz), 7.14 
(dd, 1H, J = 8.7 Hz, 3.0 Hz), 7.26-7.29 (m, 1H), 7.45 (bs, 1H), 7.58 (d, 1H, J = 3.0 Hz), 7.77 (s, 
1H); 13C NMR (75 MHz, CDCl3) δ 24.5, 28.8, 46.7, 50.9, 53.6, 55.8, 114.4, 119.6, 124.6, 126.3, 
130.7, 131.2, 134.3, 134.9, 159.2, 161.5, 163.8; HRMS (ESI) (M+H)+, calcd. for C20H25N4O3 




zo[5,1-c]pyrrolo[1,2-a][1,4]diazepine-1-carboxamide (18a)  
The N-tert-butyl amide 18a was prepared from acid 9a following the general procedure with tert-
butyl amine as the nucleophile. The crude residue was purified by flash column chromatography 
[neutral alumina, EtOAc/hexane (8:2)] to yield pure amide 18a as a solid in 85% yield: M.p = 153-
155 ˚C; 1H NMR (300 MHz, CDCl3) δ 1.49 (s, 9H),  2.12-2.39 (m, 3H), 3.51-3.61 (m, 1H), 3.75-
3.94 (m, 2H), 4.73 (d, 1H, J = 7.9 Hz), 7.14 (dd, 1H, J = 8.8 Hz, 2.9 Hz), 7.27-7.30 (m, 1H), 7.39 
(bs, 1H), 7.59 (d, 1H, J = 2.9 Hz), 7.68 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 24.6, 28.9, 46.7, 
50.9, 53.7, 114.4, 119.7, 124.5, 126.5, 130.7, 131.4, 134.3, 134.8, 159.3, 161.7, 163.8; HRMS 
(ESI) (M+H)+, calcd. for C20H21
2H3N4O3 372.2108; Found 372.2109.  
7.31 (S)-N-Cyclopropyl-7-methoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-
c]py-rrolo[1,2-a][1,4]diazepine-1-carboxamide (19)  
The N-cyclopropyl amide 19 was prepared from acid 9 following the general procedure with dry 
cyclopropylamine as the nucleophile. The crude residue was purified by flash column 
chromatography [neutral alumina, EtOAc/hexane (1:1)] to yield pure amide 19 as a solid in 82% 
yield: M.p = 189-190 ˚C; [α]D
25= -6.67 (c 0.3%, in CH2Cl2); 
1H NMR (300 MHz, CDCl3) δ 0.54-
0.59 (m, 2H),  0.76-0.82 (m, 2H), 2.06-2.18 (m, 2H), 2.25-2.36 (m, 1H), 2.75-2.81 (m, 1H), 3.43-
3.53 (m, 1H), 3.68-3.81 (m, 2H), 3.84 (s, 3H), 4.65 (d, 1H, J = 8.1 Hz), 7.07 (dd, 1H, J = 8.7 Hz, 
2.8 Hz), 7.19-7.22 (m, 1H), 7.50 (bs, 1H), 7.52 (d, 1H, J = 2.8 Hz), 7.61 (s, 1H); 13C NMR (75 
MHz, CDCl3) δ 6.5, 6.6, 22.3, 24.6, 28.8, 46.6, 53.6, 55.8, 114.4, 119.6, 124.4, 126.3, 130.0, 130.7, 





zo[5,1-c]pyrrolo[1,2-a][1,4]diazepine-1-carboxamide (19a)  
The N-cyclopropyl amide 19a was prepared from acid 9a following the general procedure with 
dry cyclopropylamine as the nucleophile. The crude residue was purified by column 
chromatography [neutral alumina, EtOAc/hexane (1:1)] to yield pure amide 19a as a solid in 86% 
yield: M.p = 189-190 ˚C; 1H NMR (300 MHz, CDCl3) δ 0.62-0.67 (m, 2H),  0.84-0.90 (m, 2H), 
2.12-2.26 (m, 2H), 2.33-2.46 (m, 1H), 2.83-2.89 (m, 1H), 3.51-3.60 (m, 1H), 3.75-3.93 (m, 2H), 
4.73 (d, 1H, J = 8.2 Hz), 7.15 (dd, 1H, J = 8.8 Hz, 2.9 Hz), 7.27-7.31 (m, 1H), 7.57-7.60 (m, 2H), 
7.69 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 6.5, 6.6, 22.3, 24.7, 28.8, 46.7, 53.6, 114.4, 119.7, 
124.5, 126.3, 130.1, 130.8, 134.6, 135.3, 159.3, 163.7, 163.8; HRMS (ESI) (M+H)+, calcd. for 
C19H18
2H3N4O3 356.1796; Found 356.1796. 
7.33 (S)-(2H3)--ethyl-7-methoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]-
pyrolo[1,2-a][1,4]diazepine-1-carboxylate (23) 
To an oven dried round bottom flask, acid 9 (0.6 g, 1.92 mmol) and Cs2CO3 (1.3 g, 3.8 mmol) 
were dissolved in dry DMF (5 mL) at rt. The 1,1-dideuterated bromoethane (0.2 ml, 2.9 mol) was 
added via a syringe in one portion and the reaction was stirred for 2 hr at rt. The reaction mixture 
was then filtered to remove precipitate (CsBr), and the solid was rinsed with EtOAc (2ml). The 
organic layers were combined, and the solvent was removed under reduced pressure. The residue, 
that resulted, was purified by flash chromatography (silica gel, 10% methanol in DCM) which 
provided pure C(3) substituted d2-ethyl ester 23 as a white solid (0.398 g) in 61% yield: 1H NMR 
(300 MHz, CDCl3) δ 7.81 (s, 1H), 7.59 (d, J = 2.9 Hz, 1H), 7.31 (t, J = 8.4 Hz, 1H), 7.16 (dd, J = 
8.8, 3.0 Hz, 1H), 4.75 (d, J = 7.0 Hz, 1H), 3.91 (s, 3H), 3.87 – 3.70 (m, 1H), 3.70 – 3.35 (m, 2H), 
2.50 – 2.03 (m, 3H), 1.43 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 163.8, 162.9, 159.4, 137.7, 135.9, 
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130.6, 127.7, 126.2, 124.6, 119.8, 114.5, 60.6 (quint), 55.9, 53.5, 46.6, 28.4, 24.4, 14.2. LCMS 
(ESI, m/z, relative intensity (ESI), calcd. for C18H17D2N3O4 (M+H)
+ 343.37; Found 343.07. 
7.34 (S)-1-(3-isopropyl-1,2,4-oxadiazol-5-yl)-7-methoxy-11,12,13,13a-tetrahydro-9H-benzo-
[e]imidazo[5,1-c]pyrrolo[1,2-a][1,4]diazepin-9-one (24) 
The ethyl ester 5 (0.20 g, 0.58 mmol) was dissolved in dry THF (20 mL) under argon at rt. In a 
separate oven dried round bottom flask which contained 3Å molecular sieves, N'-
hydroxyisobutyrimidamide (0.24 g, 2.34 mmol) was dissolved in dry THF (20 mL) under argon 
and treated with sodium hydride (60% dispersion in mineral oil, 0.058 g, 1.46 mmol). The mixture, 
which resulted, was then stirred for 15 min at which point the solution of ethyl ester 5 was added. 
The reaction mixture, which resulted, was stirred at rt for 2h. After completion of the reaction 
(TLC, silica gel), the mixture was quenched with a saturated aq NaHCO3 solution (5 mL). Then 
water (30 mL) was added and the product was extracted with EtOAc (3 x 50 mL). The combined 
organic layer was then washed with brine and dried (Na2SO4). The solvent was removed under 
reduced pressure and the residue was purified by flash column chromatography [silica gel, 
EtOAc/hexane (1:1)] to yield pure isopropyl oxadiazole 24 as a solid (0.19 g) in 84% yield: 1H 
NMR (300 MHz, CDCl3) δ 7.93 (s, 1H), 7.58 (d, J = 2.8 Hz, 1H), 7.36 (d, J = 8.8 Hz, 1H), 7.16 
(dd, J = 8.8, 2.8 Hz, 1H), 4.82 (d, J = 7.7 Hz, 1H), 3.90 (s, 3H), 3.78 (dd, J = 14.6, 5.2 Hz, 1H), 
3.58 (dd, J = 19.4, 9.6 Hz, 2H), 3.17 (dt, J = 13.8, 6.9 Hz, 1H), 2.43 – 1.92 (m, 3H), 1.37 (d, J = 
6.3 Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 175.2, 170.7, 163.7, 159.5, 137.3, 135.6, 130.5, 125.9, 
124.6, 122.1, 119.7, 114.7, 55.9, 53.1, 46.6, 28.1, 26.7, 24.2, 20.5; HRMS (ESI) (M+H)+, calcd. 






The ethyl ester 5 (0.20 g, 0.58 mmol) was dissolved in dry THF (20 mL) under argon at rt. In a 
separate oven dried round bottom flask, which contained 3Å molecular sieves, N'-
hydroxypropionimidamide (0.21 g, 2.34 mmol) was dissolved in dry THF (20 mL) under argon 
and treated with sodium hydride (60% dispersion in mineral oil, 0.058 g, 1.46 mmol). The mixture, 
which resulted, was then stirred for 15 min at which point the solution of ethyl ester 5 was added. 
The reaction mixture which resulted was stirred at rt for 2h. After completion of the reaction (TLC, 
silica gel), the mixture was quenched with a saturated aq NaHCO3 solution (5 mL). Then water  
(30 mL) was added and the product was extracted with EtOAc (3 x 50 mL). The combined organic 
layer was then washed with brine and dried (Na2SO4). The solvent was removed under reduced 
pressure and the residue was purified by flash column chromatography [silica gel, EtOAc/hexane 
(1:1)] to yield pure ethyl oxadiazole 25 as a solid (0.09 g) in 42% yield: 1H NMR (300 MHz, 
CDCl3) δ 7.95 (s, 1H), 7.61 (d, J = 2.9 Hz, 1H), 7.38 (d, J = 8.8 Hz, 1H), 7.18 (dd, J = 8.8, 3.0 Hz, 
1H), 4.91 – 4.72 (m, 1H), 3.93 (s, 3H), 3.87 – 3.71 (m, 1H), 3.71 – 3.49 (m, 2H), 2.85 (q, J = 7.6 
Hz, 2H), 2.43 – 2.07 (m, 3H), 1.39 (t, J = 7.6 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 171.9, 170.9, 
163.8, 159.5, 137.3, 135.6, 130.5, 125.9, 124.6, 122.1, 119.8, 114.7, 55.9, 53.1, 46.7, 28.1, 24.2, 








The ethyl ester 5 (0.20 g, 0.58 mmol) was dissolved in dry THF (20 mL) under argon at rt. In a 
separate oven dried round bottom flask, which contained 3Å molecular sieves, N'-
hydroxyacetimidamide (0.17 g, 2.34 mmol) was dissolved in dry THF (20 mL) under argon and 
treated with sodium hydride (60% dispersion in mineral oil, 0.058 g, 1.46 mmol). The mixture, 
which resulted, was then stirred for 15 min at which point the solution of ethyl ester 5 was added. 
The reaction mixture which resulted was stirred at rt for 2h. After completion of the reaction (TLC, 
silica gel), the mixture was quenched with a saturated aq NaHCO3 solution (5 mL). Then water 
(30 mL) was added and the product was extracted with EtOAc (3 x 50 mL). The combined organic 
layer was then washed with brine and dried (Na2SO4). The solvent was removed under reduced 
pressure and the residue was purified by flash column chromatography [neutral alumina, 5% 
CH3OH in CH2Cl2 ] to yield pure methyl oxadiazole 26 as a solid (0.15 g) in 69% yield: 
1H NMR 
(300 MHz, CDCl3) δ 7.94 (s, 1H), 7.59 (d, J = 2.9 Hz, 1H), 7.37 (d, J = 8.8 Hz, 1H), 7.17 (dd, J = 
8.8, 3.0 Hz, 1H), 4.91 – 4.75 (m, 1H), 3.91 (s, 3H), 3.77 (ddd, J = 10.5, 7.2, 3.0 Hz, 1H), 3.67 – 
3.44 (m, 2H), 2.47 (s, 3H), 2.37 – 1.93 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 171.0, 167.5,163.8, 
159.5, 137.3, 135.7, 130.5, 125.9, 124.6, 122.0, 119.8, 114.7, 55.9, 53.1, 46.7, 28.1, 24.2, 11.8. 
HRMS (ESI) (M+H)+, calcd. for C18H18N5O3 352.1404; Found 352.1400. 
Representative example: ethyl oxime “N'-hydroxypropionimidamide” 
Hydroxylamine hydrochloride (9.73 g, 0.14 mol) and potassium carbonate (41.5 g, 0.3 mol) were 
added into methanol (400 mL) and water (80 mL). The suspension, which resulted, was stirred at 
rt for 15 min after which it was heated to reflux. The propionitrile (7.1 mL, 0.1 mol) was added 
dropwise and the reaction, which resulted, was stirred at reflux for 16 h.  After that, the reaction 
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mixture was cooled to 0 oC and the precipitate which formed was filtered off. The solvent from 
the filtrate was removed under reduced pressure. The solid residue was dissolved in EtOAc and 
washed with water, brine, and dried (Na2SO4), after which the solvent was removed under reduced 
pressure to afford the ethyl oxime as a white solid (6.05 g, 69%): HPLC-MS (ESI) m/z (M+H) 
89.06. This material was used for the next step without further characterization. 
By following the same procedure with isobutyronitrile (6.49 mL, 72.3 mmol), this process 
furnished isopropyl oxime “N'-hydroxyisobutyrimidamide” (5.54 g, 75%). The same process with 




The DIBAL-H (1.2 M, 6.2 mL, 7.4 mmol) was added at 0 ˚C to a solution of NaOtBu (0.76 g, 7.9 
mmol) in 20 mL of dry THF. The mixture which resulted, was stirred for 1 h at rt under an argon 
atmosphere. The compound 5 (1.5 g, 4.4 mmol) was then added to the above solution at 0 ˚C and 
the mixture was stirred for 3 h (or until the complete consumption of 5) at room temperature under 
Ar. After completion of the reaction, excess DIBAL-H was quenched by careful addition of 
methanol (~ 15 mL), and this was followed by 5% aq HCl (20-30 mL) at 0 ˚C. After this the 
mixture, which resulted, was allowed to warm to rt. The aq layer was extracted with CH2Cl2 (2x 
50 mL). The combined organic layers were washed with brine and dried (Na2SO4). The solvent 
was removed under reduced pressure to afford the crude aldehyde 27. This residue was purified 
by flash chromatography (2:1 ethyl acetate/hexane) to afford the pure diazepine aldehyde 27 as a 
white solid, (3.325 g, 93%). 1H NMR (300 MHz, CDCl3)  10.05 (s, 1H), 7.91 (s, 1H), 7.61 (d, J 
= 3.0 Hz, 1H), 7.38 (d, J = 9.0 Hz, 1H), 7.19 (dd, J = 3.0, 9.0 Hz, 1H), 4.72 (d, J = 8.4 Hz, 1H), 
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3.93 (s, 3H), 3.78-3.86 (m, 1H), 3.51-3.61 (m, 1H), 3.41-3.45 (m, 1H), 2.14-2.34 (m, 3H). 13C 
NMR (75 MHz, CDCl3)  186.9, 163.5, 159.6, 137.3, 136.8, 134.7, 130.7, 125.6, 124.5, 119.8, 
114.8, 55.9, 53.0, 46.6, 28.8, 24.3; LCMS (ESI m/z) 298.35 (M+H)+. 
The toluenesulfonylmethyl isocyanide, TosMIC (3.28 g, 16.8 mmol), was placed in a dry two neck 
round bottom flask and dissolved in dry MeOH (40 mL) under an argon atmosphere. At rt, K2CO3 
(4.64 g, 33.57 mmol) was added, as well as the aldehyde 27 (3.325 g, 11.18 mmol) to the reaction 
and the mixture was heated to reflux for 3 h. After completion of the reaction, as indicated by TLC 
(silica gel), the reaction mixture was quenched with cold water. After this, 1/3 of the solvent was 
removed under reduced pressure and the remainder extracted with EtOAc (3x 20 mL). The 
combined organic layers were washed with water and brine successively and dried (Na2SO4). The 
solvent was then removed under reduced pressure and the residue was purified by silica gel flash 
chromatography to give the pure oxazole 28 as white solid (2.83 g, 75 %). M.p: 228-230 oC. 1H 
NMR (300 MHz, CDCl3)  8.03 (s, 1H), 8.00 (s, 1H), 7.60 (d, J = 2.7 Hz, 1H), 7.42 (s, 1H), 7.38 
(d, J = 8.7 Hz, 1H), 7.18 (dd, J = 3.0, 8.7 Hz, 1H), 4.82 (dd, J = 2.7, 8.1 Hz, 1H), 3.93 (s, 3H), 
3.62-3.81 (m, 2H), 2.64-2.72 (m, 1H), 2.22-2.35 (m, 1H), 1.94-2.04 (m, 2H). 13C NMR (75 MHz, 
CDCl3)  164.1, 159.1, 150.7, 145.5, 136.3, 131.9, 130.1, 126.3, 126.1, 124.4, 123.6, 119.7, 114.8, 
55.87, 52.5, 46.9, 27.8, 23.8; HRMS (ESI) (M+H)+, calcd. for C18H17N4O3 337.1301; found 
337.1299. 
In an oven dried round bottom flask, dry CH2Cl2 (50 mL) was added and then cooled to 0 ̊ C.  Then 
AlCl3 (3.33 g, 24.97 mmol) and ethanethiol (5.0 ml, 67.52 mmol) were added to the above flask 
slowly at 0 ˚C. The ice bath was removed and the reaction was allowed to warm to rt. After the 
AlCl3 dissolved completely, the oxazole 28 (2.8 g, 8.32 mmol; dissolved in DCM) was added to 
the mixture at rt and the mixture was stirred for 24h under Ar. After completion of the reaction 
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(TLC, silica gel) the solution was poured onto ice and the mixture was acidified using 2N aq HCl 
solution. The solution was extracted 5-7 times with CH2Cl2 and 3-4 times with EtOAc, separately. 
The combined organic layer was washed with brine and dried (Na2SO4). The solvent was removed 
under reduced pressure and the residue was purified by flash column chromatography [silica gel, 
4% MeOH in CH2Cl2] to furnish phenol 29 as a solid (2.36 g) in 88% yield: 
1H NMR (500 MHz, 
CDCl3): δ 1.97-2.08 (m, 2H), 2.25-2.35 (m, 1H), 2.65-2.73 (m, 1H), 3.63-3.71 (m, 1H), 3.76-3.84 
(m, 1H), 4.84-4.88 (m, 1H), 7.10 (dd, 1H, J = 8.6, 2.2 Hz), 7.30 (d, 1H, J = 5.3 Hz), 7.40 (s, 1H), 
7.75 (d, 1H, J = 1.9 Hz), 7.95 (s, 1H), 8.02 (s, 1H), 9.85 (s, 1H); 13C NMR (125 MHz, CDCl3): δ 
23.9, 27.8, 47.2, 52.8, 117.6, 120.8, 123.5, 124.7, 125.3, 126.2, 129.3, 131.9, 136.5, 145.4, 150.9, 
157.5, 164.8; HRMS (ESI) (M+H)+, calcd. for C17H15N4O3 323.1139; found 323.1130. 
7.38 (S)-7-Methoxy-1-(1H-tetrazol-5-yl)-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-
c]pyrrolo[1,2-a][1,4]diazepin-9-one (31) 
The DIBAL-H (1.2 M, 6.2 mL, 7.4 mmol) was added at 0 ˚C to a solution of NaOtBu (0.76 g, 7.9 
mmol) in 20 mL of dry THF. The mixture which resulted, was stirred for 1 h at rt under an argon 
atmosphere. The ethyl ester 5 (1.5 g, 4.4 mmol) was then added to the above solution at 0 ˚C and 
the mixture was stirred for 3 h (or until the complete consumption of 5) at rt under Ar. Then, 
concentrated aq NH3 (28%, 20 mL) and I2 (4.57 g, 18.0 mmol) were added at 0 ˚C and the mixture 
which resulted, was stirred at rt for 3h. After complete disappearance of the aldehyde intermediate, 
the reaction mixture was treated with a saturated solution of sodium thiosulfate (~10 mL) and 
extracted with EtOAc (3x 30 mL). The combined organic layer was washed with brine, dried 
(Na2SO4) and the solvent was removed under reduced pressure. The residue was purified by silica 
gel flash column chromatography (70% EtOAc in hexanes) to furnish the nitrile 30 as a white 
solid, 1.22 g, 95%. At this point, to a solution of the nitrile 30 (0.295 g, 1.0 mmol) in 30 mL of 
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THF, ZnBr2 (0.34 g, 1.50 mmol) and NaN3 (78 mg, 1.20 mmol) were added and the mixture was 
heated to reflux for 36 h (or until complete consumption of 30, by TLC, silica gel). The solution 
was then treated with aq 1M HCl to dissolve the solid material and bring the pH of the solution to 
1 by pH paper. The solution, which resulted, was extracted with EtOAc (4x 40 mL). The solvent 
was evaporated under reduced pressure and the residue was passed through a short pad of silica 
gel with 7% MeOH in DCM to furnish 196 mg of 31, (yield,58 %). 1H NMR (300 MHz, DMSO-
d6): δ 1.96-2.14 (m, 2H), 2.23-2.40 (m, 1H), 3.40-3.50 (m, 1H), 3.5-3.66 (m, 1H), 3.89 (s, 3H), 
3.96-4.10 (m, 1H), 4.95 (d, 1H, J = 8.34 Hz), 7.31-7.38 (m, 1H), 7.43 (d, 1H, J = 2.8 Hz), 7.69 (d, 
1H, J = 8.8 Hz), 8.60 (s, 1H); 13C NMR (75 MHz, DMSO-d6): δ 24.7, 27.9, 46.6, 52.3, 56.3, 115.1, 
119.2, 123.5, 126.0, 126.5, 130.9, 137.7, 155.4, 159.3, 163.3; HRMS (ESI) (M+H)+, calcd. for 
C16H16N7O2 336.1360; found 336.1357. 
7.39 (S)-7-Hydroxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]pyrolo[1,2-a]-
[1,4]di-azepine-1-carboxylic acid (32)  
The ester 6 (1.52 g, 4.6 mmol) was dissolved in a mixture of EtOH (4 mL) and H2O (3 mL), after 
which solid NaOH (1.0 g, 25.0 mmol) was added to the solution. This reaction mixture was heated 
to 50 ̊ C for 15 min and the EtOH was removed under reduced pressure. The remaining aq solution 
was stirred at 0 ˚C for 10 min and then conc HCl was added dropwise to the solution until the pH 
was 3-4 (pH paper). A pale-yellow precipitate, which formed, was left in the solution and the 
mixture was allowed to stir at rt for 2 h. Then the precipitate was collected by filtration, washed 
with cold water (2-5 mL) and the aq layer was allowed to stand at rt for 10 h to obtain additional 
solid acid 32. The combined solids were dried in a vacuum oven at 80 ˚C for 7 h to get pure dry 
32 in 65% yield: 1H NMR (300 MHz, CD3OD): δ 2.14-2.29 (m, 3H), 3.50-3.63 (m, 2H), 3.70-3.78 
(m, 1H), 4.95 (d, 1H, merged with solvent peak), 7.15 (d, 1H, J = 8.7 Hz, 3.0 Hz), 7.38-7.43 (m, 
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1H), 7.53 (d, 1H, J = 8.76 Hz), 8.48 (m, 1H); 13C NMR (75 MHz, CD3OD) δ 24.0, 27.7, 46.2, 
53.4, 116.2, 119.8, 124.5, 125.4, 128.4, 130.2, 136.2, 137.5, 158.2, 162.5, 164.4; HRMS (ESI) 
(M+H)+, calcd. for C15H14N3O4 300.0979; found 300.0990. 
7.40 (S)-N,7-Dimethoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]pyrolo-
[1,2-a][1,4]diazepine-1-carboxamide (33) 
A mixture of acid 9 (0.15 g), thionyl chloride (1 mL) and dry CH2Cl2 (8 mL) was added to an oven 
dried round bottomed flask under argon. This suspension was allowed to reflux at 52 ºC (the 
outside oil bath temperature was at 60 ºC) for 1 h under an atmosphere of argon. The solution 
became a clear yellow color. The absence of the starting material was confirmed by the 
examination of the solution by TLC (silica gel). The organic solvent and excess thionyl chloride 
were removed under reduced pressure. This flash evaporation with dry DCM was repeated two 
times with dry CH2Cl2 (5 mL) to remove excess thionyl chloride and any HCl. The yellow residue, 
which was obtained, was dissolved in dry CH2Cl2 (10 mL) and cooled to 0 ºC for 10 min under 
argon. Then methyl hydroxylamine hydrochloride (2.5 eq), followed by Et3N (5 eq) was added to 
the reaction mixture at 0 ºC and the mixture was then allowed to warm to rt and stirred for 4 h. 
After the completion of the reaction (TLC, silica gel), the solvent was removed under reduced 
pressure and acetone (4 mL) was added to the residue. The salt was removed by filtration and the 
solvent was removed under reduced pressure to provide MRS-III-87 in 70 % yield: 1H NMR (300 
MHz, CDCl3) δ 2.14-2.22 (m, 2H), 2.30-2.39 (m, 1H), 3.08-3.10 (m, 1H), 3.51-3.57 (m, 1H), 3.75-
3.80 (m, 1H), 3.88 (s, 3H), 3.91 (s, 3H), 4.72 (d, 1H, J = 8.0 Hz ), 7.14 (dd, 1H, J = 8.8 Hz, 2.7 
Hz), 7.28 (d, 1H, J = 8.8 Hz), 7.58 (d, 1H, J = 2.7 Hz), 7.69 (s, 1H), 9.84 (bs, 1H); LCMS (ESI, 
m/z, relative intensity (ESI), calcd. For C17H17N4O4 (M-H)





A mixture of acid 9 (0.15 g), thionyl chloride (1 mL) and dry CH2Cl2 (8 mL) was added to an oven 
dried round bottomed flask under argon. This suspension was allowed to reflux at 52 ºC (the 
outside oil bath temperature was at 60 ºC) for 1 h under an atmosphere of argon. The solution 
became a clear yellow color. The absence of the starting material was confirmed by the 
examination of the solution by TLC (silica gel). The organic solvent and excess thionyl chloride 
were removed under reduced pressure. This evaporation was repeated a couple of times with dry 
CH2Cl2 (5 mL) to remove excess thionyl chloride and any HCl. The yellow residue, which was 
obtained, was dissolved in dry CH2Cl2 (10 mL) and cooled to 0 ºC for 10 min under argon. The 
methyl cyanamide (2.5 eq), followed by Et3N (5 eq.) was added to the reaction mixture at 0 ºC and 
the mixture was then allowed to warm to rt and stirred for 5 h. After the completion of the reaction 
(TLC, silica gel), the solvent was removed under reduced pressure and acetone (4 mL) was added 
to the residue. The salt was filtered off and the solvent was removed under reduced pressure to 
obtain MRS-III-90 in 70% yield. 1H NMR (300 MHz, DMSO-d6) δ 2.10-2.13 (m, 2H), 3.34-3.58 
(m, 3H), 3.88 (s, 3H), 3.91 (s, 3H), 4.73 (d, 1H, J = 7.5 Hz, major rotamer 83%), 4.84 (d, J = 7.5 
Hz, minor rotamer, 17%), 7.27-7.29 (m, 1H, major rotamer), 7.31-7.33 (m, minor rotamer), 7.38 
(d, 1H, J = 2.0 Hz, major rotamer), 7.41 (d, J = 2.5 Hz, minor rotamer), 7.57 (d, 1H, J = 8.5 Hz, 
major rotamer), 7.64 (d, J = 9.0 Hz, minor rotamer), 8.00 (s, 1H, major rotamer), 8.21 (s, minor 
rotamer), 9.49-10.11 (bs, 1H); LCMS (ESI, m/z, relative intensity (ESI), calcd. for C17H14N5O3 





7.42 General method for the synthesis of alkyl ethers at the C-8 position (35-39) 
To a solution of phenol 6 (0.15 g) in CH2Cl2 (5 mL), Cs2CO3 (0.3 g) was added and the mixture 
was stirred at rt for 30 min. Then the alkyl halide [ethyl iodide; ethyl iodide-d5; cyclopropyl 
bromide;  isopropyl iodide or t-butyl bromide (0.5 mL)] was added (individually) slowly and the 
reaction mixture was stirred at rt for 24 h. After completion of the reaction (TLC, silica gel) the 
mixture was quenched with cold water and extracted with CH2Cl2. The combined organic layer 
was washed with brine and dried (Na2SO4). The solvent was removed under reduced pressure and 
the solid residue (ester) was used directly for the next step. The ester [from first step], was 
dissolved in a mixture of EtOH (4 mL) and H2O (3 mL), after which solid NaOH (5 eq) was added 
to the solution. This reaction mixture was heated to 50 ºC for 15 min and then the EtOH was 
removed under reduced pressure. The remaining aq solution was stirred at 0 ºC for 10 min and 
then conc. HCl was added dropwise to the solution until the pH was 3-4 (pH paper). A pale yellow 
precipitate, which formed, was left in the solution and the mixture was allowed to stir at rt for 2 h. 
The precipitate was collected by filtration, washed with cold water (2 X 5 mL) and the aq layer 
also was extracted with CH2Cl2 (2 to 3 X). The combined organic layer was washed with brine and 
dried (Na2SO4). The solvent was removed under reduced pressure to provide additional amounts 
(individually) of acids 35-39.  
 
7.43 (S)-7-Ethoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]pyrrolo[1,2-a]-
[1,4]diazepine-1-carboxylic acid (35) 
70 % yield: 1H NMR (500 MHz, DMSO-d6) δ 1.38 (t, 3H, J = 7.0 Hz), 2.06-2.16 (m, 3H), 3.30-
3.32 (m, 1H), 3.42-3.46 (m, 1H), 3.59-3.62 (m, 1H), 4.15 (q, 2H, J = 7.0 Hz), 4.86 (d, 1H, J = 7.5 
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Hz), 7.30 (dd, 1H, J = 9.0 Hz, 3.0 Hz), 7.39 (s, 1H), 7.64-7.66 (m, 1H), 8.77-8.89 (bs, 1H); LCMS 
(ESI, m/z, relative intensity (ESI), calcd. for C17H16N3O4 (M-H)
+ 326.33; Found 326.00  
7.44 (S)-7-(2H5)Ethoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]pyrrolo-
[1,2-a][1,4]diazepine-1-carboxylic acid (36) 
65 % yield: 1H NMR (500 MHz, DMSO-d6) δ 2.04-2.17 (m, 2H), 3.42-3.46 (m, 4H merged with 
DMSO+H2O peak), 4.83(d, 1H, J = 7.5 Hz), 7.29 (dd, 1H, J = 9.0 Hz, 3.0 Hz), 7.37-7.38 (m, 1H), 
7.61 (d, 1H, J = 9.0 Hz), 8.20 (s, 1H); 2H NMR (500 MHz, DMSO, number of scans =128) δ 1.25 
(3D) and 4.04 (2D). LCMS (ESI, m/z, relative intensity (ESI), calcd. for C17H13D5N3O4 (M+H)
+ 
333.37; Found 333.25. 
7.45 (S)-7-Cyclopropoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]pyrrolo-
[1,2-a][1,4]diazepine-1-carboxylic acid (37) 
30 % yield: 1H NMR (500 MHz, CDCl3) δ 2.19-2.29 (m, 3H), 3.35-3.57 (m, 1H), 3.68-3.71 (m, 
1H), 3.77-3.81 (m, 1H), 4.61- 4.69 (m, 2H), 4.72 (d, 1H, J = 7.0 Hz), 5.35 (d, 1H, J = 13.5 Hz), 
5.46 (d, 1H, J = 13.5 Hz), 6.02-6.10 (m, 1H), 7.19 (dd, 1H, J = 8.5 Hz, 2.3 Hz), 7.31-7.33 (m, 1H), 
7.61 (d, 1H, J = 2.3 Hz), 7.78 (s, 1H); LCMS (ESI, m/z, relative intensity (ESI), calcd. for 
C18H18N3O4 (M+H)
+ 340.35; Found 340.20.  
7.46 (S)-7-Isopropoxy-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]pyrrolo-
[1,2-a][1,4]diazepine-1-carboxylic acid (38) 
70 % yield: 1H NMR (500 MHz, CDCl3) δ 1.38 (d, 3H, J = 6.3 Hz),  1.40 (d, 3H, J = 6.3 Hz),  
2.19-2.26 (m, 3H), 3.51-3.57 (m, 1H), 3.65-3.68 (m, 1H), 3.77-3.80 (m, 1H), 4.66-4.74 (m, 2H), 
7.13-7.16 (m, 1H), 7.39 (bs, 1H), 7.57 (d, 1H, J = 2.5 Hz), 7.89 (bs, 1H); LCMS (ESI, m/z, relative 
intensity (ESI) calcd. for C18H20N3O4  (M+H)




[1,2-a][1,4]diazepine-1-carboxylic acid (39) 
65 % yield: 1H NMR (500 MHz, CDCl3) δ 1.43 (s, 9H),  2.20-2.29 (m, 3H), 3.51-3.57 (m, 
1H),3.67-3.69 (m, 1H), 3.76-3.80 (m, 1H), 4.74 (d, 1H, J = 7.0 Hz ), 7.23 (dd, 1H, J = 8.7 Hz, 2.2 
Hz), 7.30 (d, 1H, J = 8.7 Hz), 7.72 (d, 1H, J = 2.2 Hz), 7.39 (s, 1H), 7.83 (bs, 1H); LCMS (ESI, 
m/z, relative intensity (ESI), calcd. for C19H22N3O4 (M+H)
















































Type A γ-aminobutyric acid receptors (GABAA) is the primary target receptor for GABA, which 
is the major inhibitory neurotransmitter of the central nervous system.94,227 These systems are 
ligand-gated chloride ion pores that are transmembrane hetero-pentameric in structure. Since it is 
the principal target receptor for its indigenous ligand (GABA), GABAA receptors regulate a wide 
range of functions within the brain and the across the central nervous system.239 A variety of 
GABA-ergic ligands can positively or negatively modulate different subtypes of GABAA receptors 
and thus can exert various CNS effects (see Part I, Table 1). As described earlier in part I, 
benzodiazepines (BZDs) are a class of drugs that binds to GABAARs and exerts allosteric effects 
on GABAR efficacy.227,239 It is known that classical BZDs such as diazepam bind to the 
extracellular region at the interface between the α+γ- protein subunits and acts as a positive 
modulator (PAM) at α1-3,5βγ2 subtypes of the GABAARs.
13,227,239,240 BZDs have been used in clinic 
for more than five decades, although these drugs exhibit various undesired adverse CNS 
effects.227,239 Diazepam, for instance, though among the very limited options available for CNS 
disorders including anxiety, convulsions and insomnia, can evoke side effects such as sedation, 
ataxia, amnesia, and addiction.132,239,241-243 Moreover, it is not effective in all patients and has a 
limited long-term application as a prescription drug due to some of these adverse effects. On the 
other hand, due to the absence of suitable replacements in terms of better subtype selectivity and 
efficacy that are devoid of the undesired effects, they are still among the mainstays for treatment 
of CNS disorders.227,239,243 
A large number of studies suggest that the development of novel α2β2/3γ2 and α3β2/3γ2 subtype 
selective GABAAR ligands is a promising avenue for the development of better agnostic efficacy. 
These subtype selective agents would exert anxiolytic, antinociceptive, and anticonvulsant 
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activity, while avoiding the undesired effects, which stem from efficacy at α2β2/3γ2.
132,227,239,244-
251,252,253 According to the recent literature this class of α2/3 subtype selective GABAAR allosteric 
modulators are believed to be better treatments for seizures,235,254 antihyperalgesia,255,256 and 
anxiety132-134 without causing sedation, amnesia, ataxia, addiction and dependence, as well as 
tolerance.257-259 As a consequence of rigorous studies and development in this vein, a number of 
promising drug candidates227,235,244,248,260,261 have appeared, but most of them failed to remain in 
the development process due to poor pharmacokinetic properties227,262 and/or adverse CNS 
effects.227,244,263,264 As a consequence, due to the unmet demands for drugs with superior α2/3 
subtype efficacy, which lack the undesired CNS side effects from efficacy at α1 subtypes, there is 
a need to develop novel selective GABAA ligands for various disorders.  
 
2. Background 
The continued research over the last decade resulted in a series of α2/3 subtype selective 
imidazodiazepine (IBZ) GABAAR ligands (agonists), designed and synthesized based on the 
unified pharmacophore model.13,227,239,265 Among the initial lead compounds which contained the 
“privileged” IBZ scaffold were XHe-II-053 1, Hz-166 2, and JY-XHe-053 3,  (see Figure 1). They 
have been characterized for their selectivity towards α2/3 subtypes over α1.
227,252 It has been 
illustrated that Hz-166 (ligand 2) can evoke anxiolytic effects without causing sedation associated 
with non-selective PAMs such as diazepam.246,253 It is evident that the presence of an acetylene 
function at the C(8) position of these ligands was the reason behind the diminished binding affinity 
and efficacy at the sedating α1β3γ2 ion channels.
13,239,265 Ligand Hz-166 2 has shown antiseizure 
activity in mice and rats both from oral and i.p. administrations in a subcutaneous metrazole-
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induced seizure (scMET) test.266 Moreover it did not develop tolerance to the anticonvulsant 
effects; a very special Bz/GABAR ligand.252 Furthemore, in primate studies with rhesus monkeys, 
Hz-166 2 engendered non-sedating anxiolytic effects in the Geller-Seifter conflict assay at 1 mg/kg 
dose.246 In addition, Hz-166 2 showed a dose dependent antihyperalgesic effect in inflammation 
and neuropathic pain models without causing sedation, sensorimotor impairment nor tolerance 
unlike the commonly used antinociceptive molecules morphine, diazepam and gabapentin.255 
Ligand Hz-166 2, although stable enough on human liver microsomes (HLMs), was rapidly 
metabolized in mouse liver microsomes (MLMs). The labile nature of the ester function at C(3) in 
the presence of microsomal enzymes (especially in the liver) was responsible for the hydrolysis to 
the carboxylic acid which retarded the ability of the ligand to cross the blood brain barrier (BBB) 
and achieve the desired effects. The metabolite (the acid) was excreted to rapidly form the 
system.267 Similar results were also observed for XHe-II-053 1 and JY-XHe-053 3.227 This limited 
the ADME toxicity studies in rodents and is a concern because poor pharmacokinetic profiles are 
one of the major reasons for the failure of promising drug candidates in the development process. 
As a result, strategies were undertaken to develop new ligands, which would retain the anxiolytic 
properties of Hz-166 2 while achieving better stability on liver microsomes to increase plasma and 
brain exposure.227 The prevention of the ester from being metabolized by blocking its metabolic 





Figure 1. Initial lead compounds which contain the “privileged” IBZ scaffold 
Bioisosteric alteration of labile functional groups has been key among the modern strategies for 
generating novel compounds that are similar in activity despite being different structures. They 
are, however, recognized similarly by the biological systems. It follows that a bioisostere should 
retain the biological properties, while being structurally different and devoid of activity toward the 
common metabolic pathways that motivated ligand Hz-166.217 Accordingly, a bioisosteric 
replacement of the ester function, which is more stable under enzymatic metabolism would be a 
logical strategy. The 1,2,4-oxadiazole and 1,3-oxazole are known to be ester bioisosteres, which 
are more stable metabolically, although the latter is less-commonly used. As a result, conversion 
of the ester function at C(3) into an 1,2,4-oxadiazole or 1,3-oxazole would increase their stability 
and would increase plasma and brain exposure for the desired efficacy.9,217 Moreover, the 1,3-
oxazole is not a normal bioisostere for an ethyl ester and increased the strength of IP protection. 
Alternatively, incorporation of deuterium to block a primary site of oxidative metabolism of the 
ethyl esters (1-3) by replacing the -CH2- function with a -CD2- should also increase their stability 





3. Aims of this Work 
As indicated, from the in vitro and in vivo studies, bioisosteric replacement of the ester function 
is more likely to be a better strategy to design novel α2/α3 subtype selective ligands for the 
treatment of various CNS disorders. Further modification of the newly achieved lead compounds 
would result in ligands with even better drug like properties. A series of ester bioisosteres with 
suitable functional groups at different substituents on the heterocyclic ester bioisostere moiety, as 
well as incorporation of deuterium at the key metabolic sites should also be explored further. In 
addition, improvement of the current synthetic route to these ligands would also be highly desired.  
 
4. Chemistry and Results 
As discussed above, HZ-166 2, the initial lead ligand possessed all the desired biological properties 
except metabolic stability in rodents. Although it was stable on human liver microsomes (HLM), 
it was comparatively labile in mouse, and rat liver microsomes (MLM and RLM) due to the effect 
of enzymes which converted it into the carboxylic acid 4.239,267 Since the carboxylic acid was more 
hydrophilic, it was less able to cross the BBB, and effect the desired CNS effects in brain.239 As a 
result, the potential ligand did have low plasma and brain exposure. Accordingly, it was felt that 
by increasing the metabolic stability of the ester function at C(3), while retaining its biological 
properties would  be the key step in achieving the next generation of α2/α3 stable subtype selective 
ligands for CNS disorders.  
In accordance with this hypothesis, several ester bioisosteres were synthesized and evaluated for 
their in vitro and in vivo metabolic stability, as well as general anxiolytic effects. Among the newly 
designed ligands, MP-III-80 7 and KRM-II-81 9 were found to possess superior drug stability, 
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pharmacokinetic profiles and anxiolytic efficacy, as well as the absence of significant sensorimotor 
impairment, which is indicative of CNS side-effects.227 The 1,2,4-oxadiazoles (ligands 6, 7) were 
less potent (EC50 = 5.15 and 3.02 µM, respectively) than the corresponding 1,3-oxazoles (8-10, 
EC50 = 0.94 µM) towards α3β3γ2 GABAAR over α1β3γ2 (EC50 > 20 µM for all ligands) in the FLIPR 
assay.227  
 
Figure 2. Representative examples of the new generation of α2/α3 subtype selective GABAAR ligands 
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The 2ʹ-F (in the pendant phenyl ring) ligands 3 and 10 exhibited EC50s in the nanomolar range 
(EC50 = 29 and 11 nM, respectively) while the deuterated ester 5 showed potency similar to the 
non-deuterated counterpart 2.227 Due to their lack of efficacy at the α1β3γ2 site, these compounds 
were expected to be devoid of tolerance and dependence.257-259 As expected, the carboxylic acid 4 
which was hydrophilic, did not travel across the BBB in appreciable amounts and thus was not 
detected in the brain in PK studies when administered as the acid 4 itself or as a metabolite of the 
esters 2 and 5.  
 
Figure 3. Comparison between the efficacies at various subtypes (α1-α6) GABAARs determined in HEK cells by 
GABA induced EC3 currents at 100 nM concentrations of ligands. This is work of Janet Fischer at the 
University of South Carolina. Presented at ASPET Annual Meeting at EB, Orlando, April 9, 2019.268 
 
































Illustrated in Figure 3, Hz-166 2, MP-III-80 7 and KRM-II-81 9 are more efficacious at α2 and α3 
over α1 subtypes ion channels while typical benzodiazepines such as diazepam elicit efficacy at α1 
(and α5) subtypes, as well. While all three ligands show similar efficacy at α2/α3 subtypes, KRM-
II-81 9 exhibited the highest efficacy at these sites (Figure 3). Both MP-III-80 7 and KRM-II-81 9 
exhibited lower efficacies at α1 subtypes compared to diazepam and the parent ligand HZ-166 2. 
In addition, their efficacies at α2/α3 subtypes were higher (or similar to) than that of Hz-166 2, 
while the efficacy at α5 subtypes was poorer than at HZ-166 2. This indicates MP-III-80 7 and 
KRM-II-81 9 are new generation GABAAR PAMs with better or similar α2/α3 efficacies over α1 
(and α5) efficacy, which is highly desired to avoid sedation, tolerance, dependence and related 
CNS side-effects.  
In the evaluation of metabolic stability as expected, the incorporation of deuterium at the key 
metabolic sites indeed resulted in increased stability in HLM, MLM. In addition, the heterocyclic 
ester bioisosteres were more stable in liver microsomes, as well. The overall outcome of these 
studies was the identification of KRM-II-81 9 as a unique and promising lead compound with 
desirable α2/α3 GABAAR selectivity, low molecular weight (MW = 351), superior lipophilicity 
(clogP = 2.3), good solubility at pH 7, excellent plasma and brain exposure (26 and 18%, 
respectively), as well as in vivo anxiolytic activity in a rodent model.227 It is hoped these ligands 
will soon be evaluated further in models of epilepsy and neuropathic pain. Likewise, MP-III-080 
7 exhibited marked improvement in pharmacokinetic properties over the parent compound HZ-
166 2, as well.227 In a mouse marble burying assay, which is a model of anxiety, MP-III-080 7 at 
10 mg/kg, significantly reduced marble burying activity, which indicated its potent anxiolytic 
activity (Figure 4). Ligand 7 also showed effective anticonvulsant effects versus GABAA NAM 
pentylenetetrazole (PTZ)-induced seizures with very mild sedation at 30 mg/kg i.p. dosage.227 The 
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effect of these compounds on sensory motor ability via the rotarod assay was performed using the 
same mice used for the marble burying assay. At 30 mg/kg dosage all compounds showed minor 
motor impairment except for KRM-II-81 9 (Figure 5). 
 
 
Figure 4. Assessment of anxiolytic-like activity of ligands 2 and 6−10 in the marble burying assay. Male NIH 
Swiss Webster mice (n = 10) were injected ip with vehicle or a test compound (10 or 30 mg/kg) 30 min prior to 
testing. Data were analyzed using ANOVA. Dunnett’s test: (∗) P < 0.05 vs vehicle; (a) mild sedation-like 





Figure 5. Assessment of ataxic effects of ligands 2 and 6−10 in the rotarod assay. Mice, as treated in the marble 
burying assay, were placed on a rotarod set at 4 rpm, and the testing time was 2 min. Mice not falling off during 
the test were given a “Success” designation, while mice that fell once were assigned a “Partial” designation. 
Mice falling twice during the 2 min time period failed the test (modified from the Figures in Poe et al.).227 
 
In the Vogel conflict assay in rats, imidazo[1,5-a][1,4] diazepine esters were inactive due to their 
low bioavaiabilities.251 This result is consistent with the previous observation by Poe et al.227 Both 
oral and i.p. dosing resulted in low drug exposures,227 which explained their inactivity in in vivo 
experiments. On the other hand, ligand 7 exhibited profound efficacy in this anxiolytic-detecting 







Figure 6. Effects of MP-III-080 (7) on punished (unfilled circles) and non-punished (filled circles) drinking of 
rats. Each point represents the mean ± S.E.M. of 8 rats/dose condition. Chlordiazepoxide (20 mg/kg, i.p.) was 
studied as a comparator. Data were analyzed by ANOVA followed by post-ho c Dunnett's test. *: p < 0.05. Non-
punished responding: F3,28 = 2.4, p =0.1.1. Punished responding: F3,2 = 8.7, p < 0.001. *p < 0.05 by post-hoc 
Dunnett's test (modified from the Figures in Witkin et al.).251 
 
It has been illustrated previously by Poe et al. that ester bioisosteres effected pronounced 
improvement in plasma and brain exposures as compared to the parent esters.227 Although direct 
dose/exposure comparisons are not available, data document that both the MP-III-80 (7, anxiolytic 
active) and the oxazole KRM-II-82 (8, anxiolytic inactive) exhibited high exposure in both brain 
and plasma of rats after i.p. dosing.251 
The distinctive nature of oxadiazole 7 and oxazole 8 in behavioral effects was deemed to be due 
to a yet to be determined ancillary action of oxadiazole 7 that supplemented its effects at GABAA 
α2/3 receptors. The oxazole 8 exhibited anti-depressant activity as compared to oxadiazole 7, while 




Alcohol abuse and alcohol (ethanol) use disorder (AUD) have consequences on global public 
health. According to WHO, alcohol related health problems represent the 5th largest factor for 
premature death and disability.269 Currently available treatment options are only partially effective 
and the global concern of alcohol abuse and use related complications are still prevalent even with 
decades of research.270 As a result there is an unment demand for novel treatment options and 
further research for discovery and development of improved treatment options for alcohol abuse 
related behavioral effects, as well as understanding the neuropharmacological mechanisms 
involved in alcohol abuse. 
 
It is known that ethanol induces its abuse-related effects, in part, by potentiating the activity of γ-
aminobutyric acid at GABAA receptors.
271 Genetic studies in humans and preclinical studies with 
mutant mice indicated that  α2 and/or α3 GABAA receptors play a role in the effects of ethanol. 
Consequetly, the design and synthesis of novel GABAAR PAMs with α2 and α3 efficacies would 
permit evaluation of the effects of these subtypes in preclinical models of discriminative stimulus 
and reinforcing effects of ethanol use in primates by Platt et al.269 
In a recent study by Berro et al, it has been illustrated that there is a key role for α2 GABAA and/or 
α3 GABAA receptors in the reinforcing effects of ethanol. Investigation on a series of functionally 
selective PAMs at α2 and α3 GABAA receptors (HZ-166 2, XHe-II-053 3, YT-III-31, YT-III-271) 






                          
Figure 7. Effects of α2GABAA and α3GABAA Receptor-Preferring PAMs. All α2/α3 GABAA receptor ligands 
reproduced the discriminative stimulus effects of ethanol (Figure 7a), engendering dose-dependent increases in 
ethanol-lever responding that were significantly different from that engendered by vehicle [L-838, 417: F(4,12) 
= 14.68, p<0.001; Bonferroni t-tests, p<0.05 vs. vehicle; HZ-166: F(4,9) = 14.47, p<0.001; Bonferroni t-tests, 
p<0.05 vs. vehicle; YT-III-31: F(3,9) = 120.45, p<0.001; Bonferroni t-tests, p<0.05 vs. vehicle]. L-838,417 
(functionally selective PAM at α2GABAA, α3GABAA, and α5GABAA receptors), HZ-166 (functionally selective 
PAM at α2GABAA and α3GABAA receptors) as well as YT-III-31 (functionally selective PAM at α3GABAA 
receptors) induced almost exclusive responding on the ethanol-paired lever over the dose ranges tested, 
generating 97%, 84% and 99% ethanol-lever responding, respectively. None of these compounds significantly 
altered average rates of responding when compared to average rates following vehicle administration (Figure 










Figure 8. The effects of pretreatments with different doses of α2GABAA and α3GABAA receptor-preferring 
compounds on ethanol and sucrose intake. Daily pretreatment with the functionally selective PAMs at 
α2GABAA and α3GABAA receptors XHe-II-053 [group X dose: F(3,24) = 7.20, p<0.005] and HZ-166 [group X 
dose: F(3,24) = 5.39, p<0.01] resulted in significant increases in ethanol intake at 1 mg/kg without affecting 




As suggested by these results, the parent lead compound Hz-166 2 metabolized fast in rodents. 
Bioisosteric modification of the ester function in Hz-166 2 into 1,3-oxazole 9 and 1,2,4-
oxaidiazole 7 resulted in novel α2/α3 subtype selective positive allosteric modulators (PMAs) of 
GABAARs and are stable in human, mouse, rat, and dog live microsomes.
227,239 These desired 
results suggest further evaluations of oxazole 9 and oxadiazole 7 in animal models of epilepsy, 
neuropathic pain, anxiety, and respiration in rodents, as well as in primates. These animal studies 
would require these ligands in gram quantities. 
From a synthetic point of view, Hz-166 2 is a key ligand which is not only a primary lead itself 
but also serves a as a key precursor for several potential drug candidates such as the 1,2,4-
oxadiazoles and 1,3-oxazoles.239 A sustainable supply of Hz-166 2 is a prerequisite for availing 
gram quantities of the newly designed ligands MP-III-080 7 and KRM-II-81 9. The ethyl 
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oxadiazole (MP-III-80 7) was previously synthesized in 40-71% yields from ester 2 (Hz-
166).227,252,253 More importantly, the oxazole 9 was available only in a mere 28% yield on a 3g 
scale process, which posed a major drawback in its synthesis.227 In addition, very low overall yields 
toward Hz-166 (17% in a five step process) also posed a major hurdle in a robust supply of the 
desired ligands.252,239 Consequently, an improved synthetic strategy was desired for accessing the 
ligands in deca-gram quantities for animal and pre-clinical studies.  
An optimized route for the total synthesis of HZ-166 2 is depicted in Scheme 1, as developed 
recently by Li et at.239 After numerous modifications and fine-tuning in each of the five steps, the 
optimized route furnished the target compound Hz-166 2 in a 56% overall yield from the 
beginning, while the previously available route provided Hz-166 2 in a mere 17% overall yield.239 
First, acylation of the aniline 11 with bromoacetyl bromide resulted in synthesis of the acylated 
aniline 12, which could be used in the subsequent reaction without purification. The treatment of 
the crude 12 with dry methanol saturated with ammonia gas at 0 oC was followed by gradual 
heating to reflux to furnish the 1,4-benzodiazepine 13 in 78% yield over two steps. Both of these 
steps could be performed on hundred-gram scales. The 1,4-benzodiazepine amide 13 could be 
purified by recrystallization instead of chromatographic purification. The imidazole top was 
attached via the modified procedure.272 the amide 13 was stirred with potassium tert-butoxide and 
this was followed by diethylchlorophosphate at -50 oC in THF for an hour. Afterwards, the mixture 
was allowed to warm to 0 oC. After stirring for an additional couple of hours at 0 oC, the reaction 
was cooled to -78 oC and treated with ethyl isocyano acetate followed by another equivalent of 
potassium tert-butoxide to furnish the imidazodiazepine scaffold 14 in 81% yield. This step could 
be executed on 80 gram scales and the impurities were removed by washing with 10% EtOAc in 
hexanes. The Heck-type Sonogashira coupling of trimethylsilyl acetylene with the bromo-arene  
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incorporated the acetylene function into 14 in 92% yield. The Hz-166 2 was furnished in 96% 
yield simply by de-silylation of the protected acetylene 15 (TBAF˟H2O). The pure target 
compound Hz-166 2 could be obtained by recrystallization of the crude solid from hot methanol.  
Scheme 1. Optimized synthetic Scheme for the synthesis of Hz-166 2 in 56% yield form 




The 1,2,4-oxadiazole bioisostere, MP-III-80 7 of the ethyl ester 2 is a promising anxiolytic, 
anticonvulsant, as well as antinociceptive ligand. As a consequent, a steady supply of this ligand 
is required for further pre-clinical studies. The previous method for preparing this 1,2,4-oxadiazole 
7 from the ethyl ester 2 suffered from inconsistent yields, harsher conditions or extra steps.273 
Consequently, the optimization of this process by Li et al. by treating the ethyl ester 2 with 
amidoxime and sodium hydride at room temperature in the presence of 3Å molecular sieves to 
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push the reaction further by capturing the released water furnished the 3-ethyl-1,2,4-oxadiazole 7 
in 88% yield.  





               
Figure 9. Structure and oocyte efficacy data of isopropyl oxadiazole 16. Concentration curve of oxadiazole 16 
on GABAA receptors using an EC3 GABA concentration (n = 3), as reported in Namjoshi, et al.274 
  
It has been illustrated previously, that isopropyl oxadiazole 16 in Figure 9, could significantly 
increase metabolic stability as compared to Hz-166 2.267 In contrast, isopropyl oxadiazole 16 lost 
efficacy at the α2 subtype, while it remained potent at α3 subtypes. This loss of efficacy at α2 
179 
 
suggested that replacement of the ethyl function at C(3) with an isopropyl oxadiazole moiety had 
a negative impact on the efficacy profile.267 Consequently, the corresponding cyclopropyl 
oxadiazole was synthesized, and awaits biological testing. 




In addition, as hypothesized, incorporation of deuterium at a key metabolic site would increase the 
metabolic stability of a drug candidate. Consequently, the d3-version of MP-III-080 18 was 
prepared. In addition, the d3-deuterated methyl ester version of the parent compound Hz-166 20 
was also prepared since metabolic instability of Hz-166 2 was its only drawback. By refluxing 
MP-III-80 7 in d4-methanol in the presence of potassium carbonate, this resulted in the 
incorporation of deuterium at four different positions in the IBZ scaffold (Scheme 4).275 On stirring 
the d4-MP-III-80 19 in methanol and this was followed by evaporation (5-6 cycles) of CH3OH 
under reduced pressure the acetylene (C-D) proton was replaced back by C-H and this resulted in 
the desired d3-MP-III-80 18 (>98% d). The extent of the deuterium incorporation was confirmed 
by NMR spectroscopic analysis (Figure 10). The same process on the ethyl ester Hz-166 effected 
the exchange of the same protons with deuterium. The ethyl ester was trans-esterified with the 
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solvent CD3OD to furnished d3-Hz-166-OCD3 ester 20 (Scheme 5). On the other hand, the 
carboxylic acid of Hz-166 4 when reacted under the same conditions, gave the d5-version of 4 
(23). The carboxylic acid deuterium proton was exchanged back to the acid proton by stirring it in 
CH3OH to furnish the d3-HZ-166 acid 22 (Scheme 6). In all cases, the extent of deuterium 
incorporation was at least 98%.  














Figure 10. Typical 1H NMR (CDCl3) of deuterium exchange reaction of MP-III-80 (δ 8.7-4.0). 
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The d3-MP-III-80 18 was investigated for its stability in both acidic (near stomach pH) and alkaline 
(more than gut pH) pH and was found stable in both acidic and alkaline solutions (Tables 1 and 
2). This is an important experiment to illustrate the applicability of d3-MP-III-80 18 in oral dosage. 
Results indicated that d3-MP-III-80 18 is stable enough in both stomach and gut pH, which infers 
that incorporation of deuterium would be beneficial towards improving metabolic stability in vivo. 
Table 1. Stability of d3-MP-III-080 (18) at the pH 2 of the stomach275 
 
pH 2.2 buffer study: 
The preparation of the pH 2.2 buffer solution: The buffer solution was prepared according to the 
previous procedure. 
Procedure: 5 mg of d3-MP-III-080 was dissolved in a minimum amount of methanol and 5 mL of 
above buffer solution was added. The solution was kept stirring at the desired temperature for 6 
hours. At different time intervals 0.3 ml of the solution was collected, diluted with 0.3 ml H2O and 
extracted with EtOAc (2x0.5 ml) and the combined organic layer were washed with brine and used 
for LC-MS analysis. 
Results: 
Compound LC-MS m/z [M + H]+ peaks 
MP-III-080 7 381 major 
Deuterated d3-MP-III-080 18 384 (d3) 
 At room temperature At 37 °C 
After 1 h After 6 h After 1 h After 6 h 
Deuterated d3-MP-III-080 in pH 














Table 2. Stability of d3-MP-III-080 at pH 9.7-9.9; much more alkaline than gut (around 8.5-
9)275 
 
The pH 9.7-9.9 buffer solution preparation: buffer solution was prepared according to the previous 
procedure. 
Procedure: 5 mg of d3-MP-III-080 was dissolved in a minimum amount of methanol and 5 mL of the above 
buffer solution was added. The solution was stirred at the desired temperature for 6 hours. At different time 
intervals 0.3 ml of the solution was collected, diluted with 0.3 ml H2O and extracted with EtOAc (2x0.5 
ml) and the combined organic layer were washed with brine and used for LC-MS analysis. 
Results: 
Compound LC-MS m/z [M + H]+ peaks 
MP-III-080 381 major 
Deuterated d3-MP-III-080 384 (d3) 
 At room temperature At 37 °C 
After 1 h After 6 h After 1 h After 6 h 
Deuterated d3-MP-III-080 in pH 

























The strategic implication of the bioisosteric alteration of the ester functional group in the initial 
α2/α3 subtype selective GABAAR PAM lead compound HZ-166 2 resulted in a new better 
generation of lead compounds with 1,2,4-oxadilxole or 1,3-oxazole moieties at C(3). These novel 
ligands retaining the desired efficacies at α2/α3 receptor subtypes of GABAARs, which avoided the 
CNS adverse effects associated with efficacies at α1, as well as improved metabolic stability. 
Among the newly achieved lead compounds, the 3-ethyl-1,2,4-oxadiazole MP-III-80 7 exhibited 
anxiolytic and antinociceptive properties. In recent investigations, it has been illustrated that α2/α3 
subtype selective GABAAR PAMs might have important applications in alcohol use and alcohol 
abuse disorders. Incorporation of deuterium at key metabolic sites of the lead compounds MP-III-
80 7, HZ-166 2, and Hz-166-acid 4 furnished new derivatives of the PAMs, which would be more 
bioavailable due to better metabolic stability. Preliminary experiments have indicated the viability 
of this strategy. In addition, further derivatization of the lead compounds resulted in several newer 
ligands which are felt to be promising novel compounds. Although, most of the newly designed 
and synthesized ligands await full biological evaluation including pharmacokinetic profiles, this 
new set of GABAA PAMs with improved efficacies at the desired α2/α3 subtypes will add to the 
arsenal of imidazodiazepine drugs for the treatment of various CNS disorders. These ligands 
should meet the unmet need for better psychopharmaceutics which may be applicable in all 
patients including the elderly. These anxiolytic, anticonvulsant and antinociceptive ligands should 
be better for long term treatment and avoid adverse complications. It is hoped that the newly 
synthesized compounds will be evaluated by our collaborators in the near future. Especially d3-





6.1 Marble Burying (CRO)227  
Mice were tested in the marble burying assay using methods previously described (Li, et al., Life 
Sci., 2006, 78, 1933 – 1939). Mice were dosed i.p. with either vehicle (1% carboxymethyl 
cellulose) or a test compound 30 min prior to testing. Mice were placed in a 17 x 28 x 12 cm high 
plastic tub with 5 mm sawdust shavings (Harlan Sani-Chips, HarlanTeklad, Indianapolis, IN) on 
the floor that were covered with 20 blue marbles (1.5 cm diameter) placed in the center. Mice were 
left in the tub for 30 min. The number of marbles buried (2/3 covered with sawdust) were counted 
and recorded. 
6.2 Rotarod (CRO)227 
Male NIH Swiss mice (Harlan Sprague-Dawley, Indianapolis, IN) were tested in the rotarod assay 
in a dimly lit testing room according the general methods previously described (Li, et al., Life Sci., 
2006, 78, 1933 – 1939). After being acclimated to the experimental room for one hour, the mice 
(n = 10 per group) were dosed i.p. 30 min prior to testing with either vehicle (1% CMC) or 
compound (10 or 30 mg/kg). Mice were placed on a rotarod (Ugo Basile 7650) operating at 4 rpm 
and observed for falling for 2 min. Mice that did not fall during the 2 min of testing were given a 
“Success” designation. Mice that fell once were given a “Partial” score, while the mice that fell 






6.3 Vogel Conflict Behavior (CRO)251 
 
Day 1, animals are moved from colony room into test room and put into operant chambers with 
water available, white noise, and houselight on (program title Vogel train). A timer starts when the 
first lick is made. For the first 3 min after the first lick, data is recorded as unpunished licks. After 
3 min, the second component becomes active for 3 min. All licks in the second component are 
recorded as punished licks. At the end of the 6 min, the chamber goes dark. Animals are removed 
and returned to home cages. After all groups of animals have been exposed to the chambers, water 
is made available in the home cage for 30 min. After 30 min, water is removed and animals are 
transported back to colony room. Data for both components is recorded as the number of licks. 
Sometime data for day 1 and day 2 is not recorded due to operant chambers being used for other 
testing protocols. Data is always recorded for day 3. 
Day 2 conditions were identical to day one training. On day 3, animals were randomly assigned to 
dose groups and drugged according to route and pre-treatment times recorded below. Animals are 
run on program Vogel FR20, which is identical to Vogel training with the exception of during the 
2nd component (punished), every 20th lick is shocked. Data for both components is recorded as 
the number of licks. Shock intensity = 0.5 mA, duration = 100 ms. Shock is delivered through the 
water sipper tube. Chlordiazepoxide (CDAP) 20 mg/kg, i.p., 30 min pre-session is used as a 







6.4 Ethanol or Sucrose Self-Administration (Dr. Donna Platt at University of 
Mississippi Medical Center)269 
Drinking sessions occurred 5 d/wk in the animal’s home cage, as previously described (Sawyer et 
al., 2014). Each session lasted 3 hours. Animals were trained to drink either ethanol (2%, w/v; 
n=5) or sucrose solution (0.3 or 1%, w/v, depending on the animal; n=5) using an operant drinking 
panel mounted on the side of the home cage. The ethanol concentration was chosen because it 
maintained intake significantly above water levels and is on the ascending limb of the 
concentration-effect curve (see Ruedi-Bettschen et al., 2013), thus allowing us to detect either 
increases or decreases in drinking after pretreatment administration. The sucrose concentrations 
were chosen because they maintained approximately equivalent levels of intake to ethanol (EtOH) 
under baseline conditions (Ruedi-Bettschen et al., 2013; Sawyer et al., 2014). 
The drinking panel contained two retractable sippers (Med Associates) connected with tygon 
tubing to stainless steel reservoirs mounted outside of the cage. A response lever (Med Associates) 
was positioned below each sipper, and a set of colored lights were positioned above. Each lever 
press resulted in an audible click and served as a response. In these experiments, only 1 side of the 
panel was active. Illumination of white lights signaled the start of the session and ethanol or 
sucrose availability. Every 10 responses (FR 10) resulted in a switch from illumination of the white 
light to illumination of a red light and extension of the drinking spout for 30 seconds. Depression 
of the spout during extension resulted in fluid delivery, continuing as long as the sipper was both 
depressed and extended. Thus, both the actual duration (up to 30 seconds) and volume of intake 
were controlled by the subject. A brief (1 second) timeout followed each spout extension, in which 
all stimulus lights were dark and responding had no programmed consequences. Responses were 
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recorded and outputs controlled by a software program (MedPC; Med Associates). At the end of 
each session, reservoirs were drained and the amount of liquid consumed (ml) measured. 
XHe-II-053 (0.3-3 mg/kg), HZ-166 (0.3-3 mg/kg), YT-III-31 (0.1-3 mg/kg) or YT-III-271 (0.1-1 
mg/kg) were administered intramuscularly 10 minutes before the start of a self-administration 
session. Each dose of each compound was studied for a minimum of 5 consecutive sessions and 
until intake was stable, which was defined as no upward or downward trend in amount consumed 
(ml) over 3 consecutive days (i.e., for each 3-day period, intake could not be consistently 
increasing or decreasing across the consecutive days). Following evaluation of each dose, monkeys 
were returned to baseline self-administration conditions (i.e., with no pretreatment injection) until 
intake stabilized again. Doses were randomized within each treatment condition, and all doses of 













7. Experimental Section 
7.1 7-Bromo-5-(pyridin-2-yl)-1H-benzo[e][1,4]diazepin-2(3H)-one (13) 
The 2'-pyridyl ketone 11 (120 g, 433.2 mmol) was dissolved in dry DCM (1.4 L) in a 3-neck round 
bottom flask and was stirred with an overhead mechanical stirrer for 15 min to obtain a 
homogenous solution. Then solid NaHCO3 (72.8 g, 866.4 mmol) was added to the solution with 
vigorous stirring to avoid clogging of the stirrer, and the mixture was cooled to 0 °C using an ice 
bath. The bromoacetyl bromide (144.9 g, 714.8 mmol) was dissolved in dry DCM (200 mL) and 
was then added dropwise at 0 °C with an addition funnel. The reaction mixture was allowed to 
warm to rt and stirred overnight until the starting material was consumed as monitored on analysis 
by TLC (silica gel, EtOAc/hexane, 1:1). The reaction mixture was quenched with ice-water (500 
mL) and stirred at rt for 30 min. The organic layer was then separated, and the aq layer was 
extracted with DCM (3 x 250 mL). The organic layers were combined, as well as washed (200 mL 
each) sequentially with a saturated aq solution of NaHCO3, water, 10% HCl, brine and then dried 
(Na2SO4). The combined organic layer was then concentrated to 1/4
th of its original volume under 
reduced pressure. The intermediate 12, which was prepared, was used for the next step without 
further purification. 
Methanol (1.4 L) was cooled to 0 °C using an ice-water cooling bath and saturated with anhydrous 
ammonia gas. The DCM solution of intermediate 12 was added to the solution of saturated 
MeOH/NH3 at 0 °C. The mixture was allowed to warm to rt and slowly heated to reflux with 
caution (mild exotherm observed) until the starting material was consumed on analysis by TLC 
(silica gel) in 12 h. The reaction mixture was then cooled to rt and the solvent was removed under 
reduced pressure. The solid which remained was filtered and washed with water (3 x 150 mL), 
cold EtOAc (3 x 50 mL) and DCM (3 x 50 mL). The crude solid was dissolved in MeOH (600 
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mL) and DCM (100 mL) at 60 °C, and the solution was concentrated to 1/4th of its original volume. 
The amide 13 was recrystallized at rt and filtered, after which it was washed with DCM to obtain 
the majority of the pure amide 13 as white crystals. The filtrate was combined and concentrated 
under reduced pressure to an oily residue, which was further purified by flash chromatography on 
silica gel (EtOAc/hexane, 1:1 and 1% of TEA) to afford additional amide 13 (108.6 g, 78% yield 
over the two steps): M.p = 228-229 °C; Rf = 0.4 (EtOAc-hexane, 1:1 and 1% of TEA); 
1H NMR 
(300 MHz, DMSO-d6) δ 10.63 (s, 1H), 8.55 (d, J = 4.1 Hz, 1H), 8.04 (d, J = 7.7 Hz, 1H), 7.93 (d, 
J = 7.4 Hz, 1H), 7.69 (d, J = 8.6 Hz, 1H), 7.54-7.44 (m, 1H), 7.42 (s, 1H), 7.18 (d, J = 8.7 Hz, 1H), 
4.23 (s, 2H);  13C NMR (75 MHz, DMSO-d6) δ 170.34, 168.10, 156.30, 148.85, 139.28, 137.55, 
134.40, 134.15, 127.92, 125.37, 123.91, 123.57, 114.51, 57.56. HRMS (ESI/IT-TOF) [M + H]+ 




The amide 13 (80 g, 253.2 mmol) was suspended in dry THF (1.5 L), and cooled to -35 °C using 
a dry ice bath, after which potassium t-butoxide (34.1 g, 303.8 mmol) was added in one portion. 
The reaction mixture was stirred until it reached 0° C and then stirred for 0.5 h at 0 °C. The mixture 
was then cooled to -50 °C, after which diethyl chlorophosphate (61.2 g, 354.5 mmol) was added 
dropwise with an addition funnel. The dry ice bath was removed to allow the temperature to rise 
to 0 °C, after which it was allowed to stir for 2 h with an ice-water bath. The solution was then 
cooled to -78 °C with a dry-ice bath and ethyl isocyanoacetate (40.1 g, 354.5 mmol) was added, 
immediately followed by a second portion of potassium t-butoxide (34.1 g, 303.8 mmol). This 
solution was allowed to stir overnight, during which period it was allowed to warm to rt. The 
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reaction was completed after 14 h on analysis by TLC (silica gel, EtOAc/hexanes/DCM, 2:2:1, 
and 1% TEA). The reaction mixture was quenched by addition of a cold saturated aq solution of 
NaHCO3 (500 mL) and extracted with EtOAc. The organic layers were combined and washed with 
brine (2 x 200 mL), and dried (Na2SO4). The solvent was removed under reduced pressure to obtain 
a dark brown solid residue. The solid was washed with Et2O/EtOAc (9:1) to remove most of the 
impurities and further recrystallized from EtOAc and hexane (1:4), followed by washing the solid 
with cold Et2O to afford the majority of the pure ethyl ester 14. The remaining filtrate was 
combined and purified by flash chromatography to obtain additional ethyl ester 14 (silica gel, 
EtOAc/ hexanes/DCM 2/2:1 and 1% TEA) as an off-white solid (84.2 g, 81% yield): M.p = 212-
213 °C; Rf = 0.3 (EtOAc-hexane-DCM, 2:2:1 and 1% of TEA); 
1H NMR (300 MHz, CDCl3) δ 
8.60 (d, J = 4.4 Hz, 1H), 8.11 (d, J = 7.9 Hz, 1H), 8.00 (s, 1H), 7.86 (td, J = 8.0, 1.7 Hz, 1H), 7.80 
(dd, J = 8.6, 2.2 Hz, 1H), 7.60 (d, J = 2.1 Hz, 1H), 7.51 (d, J = 8.6 Hz, 1H), 7.41 (dd, J = 7.1, 5.2 
Hz, 1H), 6.13 (d, J = 10.4 Hz, 1H), 4.51 – 4.33 (m, 2H), 4.17 (d, J = 11.6 Hz, 1H), 1.44 (t, J = 7.1 
Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 167.04, 162.89, 156.17, 148.67, 138.39, 136.90, 135.27, 
134.95, 134.53, 134.45, 129.33, 128.50, 124.86, 124.28, 123.94, 120.51, 60.75, 45.00, 14.42. 
HRMS (ESI/IT-TOF) [M + H]+ calcd for C19H16BrN4O2 411.0451; found 411.0454. 
 
7.3 Ethyl-6-(pyridin-2-yl)-8-((trimethylsilyl)ethynyl)-4H-benzo[f] imidazo[1,5a]-[1,4]diaze-
pine-3-car boxylate (15) 
The ethyl ester 14 (63.8 g, 155.1 mmol) was dissolved in TEA (400 mL) and dry CH3CN (600 
mL) in a 3-neck round bottom flask with a reflux column attached. The solution was then degassed 
three times under vacuum and argon. Trimethylsilylacetylene (22.9 g, 232.7 mmol) and 
bis(triphenyl phosphine)-palladium (II) acetate (6.4 g, 8.53 mmol) were added to the solution 
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under argon, and the mixture was degassed for four times (as above). The reaction mixture was 
then heated to reflux under argon and allow to stir overnight. The reaction process was completed 
in 15 h as monitored on analysis by TLC (silica gel, EtOAc/hexanes, 7:3, and 1% TEA). The 
reaction mixture was then cooled to 0 °C, and filtered through celite. This was followed by washing 
with EtOAc, and drying (Na2SO4). The filtrate was concentrated under reduced pressure. The black 
residue, which resulted, was loaded on a silica plug (4 g of silica/1 g of the product, 
EtOAc/hexanes, 1:1 with 1% TEA) to remove the baseline impurities and the material was 
recrystallized from EtOAc. The crystals were filtered and washed with Et2O to afford pure 
trimethylsilyl ethyl ester 15. The filtrate was purified by flash chromatography to afford additional 
ester 15 as an off-white solid (61.1 g, 92% yield): M.p = 203-204 °C; Rf = 0.5 (EtOAc-hexane, 1:1 
and 1% of TEA); 1H NMR (300 MHz, CDCl3) δ 8.56 (d, J = 4.1 Hz, 1H), 8.02 (d, J = 7.8 Hz, 1H), 
7.90 (s, 1H), 7.78 (t, J = 7.7 Hz, 1H), 7.70 (d, J = 8.3 Hz, 1H), 7.51 (d, J = 9.2 Hz, 2H), 7.34 (t, J 
= 5.9 Hz, 1H), 6.08 (d, J = 9.2 Hz, 1H), 4.47 – 4.31 (m, 2H), 4.10 (d, J = 6.9 Hz, 1H), 1.41 (t, J = 
7.0 Hz, 3H), 0.21(s, 9H); 13C NMR (75 MHz, CDCl3) δ 167.80, 162.92, 156.55, 148.79, 138.47, 
136.79, 135.67, 135.15, 135.05, 134.50, 129.26, 127.03, 124.71, 123.97, 122.72, 122.24, 102.79, 
97.05, 60.71, 45.03, 14.42, -0.23. HRMS (ESI/IT-TOF) [M + H]+ calcd for C24H25N4O2Si 
429.1741; found 429.1747. 
 
7.4 Ethyl-8-ethynyl-6-(pyridin-2-yl)-4H-benzo [f]imidazo [1,5-a][1,4] diazepine-3-car-
boxylate   (HZ-166, 2) 
The trimethylsilyl ethyl ester 15 (50 g, 116.8 mmol) was dissolved in THF (1 L) and cooled to -78 
°C. Tetrabutylammonium fluoride hydrate (1 M solution in THF, 175.1 mmol) was added to the 
solution, and this was followed by water (50 mL). The reaction mixture was stirred at -78 °C until 
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the starting material was consumed in 0.5 h, as analyzed by TLC (silica gel). The reaction mixture 
was allowed to warm to 0 °C and quenched by a slow addition of water (500 mL). The organic 
layer was separated and the aq layer was extracted EtOAc (5 x 300 mL). The combined organic 
layers were washed with brine (2 x 400 mL), and dried (Na2SO4). The solvent was removed under 
reduced pressure and the residue, which resulted, was dissolved in the mixture of DCM (100 mL) 
and MeOH (400 mL) at 50 °C and the solution was concentrated to 1/3rd of its original volume. 
The majority of the ethyl ester 2 was recrystallized at rt with a seed crystal added, and the solid 
was further washed with cold MeOH. The filtrate was combined and purified by a wash column 
(silica gel, EtOAc/hexane/DCM 8:1:2, and 1% TEA) to afford additional ethyl ester 2 as a white 
powder (37.8 g, 96% yield): M.p = 243-244 °C; Rf = 0.4 (EtOAc-hexane-DCM, 8:1:2 and 1% of 
TEA); 1H NMR (300 MHz, CDCl3) δ 8.59 (d, J = 4.6 Hz, 1H), 8.08 (d, J = 7.9 Hz, 1H), 7.96 (s, 
1H), 7.83 (td, J = 7.8, 1.6 Hz, 1H), 7.77 (dd, J = 8.4, 1.7 Hz, 1H), 7.61 – 7.54 (m, 2H), 7.38 (dd, J 
= 7.0, 5.3 Hz, 1H), 6.12 (d, J = 10.6 Hz, 1H), 4.56 – 4.27 (m, 2H), 4.16 (d, J = 10.2 Hz, 1H), 3.17 
(s, 1H), 1.44 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 167.59, 162.82, 156.17, 148.62, 
138.38, 137.12, 136.18, 135.42, 135.38, 134.57, 129.23, 127.01, 124.92, 124.14, 122.92, 121.30, 
81.64, 79.58, 60.86, 44.99, 14.43. HRMS (ESI/IT-TOF): [M + H]+ calcd for C21H17N4O2 
357.1346; found 357.1344. 
 
7.5 3-Ethyl-5-(8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)-1,2-
,4-oxadiazole (MP-III-080, 7) 
The ethyl ester 2 (4.4 g, 12.4 mmol) was dissolved in dry THF (200 mL) at rt under argon. In a 
separate flask that contained 3Å molecular sieves, N-hydroxypropionimidamide (4.35 g, 19.4 
mmol) was dissolved in dry THF (50 mL) under argon and then treated with sodium hydride (60% 
194 
 
dispersion in mineral oil, 360 mg, 14.8 mmol). The mixture was allowed to stir for 15 min and was 
then added dropwise to the solution of ethyl ester 2. The reaction was completed in 3 h as analyzed 
by TLC (silica gel). The reaction mixture was quenched with a saturated aq NaHCO3 solution (10 
mL) extracted with EtOAc (3 x 250 mL). The organic layers were combined, washed with brine, 
and dried (Na2SO4) The solvent was removed under reduced pressure. The solid, which resulted, 
was purified by flash chromatography (silica gel, EtOAc/hexanes 4:1 and 1% TEA) to afford pure 
1,2,4-oxadiazole 7 as a white powder (4.1 g, 88% yield):  M.p = 204-205 °C; Rf = 0.6 (EtOAc-
hexane, 4:1 and 1% of TEA); 1H NMR (500 MHz, CDCl3) δ 8.58 (d, J = 4.3 Hz, 1H), 8.07 (d, J = 
8.0 Hz, 1H), 8.05 (s, 1H), 7.83 (dd, J = 11.8, 4.4 Hz, 1H), 7.78 (dd, J = 8.4, 1.3 Hz, 1H), 7.61 (d, 
J = 8.3 Hz, 1H), 7.57 (d, J = 1.0 Hz, 1H), 7.38 (dd, J = 6.7, 5.3 Hz, 1H), 6.16 (d, J = 11.4 Hz, 1H), 
4.29 (d, J = 11.2 Hz, 1H), 3.19 (s, 1H), 2.85 (q, J = 7.6 Hz, 2H), 1.44 (t, J = 7.6 Hz, 3H); 13C NMR 
(126 MHz, CDCl3) δ 171.9, 170.7, 167.9, 156.3, 148.7, 137.1, 136.3, 136.1, 135.9, 135.5, 135.2, 
127.1, 125.0, 124.8, 124.1, 122.9, 121.4, 81.6, 79.7, 44.9, 19.8,  11.6. HRMS (ESI/IT-TOF) [M + 




The ethyl ester 2 (0.5 g, 1.40 mmol) was dissolved in dry THF (50 mL) at rt under argon. In a 
separate flask that contained 3Å molecular sieves, N'-hydroxycyclopropanecarboximidamide (0.2 
g, 2.10 mmol) was dissolved in dry THF (10 mL) under argon and then treated with sodium hydride 
(60% dispersion in mineral oil, 2.8 mg, 1.7 mmol). The mixture was allowed to stir for 15 min and 
was then added dropwise to the solution of ethyl ester 2. The reaction was completed in 3 h as 
analyzed by TLC (silica gel). The reaction mixture was quenched with a saturated aq NaHCO3 
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solution (2 mL) extracted with EtOAc (3 x 100 mL). The organic layers were combined, washed 
with brine, and dried (Na2SO4) The solvent was removed under reduced pressure. The solid, which 
resulted, was purified by flash chromatography (silica gel, EtOAc/hexanes 4:1 and 1% TEA) to 
afford pure 1,2,4-oxadiazole 17 as a white powder (0.43 g, 78% yield): 1H NMR (300 MHz, 
CDCl3) δ 8.59 (d, J = 4.8 Hz, 1H), 8.06 (d, J = 7.9 Hz, 1H), 8.03 (s, 1H), 7.84 (td, J = 7.8, 1.6 Hz, 
1H), 7.78 (dd, J = 8.4, 1.7 Hz, 1H), 7.58 (dd, J = 7.2, 5.0 Hz, 2H), 7.43 – 7.34 (m, 1H), 6.10 (s, 
1H), 4.28 (s, 1H), 3.18 (s, 1H), 2.28 – 2.03 (m, 1H), 1.10 (dd, J = 23.7, 15.5 Hz, 4H); 13C NMR 
(126 MHz, CDCl3) δ 172.7, 170.5, 167.7, 156.1, 148.6, 137.2, 136.3, 136.1, 135.9, 135.5, 135.3, 
127.0, 124.8, 124.1, 122.9, 121.5, 81.6, 79.7, 44.9, 7.8, 6.9. HRMS (ESI/IT-TOF) [M + H]+ calcd 
for C23H16N6O 393.4127; found 393.1458. 
Representative example: ethyl oxime “N'-hydroxypropionimidamide” 
Hydroxylamine hydrochloride (9.73 g, 0.14 mol) and potassium carbonate (41.5 g, 0.3 mol) was 
added in methanol (400 mL) and water (80 mL). The suspension which resulted was stirred at rt 
for 15 min after which it was heated to reflux. Propionitrile (7.1 mL, 0.1 mol) was added dropwise 
and the reaction, which resulted, was stirred at reflux for 16 h.  After that, the reaction mixture was 
cooled to 0 oC and the precipitate which formed was filtered. The solvent from the filtrate was 
removed under reduced pressure. The solid residue was dissolved in EtOAc and washed with 
water, brine, and dried (Na2SO4), after which the solvent was removed under reduced pressure to 
afford the ethyl oxime as a white solid (6.05 g, 69%): HPLC-MS (ESI) m/z (M+H) 89.06. This 
material was used for the next step without further characterization. 
By following the same procedure with Cyclopropanecarbonitrile (6.49 mL, 72.3 mmol), this 




zepin-3-yl)-1,2,4-oxadiazole (18) [d3-MP-III-80] 
The 1,2,4-oxadiazole 7 (200 mg, 0.526 mmol) was taken in a clean and dry round bottom flask. 
K2CO3 (363 mg, 2.63 mmol) and CH3OD (3 ml) were added to the above flask and the suspension 
which resulted was refluxed for 3 h. After that the reaction mixture was cooled to rt and the CH3OD 
was evaporated under reduced pressure. Then 5 mL of distilled dry EtOAc was added to the white 
residue and it was sonicated for 5 min to dissolve the product completely. The suspension was 
then passed through a pad of celite to filter out the insoluble K2CO3 and the celite pad was washed 
with additional EtOAc (5x3 mL). The eluent was evaporated under reduced pressure. The residue 
was dissolve in dry CH3OH and evaporated by rotary evaporator. This process was repeated 5-6 
cycles to furnish completely protonated acetylene. The % deuterium incorporation was confirmed 
by NMR spectroscopy. Finally, the colored impurity was removed by re-crystallization to furnish 
the tri-deuterated MP-III-080 18 (189 mg, 94%). 1H NMR (300 MHz, CDCl3) δ 8.57-8.55 (m, 1H), 
8.07-8.04 (m, 1H), 7.80 (td, J = 7.8, 1.7 Hz, 1H), 7.76 (dd, J = 8.3, 1.8 Hz, 1H), 7.59 (brd, J = 8.3 
Hz, 1H), 7.56 (d, J = 1.8 Hz, 1H), 7.37-7.34 (m, 1H), 3.18 (s, 1H), 2.84 (q, J = 7.6 Hz, 2H), 1.39 
(t, J = 7.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 171.88, 170.73, 167.89, 156.38, 148.76, 136.88, 
136.35, 136.06, 135.35, 135.19, 127.10, 124.85, 124.73, 123.96, 122.76, 121.39, 81.58, 79.62, 








a][1,4]diazepine-3-carboxylate (20) [d3-Hz-166-OCD3 ester]  
The ethyl ester 2 (100 mg, 0.28 mmol) and K2CO3 (38 mg, 0.28 mmol) were placed in a round 
bottom flask. Dry CD3OD (5 mL) was added to the mixture under an argon atmosphere at rt. The 
reaction mixture was allowed to stir for 2 h under reflux. After 2 h TLC was taken. The excess 
solvent was removed under reduced pressure and the compound further purified by flash 
chromatography (silica gel, hexane and ethyl acetate) to afford compound 21 as a white solid (76 
mg, 78% yield). The d7-ligand 21 was dissolved in dry CH3OH (10 mL) and was added to the 
mixture under an argon atmosphere at rt. The reaction mixture was allowed to reflux for 3 h. The 
excess solvent was removed under reduced pressure to afford d6-methyl ester ligand 20 as a white 
solid (89 mg, 89% yield). d7-ligand 21: 1H NMR (300 MHz, CDCl3) δ 8.59 (bs, 1H), 8.08 (d, J = 
8 Hz, 1H), 7.83-7.76 (m, 2H), 7.58-7.55 (m, 2H), 7.38 (t, J = 6 Hz, 1H); LC-MS calcd for 
C20H8D7N4O2 350 found 350. d6-ligand 20 TLC; Rf = 0.35 (EtOAc:Hexane 3:1 and 1% of each 
MeOH and TEA) on silica gel plate; d6-ligand 20: 1H NMR (300 MHz, CDCl3) δ 8.58 (bs, 1H), 
8.07 (d, J = 8 Hz, 1H), 7.84-7.75 (m, 2H), 7.58-7.55 (m, 2H), 7.38 (t, J = 6 Hz, 1H), 3.17 (s, 1H); 
Compound 20 LC-MS calcd. for C20H9D6N4O2 (M + H)
+ 349 found 349; HRMS (ESI) calcd. For 
C20H9D6N4O2 (M + H)
+ 349.1572, found 349.1552. 
 
7.9 1,4,4-Deuteroro-8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3- 
carboxylic acid (22) [d3-Hz-166-Acid] 
The acid 4 (200 mg, 0.609 mmol) was placed in a clean and dry round bottom flask. Then K2CO3 
(421 mg, 3.046 mmol) and CH3OD (3 ml) was added to the above flask and the suspension that 
resulted was refluxed for 5 h under argon. After that, the reaction mixture was allowed cool to rt 
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and the solvent CH3OD was removed under reduced pressure. The white solid which resulted was 
then dissolved in D2O (3 ml) and cooled to 0°C in an ice bath. Then deuterium chloride (2M in 
D2O) was added dropwise until the pH reached 4. The precipitate that formed was then filtered 
and washed with D2O (2x1 mL). The white solid was dried at rt for 2 h and then at 45°C for 12h 
to furnish the tri-deuterated compound 22 (188 mg, 93%); 1H NMR (300 MHz, CDCl3): δ 8.62-
8.52 (m, 1H), 8.11 (d, J = 7.7 Hz, 1H), 7.94-7.80 (m, 1H), 7.79-7.71 (m, 1H), 7.71-7.59 (m, 1H), 
7.58-7.46 (m, 1H), 7.44-7.33 (m, 1H), 3.16 (s, 1 H); HRMS (ESI) calcd. for C19H10D3N4O2 (M + 
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III. Appendix (Part I) 
Basket Test: The Basket test is useful in assessing motor coordination and sensorimotor deficits 
in rodent models of CNS disorders. An animal is placed in the center of the basket and the basket 
is inverted. The animal is allowed to climb down the walls of the wire basket into its home cage. 
The time it takes for the animal to complete the task is scored. This test is used to evaluate novel 
chemical entities for their effect on motor performance. 
I. BASKET TEST 
Study: pilot ______________________________ 
Group: C57BL/6 mice, male ______________________________TAPE #:  
Age: 6 months ______________________________ DATE: April 1, 2015 
Table A1 
  MOUSE # 
 
GROUP Trial 1 (s) Trial 2 (s) Trial 3 (s) Mean (s) 
    1  
10 mg/kg DZP  
4 14 3 7,0 
    2 23 55 28 35,3 
    3 13 12 10 11,7 
    4 30 mg/kg 
CMD-45  
 
180 180 30 130,0 
    5 16 44 49 36,3 
    6 106 180 178 154,7 
    7 30 mg/kg 
XHE-III-74  
 
61 180 168 136,3 
    8 60 22 10 30,7 
    9 17 33 8 19,3 






Men values per group: 
10 mg/kg DZP: 15,0 s (highly incapacitating) 
30 mg/kg CMD-45: 107,0 s (moderately incapacitating) 
30 mg/kg XHE-III-74: 51,3 s (clearly incapacitating) 
Hence, when administered at high doses of 30 mg/kg, both alpha4-selective ligands diminished 
the capability of male C57BL/6 mice to perform the basket test, pointing to the effect of motor 
impairment, possibly connected with neuromuscular strength and/or motor coordination. The 
effect was more pronounced with XHE-III-74. 
Step-down Test: The Passive Avoidance step-down cage, for mice or immature rats, is based on 
the stepdown scheme in which the animal is dropped on an elevated platform. The grid 
surrounding the base will start vibrating and the latency (time on the platform) will be measured. 
Animals will be trained for this study. This test is used to evaluate novel chemical entities for 
their effect on anti-anxiety behavior. 
II. STEP-DOWN TEST 
Study: pilot ______________________________ 
Group: C57BL/6 mice______________________________TAPE #:  
Age: 6 months ______________________________ DATE: April 1, 2015 
Table A2 
  MOUSE # 
 
GROUP LATENCY TO STEP 
    DOWN (s) 
    1  
10 mg/kg DZP  
2 
    2 180 
    3 2 
    4 30 mg/kg CMD-45  
 
180 
    5 180 
    6 180 
    7 30 mg/kg XHE-III-74  
 
180 
    8 180 
    9 180 





The experiment was performed under bright light, which promotes anxious reaction and helps 
reveal anti-anxiety potential of a treatment.  
Mice dosed with 10 mg/kg DZP showed a clear tendency of decreased anxiety, while two 
alpha4-preferring ligands were devoid of any hint of anti-anxiety action. 
Rotarod: At least two weeks of training are needed to ensure that all subjects have learned the 
task to the same degree. In the fixed rotation protocol, the animals are placed on a rod which 
constantly rotates at 20 rpm. A trial is complete when the animal falls or the time period ends 
(180 s); This test is used to evaluate novel chemical entities for their effect on motor 
performance. 
III. ROTAROD TEST 
Study: pilot ______________________________ 
Group: Wistar rats, male ______________________________TAPE #:  
Age: 10 weeks ______________________________ DATE: April 1-3, 2015 
Table A3 
  RAT # 
 
GROUP Time until fall (s) 
    1 SOL 163 
    2 DZP (5mg/kg) 1 
    3 CMD-45 (15 mg/kg) 31 
    4 XHE-III-74 (15 mg/kg) 2 
    5 CMD-45 (10 mg/kg) 15 
    6 CMD-45 (10 mg/kg) 180 
    7 XHE-III-74 (10 mg/kg) 7 
    8 XHE-III-74 (10 mg/kg) 52 
    9 CMD-45 (5 mg/kg) 180 
Comments: 
During two consecutive days, 16 rats were trained to keep balance while on the rotating rod (20 
rpm, fixed velocity). On the third day, 9 of 6 animals satisfied the cut-off criterion of balancing 
without any fall during 180 s. 
During testing (20 min after i.p. administration), diazepam at 5 mg/kg and XHE-III-74 at 15 
mg/kg were exceptionally incapacitating. XHE-III-74 dosed at 10 mg/kg was still incapacitating 
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and we did not find the no-observed-effect-level of XHE-III-74. On the other hand, CMD-45 was 
incapacitating at 15 mg/kg and less so at 10 mg/kg, while 5 mg/kg appeared to be the dose close 
to the no-observed effect level of CMD-45. 
Hence, ataxia is a dose-dependent effect of both alpha4-preferring ligands. Nonetheless, the 
ataxic potential of XHE-III-74 is more pronounced. 
  
Table A4 LOCOMOTOR ACTIVITY TEST in adult male Wistar rats 2 months old (Any-maze 
software) 
 
The animals were recorded during 45 min, beginning 20 min after i.p. administration of 
treatment  
 
 Total distance travelled (m) 
 Treatment    N  Mean  SD SE Data  
 sol   6 22.6427 ±3.0003 ±1.2248 25.712, 22.019, 23.710, 23.290, 
17.028, 24.097 
 XHe III 74  10 mg/kg   6 12.0625 ±2.8401 ±1.1595 10.088, 
15.450, 9.999, 10.566, 15.978, 
10.294 
 CMD 45 10 mg/kg   6 12.1652 ±5.6081 ±2.2895 7.570, 6.207, 15.374, 9.883, 12.574, 
21.383 
 
 ANOVA :  F(2,15) = 13.7099   p = 0.000 
 Tukey test  
 sol vs. XHe III 74  10 mg/kg                              q(15,3) = 6.4443 p = 0.001 
 sol vs. CMD 45 10 mg/kg                              q(15,3) = 6.3817 p = 0.001 
 XHe III 74  10 mg/kg vs. CMD 45 10 mg/kg q(15,3) = 0.0625 p = 0.999 
 
 
 Total time mobile (s) 
 Treatment    N  Mean  SD SE Data  
 sol   6 1878.10 ±375.37 ±153.24 1587.2, 1999.2, 2251.4, 1913.5, 
2225.6, 1291.7 
 XHe III 74  10 mg/kg   6 1096.38 ±252.38 ±103.03 755.4, 
1506.5, 949.8, 1074.5, 1086.4, 
1205.7 
 CMD 45 10 mg/kg   6 1104.83 ±294.22 ±120.11 709.8, 873.4, 1521.8, 1023.1, 1261.8, 
1239.1 
 
 ANOVA:  F(2,15) = 12.4579   p = 0.001 
 Tukey test  
 sol vs. XHe III 74  10 mg/kg                              q(15,3) = 6.1464 p = 0.002 
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 sol vs. CMD 45 10 mg/kg                              q(15,3) = 6.0799 p = 0.002 
 XHe III 74  10 mg/kg vs. CMD 45 10 mg/kg q(15,3) = 0.0664 p = 0.999 
 
 Total distance travelled (m) 
  
Figure 1. Total distance travelled. The data analysed has been limited in the following 
way: Treatment = sol, XHe III 74  10 mg/kg or CMD 45 10 mg/kg. 
 
 
 Total time mobile (s) 
  
Figure 2. Total time mobile. The data analysed has been limited in the following way: 
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The line shown represents the group mean
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 Total distance travelled (m) 
  
Figure 1. Total distance travelled. The data analysed has been limited in the following 
way: Treatment = sol, XHe III 74  10 mg/kg or CMD 45 10 mg/kg  
 Total time mobile (s) 
  
Figure 2. Total time mobile. The data analysed has been limited in the following way: 
Treatment = sol, XHe III 74  10 mg/kg or CMD 45 10 mg/kg  
Comment: Both, XHe III 74 and CMD 45 dosed at 10 mg/kg were clearly sedative in 
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V. LOCOMOTOR ACTIVITY TEST in adult female Wistar rats 4 month old, weighing 350 g 
and more (Any-maze software) 
-Pilot experiment- 
 
The animals were recorded during 30 min, beginning 20 min after i.p. administration of 
treatment 
 
 Total distance travelled (m), female Wistar rat 
 Treatment    N  Mean  SD Data 
 CMD 45 30 mg/kg   2 0.1010 ±0.0665 0.054, 0.148 
 XHe III 74   30 mg/kg   2 0.0000 ±0.0000 0.000, 0.000 
 SOL   2 1.5775 ±1.1391 2.383, 0.772 
 DZP  10 mg/kg   2 0.3090 ±0.3550 0.560, 0.058 
 
 ANOVA:  F(3,4) = 3.0001   p = 0.158 
 
 Total time mobile (s), female Wistar rat 
 Treatment    N  Mean  SD Data  
 CMD 45 30 mg/kg   2 32.55 ±10.54 40.0, 25.1 
 XHe III 74   30 mg/kg   2 0.35 ±0.07 0.4, 0.3 
 SOL   2 308.75 ±168.64 428.0, 189.5 
 DZP  10 mg/kg   2 50.65 ±55.79 90.1, 11.2 
 
 ANOVA :  F(3,4) = 5.0931   p = 0.075 
 Comment:  
When dosed at 30 mg/kg, both, XHe III 74 and CMD 45 were exceptionally sedative in 
locomotor activity test in adult female rats. The effect may be even more pronounced than that 
obtainable with diazepam dosed at 10 mg/kg. Notably, the effect of XHe III 74 dosed at 30 
mg/kg was so pronounced that it cannot be distinguished – by the used method – from possible 
anesthetic action of this ligand. 
 
From all this CNS study it is obvious that both ligands are sedative and some test shows that 
XHe-III-74 is somewhat more sedative than CMD-45. But for better activity, potency and 
selectivity towards alpha 4 GABAA receptor, it was chosen as the lead compound.  
In the meanwhile, Dr. Savic’s group have done the pk study on XHe-III-74. 
Pharmacokinetic studies 
Experiment I 
In order to determine pharmacokinetic profile of XHe-III-4 rats were divided in two groups, each 
containing 18 animals i.e. three animals per one time point. The rats from group I received XHe-
III-74 nanoemulsion and rats from group II received XHe-III-74 solution into the tail vein, via 
229 
 
infusion pump,  both at doses of 2 mg/kg. At predetermined time intervals, that is, 10, 20, 40, 60, 





Figure A1. Plasma and brain concentration–time profiles of XHe-III-74 after intravenous 







Plasma and brain concentrations of XHe-III-74 after intravenous administration of solution and 




Nanoemulsion (2 mg/kg) Solution (2 mg/kg) 
Plasma (nmol/L) Brain (nmol/kg) Plasma (nmol/L) Brain (nmol/kg) 
5 1876.19 ± 738.68 1276.79 ± 554.75 4218.76 ± 502.24 12364.14 ± 2664.42 
20 1537.01 ± 449.72 1180.64 ± 444.06 2338.58 ±215.26 1745.17 ± 128.02 
40 791.06 ± 251.02 561.91 ± 193.30 656.30± 120.39 412.24 ± 125.15 
60 599.22 ± 110.53 310.77 ± 71.32 453.15 ± 150.90 220.84 ± 88.29 
180 35.90 ± 3.99 9.79 ± 1.77 325.24 ± 26.73 69.17 ± 29.92 
720 107.27 ± 106.02 2.30 ± 0.44 4.41 ± 1.05 16.65 ± 6.05 
Experiment II 
Additional pharmacokinetic experiment was performed in order to determine brain and plasma 
concentration, as well as to calculate free brain and plasma levels of XHe-III-74 dosed at 10 
mg/kg, 20 min after intravenous infusion. 
 
 Total conc. Free conc. 
Plasma 
(nmol/l) 
Nanoemulsion  6530.84±854.12 756.27±98.90635 
Solution 13752.82±2375.53 1586.27±275.09 
Brain 
(nmol/l) 
Nanoemulsion  5608.33±953.93 590.00±100.35 
Solution 12364.14±2664.42 1300.71±280.30 
 
 
Table 5. Total and estimated free concentrations of XHe-III-74 (dosed at 10 mg/kg)  in plasma 
and brain samples after 20 min (n = 3, mean±SEM) 
 
Experiment III 
XHe-III-74 nanoemulsion (concentration 2 mg/ml) was injected into the tail vein at dose of 20 
mg/kg (the dose used in LOOR experiment). At predetermined time intervals, that is, 5, 10, 20, 





Plasma concentration Brain concentration 
nmol/l ng/ml nmol/kg ng/g 
5  
73904.63 ± 3777.95 
 
27301.11 ± 1395.61 
 






52424.80 ± 3134.74 
 
19366.25 ± 1158.00 
 





20 40393.56 ± 2681.59 
 
14921.76 ± 990.61 
 
34335.14 ± 1471.47 
 
12683.74 ± 543.58 
 
40 23889.09  ± 4652.03 8824.87 ± 1718.506 19638.77 ± 3552.36 7254.76 ± 1312.28 
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60  16311.87 ± 1811.01 
 
6025.77 ± 669.00 
 
25361.54 ± 2486.93 
 
9368.81 ± 918.70 
 
180 3623.02 ± 344.13 
 




1326.02 ± 219.6 
 
720 28.69 ± 11.54 
 
10.60 ± 4.26 
 
799.76 ± 75.71 
 
295.44 ± 27.97 
 
 
Table 6. Plasma and brain concentration of XHe-III-74 after intravenous administration of  










































Figure A2. The α4β3γ2 GABAAR subtype selectivity of 16 was confirmed by comparison of its 
GABA induced current potentiation with the α1β3γ2 GABAAR 
 
 
Figure A3 (related to Figure 34). Effect of 1 and 2 on sensorimotor coordination. Swiss Webster 
mice received a single intra-gastric gavage of test compound (100 mg/kg) or diazepam (5 mg/kg 
ip) and placed on a rotarod at 15rpm for 3 minutes after 10, 30 and 60 minutes of drug 
administration. A fail was assigned to a mouse having fallen twice prior to 3 minutes. The latency 
to fall is expressed as mean ± SEM from 9 mice in each group. Vehicle and diazepam was used as 




Figure A4 (related to Figure 34). Automated patch clamp with compound 1 (phenol 6). A) 
Concentration-dependent negative current responses in the presence of EC20 concentration of 
GABA and increasing concentration of compound 1 applied together for 3 seconds using α1β3γ2 
or α4β3γ2 GABAAR expressing HEK293T cells. Negative current readings were normalized to 
EC20 concentration of GABA response set as 100% (n = 16). B) Current recordings in the presence 
of EC20 concentration of GABA and increasing concentrations of compound 1 applied together 
for 3 seconds using α4β3γ2 expressing HEK293T cells. C) Current recordings in the presence of 
EC20 concentration of GABA and increasing concentrations of compound 1 applied together for 
3 seconds using α1β3γ2 expressing HEK293T cells. 
 
Figure A5. Effect of 1 and 2 on mucous production Morphometric quantification of mucin volume 
density and B) representative images of mucin (red) in the airway epithelium (green) with periodic 
acid fluorescent Schiff’s stain. Ova s/c BALB/c mice were administered 1 via oral gavage, 100 
mg/kg twice daily for 5 days or 2 via oral gavage, 100 mg/kg twice daily for 5 days. Data represent 




Table A5. Cytotoxicity of oxadiazoles (24,25,26) determined in the presence of human kidney, 
liver and lung cells 
 
 











Figure A6. Airway smooth muscle relaxation in guinea pig tracheal ring by oxazole 28 
 
Figure A7. Sensorimotor impairment of 28 
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Table A7. Microsomal stability of compounds was tested with human and mouse liver 
microsomes.  
Compound HLM % remaining 
after 60 min 
MLM % remaining 
after 60 min 
RJ-03-57, 31 94.3 ± 0.1 98.3 ± 0.2 
RJ-02-67 90.6 ± 0.2 46.6 ± 0.3 
RJ-03-30, 29 91.8 ± 0.2 80.0 ± 0.3 
 
Table A8.  Cytotoxicity of compounds determined in the presence of human kidney and liver cells. 
None of the investigated compounds induced cytotoxicity up to a concentration of 100 µM. For 
the majority of compounds no toxicity was observed at a concentration of 400 µM.  
 
Compound LD50 HEK293 (µM) 
(Kidney) 
LD50 HEPG2 (µM) 
(Liver) 
RJ-03-57, 31 >200 >200 
RJ-02-50 >400 >400 
RJ-02-67 >400 >400 








Figure A8. Airway smooth muscle contractile force in guinea pig tracheal rings. Tracheal rings 
were contracted with 1 mM substance P and then treated with 50 mM of compounds or vehicle 
control (0.1% DMSO). The percent of remaining contractile force was measured at various time 
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points and expressed as a percent of the initial substance P induced contractile force. (N > 6) A 
2way ANOVA was used to calculate significance with *(p <0.05), ** (p < 0.01) or *** (p < 0.001) 
p-values are given for each condition. All investigated compounds except RJ-03-57 reduced the 
constriction of airway smooth muscle after 15 minutes for a period of at least 60 minutes.  
 
 
Figure A9. Effect of compounds on sensorimotor coordination. Swiss Webster mice were tested 
on a rotarod at 15 rpm for 3 min at 10, 30, and 60 min following compound exposure. Mice (N = 
10) received a single injection (i.p. or p.o.) of test compound. The time of fall was recorded if it 
occurred prior to 3 min. Data are expressed as mean ± SEM (N = 10). Student t-test was used to 
calculate significance: *(p <0.05), ** (p < 0.01) or *** (p < 0.001) significance compared to 
vehicle-treated mice. None of the investigated compounds induced any sensorimotor impairments 










Figure A10. Compound effects on airway hyperresponsiveness Specific airway resistance (sRaw) 
was measured at increasing dosages of methacholine by a DSI’s Buxco FinePointe non-invasive 
airway mechanics instrument. Ova s/c BALB/c mice were administered all compounds via oral 
gavage, 100 mg/kg twice daily for 5 days. Data represent mean ± SEM from 10 mice in each group. 
∗, ∗∗, and ∗∗∗ indicate p < 0.05, p < 0.01, p < 0.001 significance, respectively, compared to vehicle 









Figure A11. Effect of compounds on inflammatory cells. Groups of 10 ova s/c BALB/c mice were 
administered compounds at 100 mg/kg twice daily for 5 days. BALF was harvested from each 
animal and used for (A) quantification of total inflammatory cells; (B) eosinophils; (C) CD4+ T 
cells. Cells were stained with mouse CD45+ APC antibody, and samples were analyzed with BD 
FACS Calibur on high flow rate (60 μl/min) for 180 s. The gated positive events in the fourth 
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channel (FL4) were used to calculate the total inflammatory cell count as cells/ml. Quantification 
of specific leukocyte population (B) eosinophils (C) CD4+ T cell populations were stained with 
specific antibodies and detected by flow cytometry. Data represent mean ± SEM from 10 mice in 
each group. *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001 significance, respectively, 
compared to vehicle treated ova s/c BALB/c mice. Compounds GL-II-43, RJ-03-30, RJ-03-90 did 
not modulated the numbers of inflammatory cells. However, RJ-02-50 and GL-II-93 did reduce 
the numbers of eosinophils and CD4+ T cells in the asthmatic mouse lung. SH-053-2F’F-R-CH3-




Figure A12. Current recordings in the presence of 600 nM GABA and increasing concentrations 
of compounds applied together for 3 s using CD4+ T-cells isolated from ova s/c BALB/c mice 
spleen. The concentration-dependent current responses of CD4+ T-cells in the presence of 600 nM 
GABA and increasing concentration of compounds were carried out with an N of 16 and 
normalized to the current response of 600 nM GABA. Compound RJ-02-50 potentiated the 
GABA-induced membrane current more than SH-053-2F’F-R-CH3-Acid. Importantly, GL-II-93 







Figure A13. Pharmacokinetic profile of tetrazole 31 in mice blood lungs, and brain. Time-
dependent systemic distribution of compounds administered at 25 mg/kg via oral gavage. RJ-03-














tmax (min) 10 10 - 
Cmax (ng/g) 559.8 171.6 - 
Erate (min-1) 0.019 0.012 - 
t1/2 (min) 37.4 59.0 - 

































Figure A14. Cytotoxicity assay results of XHE-III-74 analogs on human liver hepatocellular 
carcinoma (HEPG2), human embryonic kidney 293T (HEK293T) and human bronchial epithelial 










X-ray Crystal Data for XHE-III-74EE (S isomer), 5  
Table A9. Crystal data and structure refinement for XHe-III-74EE 5. 
Identification code  cook115x 
Empirical formula  C18H19N3O4 
Formula weight  341.36 
Temperature  150(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 8.8015(3) Å = 90°. 
 b = 12.3627(5) Å = 90°. 
 c = 14.6328(5) Å  = 90°. 
Volume 1592.20(10) Å3 
Z 4 
Density (-123ºC) 1.424 Mg/m3 
Absorption coefficient 0.846 mm-1 
F(000) 720 
Crystal size 0.639 x 0.537 x 0.372 mm3 
θ range for data collection 4.682 to 68.183°. 
Index ranges -9<=h<=10, -14<=k<=14, -16<=l<=17 
Reflections collected 9325 
Independent reflections 2738 [R(int) = 0.2000] 
Completeness to θ = 67.679° 98.1 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7438 and 0.6141 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2738 / 0 / 229 
Goodness-of-fit on F2 1.085 
Final R indices [I>2σ(I)] R1 = 0.0507, wR2 = 0.1390 
R indices (all data) R1 = 0.0508, wR2 = 0.1392 
Absolute structure parameter -0.1(3) 
Extinction coefficient 0.022(2) 
Largest diff. peak and hole 0.375 and -0.315 e.Å-3 
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Table A10. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 5. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
N(1) 9167(3) 5590(2) 4986(2) 21(1) 
C(2) 8942(3) 5685(2) 5865(2) 21(1) 
N(3) 8473(3) 6697(2) 6104(2) 19(1) 
C(4) 8043(3) 7014(2) 7014(2) 20(1) 
C(5) 7231(3) 6282(2) 7532(2) 20(1) 
C(6) 6814(3) 6521(2) 8427(2) 22(1) 
C(7) 7204(3) 7528(2) 8786(2) 21(1) 
O(7) 6819(2) 7870(2) 9650(1) 28(1) 
C(7A) 5844(4) 7188(3) 10161(2) 34(1) 
C(8) 8046(3) 8252(2) 8271(2) 22(1) 
C(9) 8479(3) 8008(2) 7382(2) 19(1) 
C(10) 9481(3) 8813(2) 6907(2) 20(1) 
O(10) 10460(2) 9317(2) 7336(1) 26(1) 
N(11) 9259(2) 8968(2) 6009(2) 20(1) 
C(12) 10175(3) 9740(2) 5477(2) 24(1) 
C(13) 9608(3) 9573(3) 4507(2) 25(1) 
C(14) 7944(3) 9253(2) 4650(2) 22(1) 
C(15) 8008(3) 8489(2) 5463(2) 19(1) 
C(16) 8381(3) 7301(2) 5310(2) 20(1) 
C(17) 8810(3) 6598(2) 4624(2) 20(1) 
C(18) 8915(3) 6674(2) 3612(2) 21(1) 
O(18) 9603(3) 6028(2) 3153(1) 31(1) 
O(19) 8143(2) 7511(2) 3267(1) 26(1) 
C(20) 8162(4) 7610(3) 2279(2) 28(1) 




Table A11. Bond lengths [Å] and angles [°] for 5. 
_____________________________________________________ 
N(1)-C(2)  1.306(4) N(1)-C(17)  1.391(4) 
C(2)-N(3)  1.363(4) C(2)-H(2A)  0.9500 
N(3)-C(16)  1.384(4) N(3)-C(4)  1.440(4) 
C(4)-C(5)  1.380(4) C(4)-C(9)  1.395(4) 
C(5)-C(6)  1.392(4) C(5)-H(5A)  0.9500 
C(6)-C(7)  1.394(4) C(6)-H(6A)  0.9500 
C(7)-O(7)  1.375(3) C(7)-C(8)  1.385(4) 
O(7)-C(7A)  1.417(4) C(7A)-H(7AA)  0.9800 
C(7A)-H(7AB)  0.9800 C(7A)-H(7AC)  0.9800 
C(8)-C(9)  1.389(4) C(8)-H(8A)  0.9500 
C(9)-C(10)  1.500(4) C(10)-O(10)  1.235(3) 
C(10)-N(11)  1.341(4) N(11)-C(12)  1.472(4) 
N(11)-C(15)  1.484(3) C(12)-C(13)  1.519(4) 
C(12)-H(12A)  0.9900 C(12)-H(12B)  0.9900 
C(13)-C(14)  1.532(4) C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 C(14)-C(15)  1.521(4) 
C(14)-H(14A)  0.9900 C(14)-H(14B)  0.9900 
C(15)-C(16)  1.521(4) C(15)-H(15A)  1.0000 
C(16)-C(17)  1.381(4) C(17)-C(18)  1.487(4) 
C(18)-O(18)  1.206(4) C(18)-O(19)  1.336(4) 
O(19)-C(20)  1.450(3) C(20)-C(21)  1.506(5) 
C(20)-H(20A)  0.9900 C(20)-H(20B)  0.9900 
C(21)-H(21A)  0.9800 C(21)-H(21B)  0.9800 
C(21)-H(21C)  0.9800 
 
C(2)-N(1)-C(17) 105.1(2) N(1)-C(2)-N(3) 112.4(3) 
N(1)-C(2)-H(2A) 123.8 N(3)-C(2)-H(2A) 123.8 
C(2)-N(3)-C(16) 107.4(2) C(2)-N(3)-C(4) 124.5(2) 
C(16)-N(3)-C(4) 127.9(2) C(5)-C(4)-C(9) 120.6(3) 
C(5)-C(4)-N(3) 117.8(3) C(9)-C(4)-N(3) 121.6(2) 
C(4)-C(5)-C(6) 120.9(3) C(4)-C(5)-H(5A) 119.5 
C(6)-C(5)-H(5A) 119.5 C(5)-C(6)-C(7) 118.6(3) 
C(5)-C(6)-H(6A) 120.7 C(7)-C(6)-H(6A) 120.7 
O(7)-C(7)-C(8) 115.6(3) O(7)-C(7)-C(6) 124.1(3) 
C(8)-C(7)-C(6) 120.3(3) C(7)-O(7)-C(7A) 116.8(2) 
O(7)-C(7A)-H(7AA) 109.5 O(7)-C(7A)-H(7AB) 109.5 
H(7AA)-C(7A)-H(7AB) 109.5 O(7)-C(7A)-H(7AC) 109.5 
H(7AA)-C(7A)-H(7AC) 109.5 H(7AB)-C(7A)-H(7AC) 109.5 
C(7)-C(8)-C(9) 121.0(3) C(7)-C(8)-H(8A) 119.5 
C(9)-C(8)-H(8A) 119.5 C(8)-C(9)-C(4) 118.5(3) 
C(8)-C(9)-C(10) 116.8(2) C(4)-C(9)-C(10) 124.6(3) 
O(10)-C(10)-N(11) 121.8(3) O(10)-C(10)-C(9) 120.6(2) 
N(11)-C(10)-C(9) 117.6(2) C(10)-N(11)-C(12) 122.1(2) 
C(10)-N(11)-C(15) 125.3(2) C(12)-N(11)-C(15) 112.4(2) 
N(11)-C(12)-C(13) 103.1(2) N(11)-C(12)-H(12A) 111.1 
C(13)-C(12)-H(12A) 111.1 N(11)-C(12)-H(12B) 111.1 
C(13)-C(12)-H(12B) 111.1 H(12A)-C(12)-H(12B) 109.1 
C(12)-C(13)-C(14) 102.8(2) C(12)-C(13)-H(13A) 111.2 
C(14)-C(13)-H(13A) 111.2 C(12)-C(13)-H(13B) 111.2 
C(14)-C(13)-H(13B) 111.2 H(13A)-C(13)-H(13B) 109.1 
C(15)-C(14)-C(13) 103.4(2) C(15)-C(14)-H(14A) 111.1 
C(13)-C(14)-H(14A) 111.1 C(15)-C(14)-H(14B) 111.1 
C(13)-C(14)-H(14B) 111.1 H(14A)-C(14)-H(14B) 109.0 
N(11)-C(15)-C(14) 101.6(2) N(11)-C(15)-C(16) 107.7(2) 
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Table A11. (continued). 
_____________________________________________________ 
 
C(14)-C(15)-C(16) 119.5(2) N(11)-C(15)-H(15A) 109.2 
C(14)-C(15)-H(15A) 109.2 C(16)-C(15)-H(15A) 109.2 
C(17)-C(16)-N(3) 104.7(2) C(17)-C(16)-C(15) 140.7(3) 
N(3)-C(16)-C(15) 114.2(2) C(16)-C(17)-N(1) 110.4(2) 
C(16)-C(17)-C(18) 134.6(3) N(1)-C(17)-C(18) 115.0(3) 
O(18)-C(18)-O(19) 123.9(2) O(18)-C(18)-C(17) 122.9(3) 
O(19)-C(18)-C(17) 113.2(2) C(18)-O(19)-C(20) 115.9(2) 
O(19)-C(20)-C(21) 107.4(3) O(19)-C(20)-H(20A) 110.2 
C(21)-C(20)-H(20A) 110.2 O(19)-C(20)-H(20B) 110.2 
C(21)-C(20)-H(20B) 110.2 H(20A)-C(20)-H(20B) 108.5 
C(20)-C(21)-H(21A) 109.5 C(20)-C(21)-H(21B) 109.5 
H(21A)-C(21)-H(21B) 109.5 C(20)-C(21)-H(21C) 109.5 
H(21A)-C(21)-H(21C) 109.5 H(21B)-C(21)-H(21C) 109.5 
_____________________________________________________________
  
Table A12. Anisotropic displacement parameters (Å2x 103) for 5. The anisotropic 
displacement factor exponent takes the form: -22[h2a*2U11 + ... + 2 h k a* b* U12] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
N(1) 23(1)  14(1) 27(1)  -2(1) -2(1)  2(1) 
C(2) 25(1)  10(1) 27(1)  2(1) -3(1)  2(1) 
N(3) 21(1)  13(1) 22(1)  -1(1) -2(1)  1(1) 
C(4) 20(1)  16(1) 23(1)  3(1) -2(1)  3(1) 
C(5) 22(1)  12(1) 26(1)  1(1) -4(1)  -2(1) 
C(6) 22(1)  17(2) 26(1)  7(1) 0(1)  -2(1) 
C(7) 23(1)  19(1) 23(1)  3(1) 1(1)  3(1) 
O(7) 36(1)  21(1) 26(1)  -2(1) 8(1)  -4(1) 
C(7A) 45(2)  24(2) 31(2)  -1(1) 8(1)  -9(1) 
C(8) 24(1)  15(1) 26(1)  -2(1) 0(1)  1(1) 
C(9) 19(1)  14(1) 24(1)  0(1) -4(1)  0(1) 
C(10) 20(1)  13(1) 26(1)  -7(1) 1(1)  2(1) 
O(10) 27(1)  21(1) 29(1)  -1(1) -3(1)  -9(1) 
N(11) 20(1)  13(1) 27(1)  -1(1) 0(1)  -2(1) 
C(12) 22(1)  16(1) 34(2)  4(1) 3(1)  -2(1) 
C(13) 28(1)  17(1) 31(1)  5(1) 7(1)  1(1) 
C(14) 24(1)  14(1) 28(1)  -2(1) 1(1)  4(1) 
C(15) 17(1)  14(1) 27(1)  -2(1) -1(1)  0(1) 
C(16) 17(1)  17(1) 25(1)  0(1) -2(1)  -1(1) 
C(17) 17(1)  18(1) 25(1)  1(1) -2(1)  -1(1) 
C(18) 22(1)  14(1) 27(1)  -3(1) -1(1)  -2(1) 
O(18) 39(1)  27(1) 27(1)  -2(1) 4(1)  10(1) 
O(19) 36(1)  21(1) 23(1)  -1(1) -1(1)  6(1) 
C(20) 33(2)  27(2) 24(1)  1(1) 0(1)  -2(1) 




Table A13. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 103) for 5 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(2A) 9089 5113 6289 25 
H(5A) 6953 5605 7274 24 
H(6A) 6274 6009 8786 26 
H(7AA) 5649 7515 10760 50 
H(7AB) 6327 6481 10243 50 
H(7AC) 4882 7097 9833 50 
H(8A) 8332 8927 8530 26 
H(12A) 11272 9573 5527 29 
H(12B) 9998 10492 5683 29 
H(13A) 10181 8990 4195 31 
H(13B) 9692 10246 4144 31 
H(14A) 7310 9894 4787 27 
H(14B) 7531 8883 4103 27 
H(15A) 7037 8545 5815 23 
H(20A) 7458 7079 2001 34 
H(20B) 9197 7472 2041 34 
H(21A) 7713 8849 1385 54 
H(21B) 8352 9263 2348 54 




Table A14. Torsion angles [°] for 5. 
________________________________________________________________ 
C(17)-N(1)-C(2)-N(3) -0.6(3) N(1)-C(2)-N(3)-C(16) 0.4(3) 
N(1)-C(2)-N(3)-C(4) 175.7(2) C(2)-N(3)-C(4)-C(5) -38.7(4) 
C(16)-N(3)-C(4)-C(5) 135.6(3) C(2)-N(3)-C(4)-C(9) 138.7(3) 
C(16)-N(3)-C(4)-C(9) -47.0(4) C(9)-C(4)-C(5)-C(6) 0.7(4) 
N(3)-C(4)-C(5)-C(6) 178.2(2) C(4)-C(5)-C(6)-C(7) 1.4(4) 
C(5)-C(6)-C(7)-O(7) 178.1(3) C(5)-C(6)-C(7)-C(8) -2.7(4) 
C(8)-C(7)-O(7)-C(7A) 174.5(3) C(6)-C(7)-O(7)-C(7A) -6.3(4) 
O(7)-C(7)-C(8)-C(9) -178.8(2) C(6)-C(7)-C(8)-C(9) 2.0(4) 
C(7)-C(8)-C(9)-C(4) 0.2(4) C(7)-C(8)-C(9)-C(10) -175.8(2) 
C(5)-C(4)-C(9)-C(8) -1.5(4) N(3)-C(4)-C(9)-C(8) -178.9(2) 
C(5)-C(4)-C(9)-C(10) 174.1(2) N(3)-C(4)-C(9)-C(10) -3.2(4) 
C(8)-C(9)-C(10)-O(10) 35.6(4) C(4)-C(9)-C(10)-O(10) -140.1(3) 
C(8)-C(9)-C(10)-N(11) -143.6(2) C(4)-C(9)-C(10)-N(11) 40.7(4) 
O(10)-C(10)-N(11)-C(12) 0.6(4) C(9)-C(10)-N(11)-C(12) 179.9(2) 
O(10)-C(10)-N(11)-C(15) -173.0(2) C(9)-C(10)-N(11)-C(15) 6.2(4) 
C(10)-N(11)-C(12)-C(13) 175.7(3) C(15)-N(11)-C(12)-C(13) -9.9(3) 
N(11)-C(12)-C(13)-C(14) 31.0(3) C(12)-C(13)-C(14)-C(15) -41.5(3) 
C(10)-N(11)-C(15)-C(14) 158.6(3) C(12)-N(11)-C(15)-C(14) -15.6(3) 
C(10)-N(11)-C(15)-C(16) -75.0(3) C(12)-N(11)-C(15)-C(16) 110.8(3) 
C(13)-C(14)-C(15)-N(11) 34.4(3) C(13)-C(14)-C(15)-C(16) -83.8(3) 
C(2)-N(3)-C(16)-C(17) 0.1(3) C(4)-N(3)-C(16)-C(17) -175.1(3) 
C(2)-N(3)-C(16)-C(15) -174.7(2) C(4)-N(3)-C(16)-C(15) 10.1(4) 
N(11)-C(15)-C(16)-C(17) -109.8(4) C(14)-C(15)-C(16)-C(17) 5.2(5) 
N(11)-C(15)-C(16)-N(3) 62.2(3) C(14)-C(15)-C(16)-N(3) 177.3(2) 
N(3)-C(16)-C(17)-N(1) -0.4(3) C(15)-C(16)-C(17)-N(1) 172.1(3) 
N(3)-C(16)-C(17)-C(18) 177.0(3) C(15)-C(16)-C(17)-C(18) -10.5(6) 
C(2)-N(1)-C(17)-C(16) 0.6(3) C(2)-N(1)-C(17)-C(18) -177.3(2) 
C(16)-C(17)-C(18)-O(18) 164.8(3) N(1)-C(17)-C(18)-O(18) -17.9(4) 
C(16)-C(17)-C(18)-O(19) -16.6(4) N(1)-C(17)-C(18)-O(19) 160.7(2) 




Table A15. Hydrogen bonds for 5 [Å and °]. 
____________________________________________________________________________ 
        D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 C(2)-H(2A)...O(10)#1 0.95 2.27 3.173(3) 157.5 
 C(6)-H(6A)...N(1)#2 0.95 2.67 3.573(4) 158.3 
 C(7A)-H(7AB)...N(1)#2 0.98 2.62 3.445(4) 141.3 
 C(12)-H(12A)...N(1)#3 0.99 2.66 3.602(4) 158.1 
 C(14)-H(14B)...O(19) 0.99 2.16 2.960(4) 136.7 
 C(20)-H(20A)...O(10)#4 0.99 2.65 3.413(4) 134.2 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+2,y-1/2,-z+3/2    #2 -x+3/2,-y+1,z+1/2    #3 x+1/2,-y+3/2,-z+1  






X-ray Crystal Data for XHE-III-74EE (R isomer), 5ʹ 
 
Table A16. Crystal data and structure refinement for 5′ (RJ-01-17). 
Identification code  cook129 
Empirical formula  C18H19N3O4 
Formula weight  341.36 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 8.8045(5) Å = 90°. 
 b = 12.3701(9) Å = 90°. 
 c = 14.6254(10) Å  = 90°. 
Volume 1592.89(18) Å3 
Z 4 
Density (-123ºC) 1.423 Mg/m3 
Absorption coefficient 0.102 mm-1 
F(000) 720 
Crystal size 0.465 x 0.279 x 0.156 mm3 
θ range for data collection 2.156 to 29.131°. 
Index ranges -10<=h<=12, -16<=k<=16, -20<=l<=18 
Reflections collected 14196 
Independent reflections 4250 [R(int) = 0.0327] 
Completeness to θ = 25.000° 99.9 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4250 / 0 / 228 
Goodness-of-fit on F2 0.997 
Final R indices [I>2σ(I)] R1 = 0.0314, wR2 = 0.0729 
R indices (all data) R1 = 0.0355, wR2 = 0.0749 
Absolute structure parameter 0.3(3) 
Largest diff. peak and hole 0.255 and -0.199 e.Å-3 
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Table A17. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 5′. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
N(1) 1523(2) 3304(1) 8896(1) 15(1) 
C(2) 1052(2) 4319(1) 9134(1) 17(1) 
N(3) 831(2) 4410(1) 10014(1) 18(1) 
C(4) 1185(2) 3401(1) 10378(1) 16(1) 
C(5) 1616(2) 2696(1) 9693(1) 14(1) 
C(6) 1993(2) 1514(1) 9537(1) 15(1) 
C(7) 2054(2) 745(1) 10353(1) 18(1) 
C(8) 395(2) 429(1) 10500(1) 22(1) 
C(9) -175(2) 261(1) 9524(1) 20(1) 
N(10) 741(2) 1033(1) 8993(1) 16(1) 
C(11) 518(2) 1185(1) 8094(1) 16(1) 
O(11) -458(1) 681(1) 7665(1) 22(1) 
C(12) 1518(2) 1988(1) 7618(1) 15(1) 
C(13) 1953(2) 1746(1) 6730(1) 18(1) 
C(14) 2796(2) 2471(1) 6213(1) 17(1) 
O(14) 3181(2) 2130(1) 5351(1) 24(1) 
C(14A) 4155(2) 2814(1) 4840(1) 31(1) 
C(15) 3185(2) 3478(1) 6572(1) 18(1) 
C(16) 2769(2) 3720(1) 7464(1) 16(1) 
C(17) 1955(2) 2988(1) 7990(1) 15(1) 
O(18) 400(2) 3971(1) 11848(1) 28(1) 
C(18) 1085(2) 3324(1) 11386(1) 17(1) 
O(19) 1856(2) 2490(1) 11733(1) 23(1) 
C(20) 1839(2) 2388(1) 12722(1) 24(1) 




Table A18. Bond lengths [Å] and angles [°] for 5′. 
_____________________________________________________ 
N(1)-C(2)  1.3676(18) N(1)-C(5)  1.3888(18) 
N(1)-C(17)  1.4330(19) C(2)-N(3)  1.306(2) 
C(2)-H(2A)  0.9500 N(3)-C(4)  1.3924(19) 
C(4)-C(5)  1.382(2) C(4)-C(18)  1.480(2) 
C(5)-C(6)  1.5158(19) C(6)-N(10)  1.4843(19) 
C(6)-C(7)  1.528(2) C(6)-H(6A)  1.0000 
C(7)-C(8)  1.527(2) C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 C(8)-C(9)  1.527(2) 
C(8)-H(8A)  0.9900 C(8)-H(8B)  0.9900 
C(9)-N(10)  1.4713(19) C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 N(10)-C(11)  1.3416(19) 
C(11)-O(11)  1.2333(18) C(11)-C(12)  1.499(2) 
C(12)-C(13)  1.387(2) C(12)-C(17)  1.4045(19) 
C(13)-C(14)  1.389(2) C(13)-H(13A)  0.9500 
C(14)-O(14)  1.3707(18) C(14)-C(15)  1.394(2) 
O(14)-C(14A)  1.417(2) C(14A)-H(14A)  0.9800 
C(14A)-H(14B)  0.9800 C(14A)-H(14C)  0.9800 
C(15)-C(16)  1.387(2) C(15)-H(15A)  0.9500 
C(16)-C(17)  1.388(2) C(16)-H(16A)  0.9500 
O(18)-C(18)  1.2089(19) C(18)-O(19)  1.3350(19) 
O(19)-C(20)  1.4513(17) C(20)-C(21)  1.510(2) 
C(20)-H(20A)  0.9900 C(20)-H(20B)  0.9900 
C(21)-H(21A)  0.9800 C(21)-H(21B)  0.9800 
C(21)-H(21C)  0.9800 
 
C(2)-N(1)-C(5) 107.60(12) C(2)-N(1)-C(17) 124.48(12) 
C(5)-N(1)-C(17) 127.72(12) N(3)-C(2)-N(1) 111.98(13) 
N(3)-C(2)-H(2A) 124.0 N(1)-C(2)-H(2A) 124.0 
C(2)-N(3)-C(4) 105.45(12) C(5)-C(4)-N(3) 110.50(13) 
C(5)-C(4)-C(18) 134.28(14) N(3)-C(4)-C(18) 115.16(13) 
C(4)-C(5)-N(1) 104.47(12) C(4)-C(5)-C(6) 141.07(14) 
N(1)-C(5)-C(6) 114.14(12) N(10)-C(6)-C(5) 107.74(12) 
N(10)-C(6)-C(7) 101.26(11) C(5)-C(6)-C(7) 119.38(12) 
N(10)-C(6)-H(6A) 109.3 C(5)-C(6)-H(6A) 109.3 
C(7)-C(6)-H(6A) 109.3 C(8)-C(7)-C(6) 103.63(12) 
C(8)-C(7)-H(7A) 111.0 C(6)-C(7)-H(7A) 111.0 
C(8)-C(7)-H(7B) 111.0 C(6)-C(7)-H(7B) 111.0 
H(7A)-C(7)-H(7B) 109.0 C(9)-C(8)-C(7) 102.58(13) 
C(9)-C(8)-H(8A) 111.3 C(7)-C(8)-H(8A) 111.3 
C(9)-C(8)-H(8B) 111.3 C(7)-C(8)-H(8B) 111.3 
H(8A)-C(8)-H(8B) 109.2 N(10)-C(9)-C(8) 103.04(13) 
N(10)-C(9)-H(9A) 111.2 C(8)-C(9)-H(9A) 111.2 
N(10)-C(9)-H(9B) 111.2 C(8)-C(9)-H(9B) 111.2 
H(9A)-C(9)-H(9B) 109.1 C(11)-N(10)-C(9) 121.85(13) 
C(11)-N(10)-C(6) 125.27(13) C(9)-N(10)-C(6) 112.59(12) 
O(11)-C(11)-N(10) 122.02(14) O(11)-C(11)-C(12) 120.50(14) 
N(10)-C(11)-C(12) 117.48(13) C(13)-C(12)-C(17) 118.49(14) 
C(13)-C(12)-C(11) 116.99(13) C(17)-C(12)-C(11) 124.39(14) 
C(12)-C(13)-C(14) 121.24(13) C(12)-C(13)-H(13A) 119.4 
C(14)-C(13)-H(13A) 119.4 O(14)-C(14)-C(13) 115.75(13) 
O(14)-C(14)-C(15) 124.09(14) C(13)-C(14)-C(15) 120.16(14) 
C(14)-O(14)-C(14A) 116.83(12) O(14)-C(14A)-H(14A) 109.5 
O(14)-C(14A)-H(14B) 109.5 H(14A)-C(14A)-H(14B) 109.5 
O(14)-C(14A)-H(14C) 109.5 H(14A)-C(14A)-H(14C) 109.5 
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Table A18. (continued). 
_____________________________________________________ 
 
H(14B)-C(14A)-H(14C) 109.5 C(16)-C(15)-C(14) 118.88(14) 
C(16)-C(15)-H(15A) 120.6 C(14)-C(15)-H(15A) 120.6 
C(15)-C(16)-C(17) 121.09(13) C(15)-C(16)-H(16A) 119.5 
C(17)-C(16)-H(16A) 119.5 C(16)-C(17)-C(12) 120.08(14) 
C(16)-C(17)-N(1) 118.14(12) C(12)-C(17)-N(1) 121.72(13) 
O(18)-C(18)-O(19) 123.49(14) O(18)-C(18)-C(4) 122.99(14) 
O(19)-C(18)-C(4) 113.50(13) C(18)-O(19)-C(20) 116.18(12) 
O(19)-C(20)-C(21) 107.53(13) O(19)-C(20)-H(20A) 110.2 
C(21)-C(20)-H(20A) 110.2 O(19)-C(20)-H(20B) 110.2 
C(21)-C(20)-H(20B) 110.2 H(20A)-C(20)-H(20B) 108.5 
C(20)-C(21)-H(21A) 109.5 C(20)-C(21)-H(21B) 109.5 
H(21A)-C(21)-H(21B) 109.5 C(20)-C(21)-H(21C) 109.5 





Table A19. Anisotropic displacement parameters (Å2x 103) for 5′. The anisotropic 
displacement factor exponent takes the form: -22[h2a*2U11 + ... + 2 h k a* b* U12] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
N(1) 19(1)  13(1) 13(1)  0(1) -2(1)  1(1) 
C(2) 21(1)  14(1) 17(1)  0(1) -3(1)  1(1) 
N(3) 22(1)  15(1) 17(1)  -1(1) -3(1)  2(1) 
C(4) 16(1)  15(1) 16(1)  0(1) -3(1)  -1(1) 
C(5) 14(1)  14(1) 14(1)  2(1) -2(1)  -1(1) 
C(6) 15(1)  14(1) 15(1)  0(1) -1(1)  1(1) 
C(7) 24(1)  14(1) 16(1)  2(1) 0(1)  3(1) 
C(8) 27(1)  18(1) 20(1)  4(1) 6(1)  2(1) 
C(9) 19(1)  17(1) 23(1)  2(1) 5(1)  -1(1) 
N(10) 17(1)  14(1) 16(1)  1(1) 0(1)  -3(1) 
C(11) 17(1)  13(1) 17(1)  -3(1) 1(1)  1(1) 
O(11) 24(1)  22(1) 20(1)  -4(1) -3(1)  -7(1) 
C(12) 16(1)  14(1) 15(1)  1(1) -3(1)  0(1) 
C(13) 20(1)  16(1) 18(1)  -2(1) -2(1)  1(1) 
C(14) 21(1)  17(1) 13(1)  0(1) 0(1)  2(1) 
O(14) 34(1)  21(1) 16(1)  -3(1) 8(1)  -3(1) 
C(14A) 43(1)  27(1) 21(1)  0(1) 10(1)  -9(1) 
C(15) 21(1)  16(1) 16(1)  4(1) -1(1)  0(1) 
C(16) 20(1)  13(1) 17(1)  1(1) -3(1)  -1(1) 
C(17) 17(1)  15(1) 13(1)  -1(1) -2(1)  1(1) 
O(18) 36(1)  28(1) 19(1)  -2(1) 3(1)  10(1) 
C(18) 18(1)  17(1) 17(1)  -1(1) -1(1)  -3(1) 
O(19) 33(1)  23(1) 13(1)  1(1) -1(1)  6(1) 
C(20) 31(1)  26(1) 13(1)  2(1) -1(1)  -2(1) 




Table A20. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 103) for 5′. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(2A) 902 4890 8709 21 
H(6A) 2963 1459 9184 18 
H(7A) 2684 103 10214 22 
H(7B) 2472 1111 10900 22 
H(8A) 311 -245 10862 26 
H(8B) -174 1012 10811 26 
H(9A) 3 -490 9317 24 
H(9B) -1272 428 9474 24 
H(13A) 1668 1072 6471 21 
H(14A) 4407 2465 4258 46 
H(14B) 5088 2946 5187 46 
H(14C) 3641 3502 4721 46 
H(15A) 3725 3989 6212 21 
H(16A) 3047 4398 7718 20 
H(20A) 803 2523 12960 28 
H(20B) 2539 2920 13000 28 
H(21A) 2338 1158 13619 48 
H(21B) 3363 1128 12715 48 




Table A21. Torsion angles [°] for 5′. 
________________________________________________________________ 
C(5)-N(1)-C(2)-N(3) -0.17(18) C(17)-N(1)-C(2)-N(3) -175.44(14) 
N(1)-C(2)-N(3)-C(4) 0.34(19) C(2)-N(3)-C(4)-C(5) -0.39(19) 
C(2)-N(3)-C(4)-C(18) 177.28(13) N(3)-C(4)-C(5)-N(1) 0.28(17) 
C(18)-C(4)-C(5)-N(1) -176.76(16) N(3)-C(4)-C(5)-C(6) -172.35(18) 
C(18)-C(4)-C(5)-C(6) 10.6(3) C(2)-N(1)-C(5)-C(4) -0.07(16) 
C(17)-N(1)-C(5)-C(4) 175.00(15) C(2)-N(1)-C(5)-C(6) 174.86(13) 
C(17)-N(1)-C(5)-C(6) -10.1(2) C(4)-C(5)-C(6)-N(10) 109.6(2) 
N(1)-C(5)-C(6)-N(10) -62.57(16) C(4)-C(5)-C(6)-C(7) -4.9(3) 
N(1)-C(5)-C(6)-C(7) -177.11(13) N(10)-C(6)-C(7)-C(8) -34.66(14) 
C(5)-C(6)-C(7)-C(8) 83.28(15) C(6)-C(7)-C(8)-C(9) 41.62(14) 
C(7)-C(8)-C(9)-N(10) -31.17(14) C(8)-C(9)-N(10)-C(11) -175.94(13) 
C(8)-C(9)-N(10)-C(6) 9.86(16) C(5)-C(6)-N(10)-C(11) 75.46(17) 
C(7)-C(6)-N(10)-C(11) -158.45(13) C(5)-C(6)-N(10)-C(9) -110.57(13) 
C(7)-C(6)-N(10)-C(9) 15.51(15) C(9)-N(10)-C(11)-O(11) -0.4(2) 
C(6)-N(10)-C(11)-O(11) 173.00(14) C(9)-N(10)-C(11)-C(12) -179.81(13) 
C(6)-N(10)-C(11)-C(12) -6.4(2) O(11)-C(11)-C(12)-C(13) -35.6(2) 
N(10)-C(11)-C(12)-C(13) 143.75(14) O(11)-C(11)-C(12)-C(17) 140.14(16) 
N(10)-C(11)-C(12)-C(17) -40.5(2) C(17)-C(12)-C(13)-C(14) -0.2(2) 
C(11)-C(12)-C(13)-C(14) 175.81(14) C(12)-C(13)-C(14)-O(14) 178.75(14) 
C(12)-C(13)-C(14)-C(15) -2.0(2) C(13)-C(14)-O(14)-C(14A) -174.56(15) 
C(15)-C(14)-O(14)-C(14A) 6.2(2) O(14)-C(14)-C(15)-C(16) -178.11(14) 
C(13)-C(14)-C(15)-C(16) 2.7(2) C(14)-C(15)-C(16)-C(17) -1.2(2) 
C(15)-C(16)-C(17)-C(12) -0.9(2) C(15)-C(16)-C(17)-N(1) -178.11(14) 
C(13)-C(12)-C(17)-C(16) 1.7(2) C(11)-C(12)-C(17)-C(16) -174.05(15) 
C(13)-C(12)-C(17)-N(1) 178.72(14) C(11)-C(12)-C(17)-N(1) 3.0(2) 
C(2)-N(1)-C(17)-C(16) 38.5(2) C(5)-N(1)-C(17)-C(16) -135.76(16) 
C(2)-N(1)-C(17)-C(12) -138.58(16) C(5)-N(1)-C(17)-C(12) 47.1(2) 
C(5)-C(4)-C(18)-O(18) -165.19(17) N(3)-C(4)-C(18)-O(18) 17.9(2) 
C(5)-C(4)-C(18)-O(19) 16.5(3) N(3)-C(4)-C(18)-O(19) -160.49(14) 





Table A22. Hydrogen bonds for 5′ [Å and °]. 
____________________________________________________________________________ 
       D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 C(2)-H(2A)...O(11)#1 0.95 2.27 3.1672(19) 157.5 
 C(7)-H(7B)...O(19) 0.99 2.17 2.9608(18) 136.3 
 C(9)-H(9B)...N(3)#2 0.99 2.67 3.604(2) 158.2 
 C(14A)-H(14C)...N(3)#3 0.98 2.66 3.444(2) 137.3 
 C(15)-H(15A)...N(3)#3 0.95 2.67 3.5742(19) 158.3 
 C(20)-H(20B)...O(11)#4 0.99 2.65 3.419(2) 134.2 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x,y+1/2,-z+3/2    #2 x-1/2,-y+1/2,-z+2    #3 -x+1/2,-y+1,z-1/2  





X-ray Crystal Data for oxadiazole (RJ-03-13), 25 
Table A23. Crystal data and structure refinement for oxadiazole 25 (RJ-03-13). 
Identification code  cook157 
Empirical formula  C19H19N5O3 
Formula weight  365.39 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 8.7093(7) Å = 90°. 
 b = 12.3887(9) Å = 90°. 
 c = 15.9890(13) Å  = 90°. 
Volume 1725.2(2) Å3 
Z 4 
Density (-123ºC) 1.407 Mg/m3 
Absorption coefficient 0.099 mm-1 
F(000) 768 
Crystal size 0.788 x 0.639 x 0.611 mm3 
θ range for data collection 2.548 to 29.128°. 
Index ranges -11<=h<=11, -16<=k<=16, -21<=l<=21 
Reflections collected 15536 
Independent reflections 4595 [R(int) = 0.0245] 
Completeness to θ = 25.000° 99.8 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4595 / 0 / 244 
Goodness-of-fit on F2 1.107 
Final R indices [I>2σ(I)] R1 = 0.0326, wR2 = 0.0841 
R indices (all data) R1 = 0.0332, wR2 = 0.0849 
Absolute structure parameter -0.12(15) 
Largest diff. peak and hole 0.260 and -0.366 e.Å-3 
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Table A24. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 25.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
O(1) 4484(1) 9376(1) 7665(1) 24(1) 
C(1) 5460(2) 8857(1) 8056(1) 17(1) 
N(2) 5665(1) 8991(1) 8884(1) 17(1) 
C(3) 4724(2) 9757(1) 9367(1) 21(1) 
C(4) 5229(2) 9551(1) 10268(1) 24(1) 
C(5) 6920(2) 9233(1) 10168(1) 21(1) 
C(6) 6922(1) 8514(1) 9389(1) 16(1) 
C(7) 6587(1) 7330(1) 9499(1) 16(1) 
C(8) 6229(2) 6608(1) 10128(1) 17(1) 
N(9) 5914(1) 5592(1) 9802(1) 20(1) 
C(10) 6092(2) 5693(1) 8992(1) 20(1) 
N(11) 6500(1) 6725(1) 8772(1) 16(1) 
C(12) 6924(2) 7059(1) 7948(1) 16(1) 
C(13) 7767(2) 6340(1) 7463(1) 19(1) 
C(14) 8168(2) 6590(1) 6642(1) 20(1) 
C(15) 7744(2) 7591(1) 6312(1) 19(1) 
O(15) 8124(1) 7930(1) 5523(1) 27(1) 
C(15A) 9051(2) 7225(1) 5033(1) 28(1) 
C(16) 6884(2) 8307(1) 6791(1) 20(1) 
C(17) 6466(2) 8056(1) 7611(1) 17(1) 
C(18) 6231(2) 6721(1) 11033(1) 18(1) 
O(19) 5415(1) 5984(1) 11468(1) 22(1) 
N(20) 5640(2) 6239(1) 12328(1) 24(1) 
C(21) 6553(2) 7067(1) 12302(1) 21(1) 
N(22) 6962(2) 7400(1) 11508(1) 22(1) 
C(22) 7165(2) 7593(1) 13073(1) 30(1) 




Table A25. Bond lengths [Å] and angles [°] for 25. 
_____________________________________________________ 
O(1)-C(1)  1.2351(16) C(1)-N(2)  1.3458(16) 
C(1)-C(17)  1.5037(17) N(2)-C(3)  1.4717(16) 
N(2)-C(6)  1.4830(16) C(3)-C(4)  1.5277(19) 
C(3)-H(3A)  0.9900 C(3)-H(3B)  0.9900 
C(4)-C(5)  1.533(2) C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 C(5)-C(6)  1.5318(17) 
C(5)-H(5A)  0.9900 C(5)-H(5B)  0.9900 
C(6)-C(7)  1.5053(16) C(6)-H(6A)  1.0000 
C(7)-C(8)  1.3827(17) C(7)-N(11)  1.3851(15) 
C(8)-N(9)  1.3896(16) C(8)-C(18)  1.4536(17) 
N(9)-C(10)  1.3104(17) C(10)-N(11)  1.3722(16) 
C(10)-H(10A)  0.9500 N(11)-C(12)  1.4296(16) 
C(12)-C(13)  1.3903(18) C(12)-C(17)  1.4060(16) 
C(13)-C(14)  1.3926(18) C(13)-H(13A)  0.9500 
C(14)-C(15)  1.3971(17) C(14)-H(14A)  0.9500 
C(15)-O(15)  1.3697(15) C(15)-C(16)  1.3916(18) 
O(15)-C(15A)  1.4256(18) C(15A)-H(15A)  0.9800 
C(15A)-H(15B)  0.9800 C(15A)-H(15C)  0.9800 
C(16)-C(17)  1.3949(17) C(16)-H(16A)  0.9500 
C(18)-N(22)  1.3004(18) C(18)-O(19)  1.3497(16) 
O(19)-N(20)  1.4252(15) N(20)-C(21)  1.2989(19) 
C(21)-N(22)  1.3808(17) C(21)-C(22)  1.4926(19) 
C(22)-C(23)  1.522(2) C(22)-H(22A)  0.9900 
C(22)-H(22B)  0.9900 C(23)-H(23A)  0.9800 
C(23)-H(23B)  0.9800 C(23)-H(23C)  0.9800 
 
O(1)-C(1)-N(2) 121.66(12) O(1)-C(1)-C(17) 120.29(11) 
N(2)-C(1)-C(17) 118.05(11) C(1)-N(2)-C(3) 121.43(11) 
C(1)-N(2)-C(6) 125.70(11) C(3)-N(2)-C(6) 112.50(10) 
N(2)-C(3)-C(4) 103.12(10) N(2)-C(3)-H(3A) 111.1 
C(4)-C(3)-H(3A) 111.1 N(2)-C(3)-H(3B) 111.1 
C(4)-C(3)-H(3B) 111.1 H(3A)-C(3)-H(3B) 109.1 
C(3)-C(4)-C(5) 102.78(11) C(3)-C(4)-H(4A) 111.2 
C(5)-C(4)-H(4A) 111.2 C(3)-C(4)-H(4B) 111.2 
C(5)-C(4)-H(4B) 111.2 H(4A)-C(4)-H(4B) 109.1 
C(6)-C(5)-C(4) 103.61(11) C(6)-C(5)-H(5A) 111.0 
C(4)-C(5)-H(5A) 111.0 C(6)-C(5)-H(5B) 111.0 
C(4)-C(5)-H(5B) 111.0 H(5A)-C(5)-H(5B) 109.0 
N(2)-C(6)-C(7) 107.99(10) N(2)-C(6)-C(5) 102.12(10) 
C(7)-C(6)-C(5) 118.10(10) N(2)-C(6)-H(6A) 109.4 
C(7)-C(6)-H(6A) 109.4 C(5)-C(6)-H(6A) 109.4 
C(8)-C(7)-N(11) 104.33(10) C(8)-C(7)-C(6) 139.44(11) 
N(11)-C(7)-C(6) 116.10(10) C(7)-C(8)-N(9) 110.94(11) 
C(7)-C(8)-C(18) 131.42(12) N(9)-C(8)-C(18) 117.50(11) 
C(10)-N(9)-C(8) 105.15(11) N(9)-C(10)-N(11) 111.87(11) 
N(9)-C(10)-H(10A) 124.1 N(11)-C(10)-H(10A) 124.1 
C(10)-N(11)-C(7) 107.70(10) C(10)-N(11)-C(12) 124.87(10) 
C(7)-N(11)-C(12) 127.06(10) C(13)-C(12)-C(17) 119.93(11) 
C(13)-C(12)-N(11) 117.73(10) C(17)-C(12)-N(11) 122.29(11) 
C(12)-C(13)-C(14) 121.01(12) C(12)-C(13)-H(13A) 119.5 
C(14)-C(13)-H(13A) 119.5 C(13)-C(14)-C(15) 119.17(12) 
C(13)-C(14)-H(14A) 120.4 C(15)-C(14)-H(14A) 120.4 
O(15)-C(15)-C(16) 116.16(11) O(15)-C(15)-C(14) 123.83(12) 
C(16)-C(15)-C(14) 120.01(12) C(15)-O(15)-C(15A) 117.07(11) 
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O(15)-C(15A)-H(15A) 109.5 O(15)-C(15A)-H(15B) 109.5 
H(15A)-C(15A)-H(15B) 109.5 O(15)-C(15A)-H(15C) 109.5 
H(15A)-C(15A)-H(15C) 109.5 H(15B)-C(15A)-H(15C) 109.5 
C(15)-C(16)-C(17) 121.02(12) C(15)-C(16)-H(16A) 119.5 
C(17)-C(16)-H(16A) 119.5 C(16)-C(17)-C(12) 118.83(12) 
C(16)-C(17)-C(1) 116.75(11) C(12)-C(17)-C(1) 124.31(11) 
N(22)-C(18)-O(19) 113.23(12) N(22)-C(18)-C(8) 130.16(12) 
O(19)-C(18)-C(8) 116.52(11) C(18)-O(19)-N(20) 105.96(10) 
C(21)-N(20)-O(19) 103.16(11) N(20)-C(21)-N(22) 115.08(12) 
N(20)-C(21)-C(22) 122.46(13) N(22)-C(21)-C(22) 122.41(13) 
C(18)-N(22)-C(21) 102.55(11) C(21)-C(22)-C(23) 112.58(14) 
C(21)-C(22)-H(22A) 109.1 C(23)-C(22)-H(22A) 109.1 
C(21)-C(22)-H(22B) 109.1 C(23)-C(22)-H(22B) 109.1 
H(22A)-C(22)-H(22B) 107.8 C(22)-C(23)-H(23A) 109.5 
C(22)-C(23)-H(23B) 109.5 H(23A)-C(23)-H(23B) 109.5 






Table A26. Anisotropic displacement parameters (Å2x 103) for 25. The anisotropic 
displacement factor exponent takes the form: -22[h2a*2U11 + ... + 2 h k a* b* U12] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
O(1) 23(1)  23(1) 25(1)  5(1) -3(1)  6(1) 
C(1) 17(1)  14(1) 21(1)  3(1) 0(1)  0(1) 
N(2) 17(1)  14(1) 20(1)  1(1) -1(1)  2(1) 
C(3) 20(1)  16(1) 26(1)  -1(1) 4(1)  2(1) 
C(4) 28(1)  19(1) 24(1)  -3(1) 4(1)  -1(1) 
C(5) 26(1)  14(1) 22(1)  -2(1) -3(1)  -4(1) 
C(6) 16(1)  13(1) 18(1)  1(1) -2(1)  -2(1) 
C(7) 15(1)  14(1) 17(1)  0(1) -3(1)  0(1) 
C(8) 20(1)  15(1) 18(1)  0(1) -3(1)  0(1) 
N(9) 27(1)  14(1) 20(1)  1(1) -4(1)  -3(1) 
C(10) 26(1)  14(1) 20(1)  1(1) -4(1)  -3(1) 
N(11) 21(1)  12(1) 16(1)  1(1) -3(1)  -1(1) 
C(12) 19(1)  14(1) 16(1)  1(1) -3(1)  -1(1) 
C(13) 24(1)  14(1) 21(1)  1(1) -2(1)  1(1) 
C(14) 23(1)  16(1) 20(1)  -1(1) -1(1)  0(1) 
C(15) 23(1)  19(1) 16(1)  1(1) -1(1)  -2(1) 
O(15) 40(1)  22(1) 18(1)  3(1) 6(1)  2(1) 
C(15A) 39(1)  28(1) 18(1)  -2(1) 2(1)  2(1) 
C(16) 24(1)  16(1) 19(1)  2(1) -2(1)  1(1) 
C(17) 18(1)  14(1) 18(1)  1(1) -3(1)  1(1) 
C(18) 18(1)  15(1) 20(1)  2(1) -1(1)  2(1) 
O(19) 24(1)  22(1) 19(1)  3(1) -1(1)  -2(1) 
N(20) 27(1)  27(1) 17(1)  2(1) 1(1)  3(1) 
C(21) 25(1)  21(1) 18(1)  -1(1) 0(1)  6(1) 
N(22) 28(1)  21(1) 16(1)  -1(1) -2(1)  -1(1) 
C(22) 33(1)  38(1) 20(1)  -8(1) -2(1)  5(1) 




Table A27. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 103) for 25. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(3A) 3616 9608 9294 25 
H(3B) 4938 10511 9198 25 
H(4A) 4627 8960 10525 28 
H(4B) 5121 10210 10614 28 
H(5A) 7574 9878 10085 25 
H(5B) 7291 8831 10664 25 
H(6A) 7917 8603 9085 19 
H(10A) 5956 5121 8603 24 
H(13A) 8076 5668 7695 23 
H(14A) 8722 6086 6311 24 
H(15A) 9244 7554 4485 42 
H(15B) 10031 7100 5319 42 
H(15C) 8517 6535 4957 42 
H(16A) 6577 8978 6557 23 
H(22A) 8206 7308 13189 36 
H(22B) 6500 7403 13553 36 
H(23A) 7654 9122 13515 58 
H(23B) 7922 9009 12529 58 




Table A28. Torsion angles [°] for 25. 
________________________________________________________________ 
O(1)-C(1)-N(2)-C(3) 0.55(19) C(17)-C(1)-N(2)-C(3) -179.83(11) 
O(1)-C(1)-N(2)-C(6) -171.93(12) C(17)-C(1)-N(2)-C(6) 7.69(18) 
C(1)-N(2)-C(3)-C(4) 174.18(11) C(6)-N(2)-C(3)-C(4) -12.42(14) 
N(2)-C(3)-C(4)-C(5) 32.02(13) C(3)-C(4)-C(5)-C(6) -40.37(12) 
C(1)-N(2)-C(6)-C(7) -74.14(15) C(3)-N(2)-C(6)-C(7) 112.80(11) 
C(1)-N(2)-C(6)-C(5) 160.67(12) C(3)-N(2)-C(6)-C(5) -12.39(13) 
C(4)-C(5)-C(6)-N(2) 32.12(12) C(4)-C(5)-C(6)-C(7) -86.09(13) 
N(2)-C(6)-C(7)-C(8) -114.16(18) C(5)-C(6)-C(7)-C(8) 0.9(2) 
N(2)-C(6)-C(7)-N(11) 60.81(14) C(5)-C(6)-C(7)-N(11) 175.87(11) 
N(11)-C(7)-C(8)-N(9) -0.69(15) C(6)-C(7)-C(8)-N(9) 174.65(14) 
N(11)-C(7)-C(8)-C(18) 174.87(14) C(6)-C(7)-C(8)-C(18) -9.8(3) 
C(7)-C(8)-N(9)-C(10) 0.66(16) C(18)-C(8)-N(9)-C(10) -175.60(12) 
C(8)-N(9)-C(10)-N(11) -0.35(16) N(9)-C(10)-N(11)-C(7) -0.07(16) 
N(9)-C(10)-N(11)-C(12) 173.42(12) C(8)-C(7)-N(11)-C(10) 0.46(14) 
C(6)-C(7)-N(11)-C(10) -176.17(11) C(8)-C(7)-N(11)-C(12) -172.85(13) 
C(6)-C(7)-N(11)-C(12) 10.52(18) C(10)-N(11)-C(12)-C(13) -36.60(19) 
C(7)-N(11)-C(12)-C(13) 135.63(13) C(10)-N(11)-C(12)-C(17) 140.87(13) 
C(7)-N(11)-C(12)-C(17) -46.90(19) C(17)-C(12)-C(13)-C(14) -0.19(19) 
N(11)-C(12)-C(13)-C(14) 177.34(12) C(12)-C(13)-C(14)-C(15) 1.6(2) 
C(13)-C(14)-C(15)-O(15) 177.77(13) C(13)-C(14)-C(15)-C(16) -2.4(2) 
C(16)-C(15)-O(15)-C(15A) 177.80(13) C(14)-C(15)-O(15)-C(15A) -2.3(2) 
O(15)-C(15)-C(16)-C(17) -178.41(12) C(14)-C(15)-C(16)-C(17) 1.7(2) 
C(15)-C(16)-C(17)-C(12) -0.3(2) C(15)-C(16)-C(17)-C(1) -176.54(12) 
C(13)-C(12)-C(17)-C(16) -0.49(19) N(11)-C(12)-C(17)-C(16) -177.91(12) 
C(13)-C(12)-C(17)-C(1) 175.48(12) N(11)-C(12)-C(17)-C(1) -1.93(19) 
O(1)-C(1)-C(17)-C(16) 34.08(17) N(2)-C(1)-C(17)-C(16) -145.55(12) 
O(1)-C(1)-C(17)-C(12) -141.97(14) N(2)-C(1)-C(17)-C(12) 38.40(18) 
C(7)-C(8)-C(18)-N(22) -22.2(2) N(9)-C(8)-C(18)-N(22) 153.11(14) 
C(7)-C(8)-C(18)-O(19) 161.44(14) N(9)-C(8)-C(18)-O(19) -23.23(18) 
N(22)-C(18)-O(19)-N(20) 0.93(15) C(8)-C(18)-O(19)-N(20) 177.89(11) 
C(18)-O(19)-N(20)-C(21) -0.68(14) O(19)-N(20)-C(21)-N(22) 0.26(16) 
O(19)-N(20)-C(21)-C(22) -177.36(13) O(19)-C(18)-N(22)-C(21) -0.74(15) 
C(8)-C(18)-N(22)-C(21) -177.19(13) N(20)-C(21)-N(22)-C(18) 0.27(17) 






Table A29. Hydrogen bonds for 25 [Å and °]. 
____________________________________________________________________________ 
      D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 C(5)-H(5B)...N(22) 0.99 2.25 3.1223(17) 146.7 
 C(6)-H(6A)...O(19)#1 1.00 2.40 3.3934(17) 170.7 
 C(10)-H(10A)...O(1)#2 0.95 2.26 3.1520(16) 155.9 
 C(13)-H(13A)...N(20)#3 0.95 2.68 3.4894(18) 143.6 
 C(15A)-H(15C)...N(9)#3 0.98 2.69 3.5091(19) 141.0 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  




X-ray Crystal Data for oxadiazole (RJ-03-14), 26 
Table A30. Crystal data and structure refinement for 26. 
Identification code  cook156 
Empirical formula  C18H19N15O4 
Formula weight  509.48 
Temperature  150(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 4.4720(2) Å = 90°. 
 b = 18.7822(7) Å = 90°. 
 c = 20.5765(7) Å  = 90°. 
Volume 1728.30(12) Å3 
Z 4 
Density (-123ºC) 1.958 Mg/m3 
Absorption coefficient 1.259 mm-1 
F(000) 1056 
Crystal size 0.543 x 0.216 x 0.172 mm3 
θ range for data collection 3.186 to 68.149°. 
Index ranges -5<=h<=4, -22<=k<=21, -24<=l<=22 
Reflections collected 9038 
Independent reflections 3041 [R(int) = 0.0443] 
Completeness to θ = 67.679° 99.1 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7530 and 0.6333 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3041 / 3 / 253 
Goodness-of-fit on F2 1.070 
Final R indices [I>2σ(I)] R1 = 0.0335, wR2 = 0.0899 
R indices (all data) R1 = 0.0337, wR2 = 0.0900 
Absolute structure parameter 0.12(6) 
Extinction coefficient 0.0143(10) 
Largest diff. peak and hole 0.276 and -0.233 e.Å-3 
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Table A31. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 26. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 7331(4) -289(1) 5776(1) 20(1) 
O(1) 8428(4) -889(1) 5830(1) 28(1) 
N(2) 6606(4) 105(1) 6296(1) 19(1) 
C(3) 6815(5) -180(1) 6962(1) 22(1) 
C(4) 5925(5) 453(1) 7382(1) 23(1) 
C(5) 3772(5) 871(1) 6956(1) 22(1) 
C(6) 5047(4) 797(1) 6267(1) 19(1) 
C(7) 7182(4) 1352(1) 6024(1) 18(1) 
C(8) 8576(5) 1967(1) 6228(1) 20(1) 
N(9) 10402(4) 2238(1) 5742(1) 23(1) 
C(10) 10108(5) 1802(1) 5255(1) 22(1) 
N(11) 8197(4) 1255(1) 5394(1) 19(1) 
C(12) 7147(4) 731(1) 4940(1) 20(1) 
C(13) 6624(5) 951(1) 4302(1) 24(1) 
C(14) 5587(5) 473(1) 3849(1) 26(1) 
C(15) 5019(5) -232(1) 4025(1) 23(1) 
O(15) 3929(4) -658(1) 3546(1) 30(1) 
C(15A) 2955(6) -1351(1) 3721(1) 34(1) 
C(16) 5598(5) -457(1) 4655(1) 22(1) 
C(17) 6687(4) 20(1) 5118(1) 20(1) 
C(18) 8416(5) 2369(1) 6836(1) 21(1) 
O(19) 10023(5) 2969(1) 6845(1) 45(1) 
N(20) 9516(7) 3279(1) 7466(1) 45(1) 
C(21) 7715(5) 2838(1) 7745(1) 24(1) 
C(22) 6558(6) 2966(1) 8413(1) 29(1) 
N(22) 6998(4) 2254(1) 7373(1) 26(1) 




Table A32. Bond lengths [Å] and angles [°] for 26. 
_____________________________________________________ 
C(1)-O(1)  1.233(2) C(1)-N(2)  1.341(3) 
C(1)-C(17)  1.500(3) N(2)-C(3)  1.476(2) 
N(2)-C(6)  1.476(2) C(3)-C(4)  1.521(3) 
C(3)-H(3A)  0.9900 C(3)-H(3B)  0.9900 
C(4)-C(5)  1.520(3) C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 C(5)-C(6)  1.533(3) 
C(5)-H(5A)  0.9900 C(5)-H(5B)  0.9900 
C(6)-C(7)  1.499(3) C(6)-H(6A)  1.0000 
C(7)-C(8)  1.378(3) C(7)-N(11)  1.386(2) 
C(8)-N(9)  1.388(3) C(8)-C(18)  1.463(3) 
N(9)-C(10)  1.300(3) C(10)-N(11)  1.367(3) 
C(10)-H(10A)  0.9500 N(11)-C(12)  1.435(2) 
C(12)-C(13)  1.396(3) C(12)-C(17)  1.401(3) 
C(13)-C(14)  1.375(3) C(13)-H(13A)  0.9500 
C(14)-C(15)  1.395(3) C(14)-H(14A)  0.9500 
C(15)-O(15)  1.360(2) C(15)-C(16)  1.388(3) 
O(15)-C(15A)  1.420(3) C(15A)-H(15A)  0.9800 
C(15A)-H(15B)  0.9800 C(15A)-H(15C)  0.9800 
C(16)-C(17)  1.396(3) C(16)-H(16A)  0.9500 
C(18)-N(22)  1.293(3) C(18)-O(19)  1.336(3) 
O(19)-N(20)  1.421(2) N(20)-C(21)  1.290(3) 
C(21)-N(22)  1.375(3) C(21)-C(22)  1.487(3) 
C(22)-H(22A)  0.9800 C(22)-H(22B)  0.9800 
C(22)-H(22C)  0.9800 O(1S)-H(1SA)  0.869(12) 
O(1S)-H(1SB)  0.865(12) 
 
O(1)-C(1)-N(2) 121.93(18) O(1)-C(1)-C(17) 120.75(18) 
N(2)-C(1)-C(17) 117.30(16) C(1)-N(2)-C(3) 121.72(15) 
C(1)-N(2)-C(6) 124.72(16) C(3)-N(2)-C(6) 112.69(15) 
N(2)-C(3)-C(4) 103.15(15) N(2)-C(3)-H(3A) 111.1 
C(4)-C(3)-H(3A) 111.1 N(2)-C(3)-H(3B) 111.1 
C(4)-C(3)-H(3B) 111.1 H(3A)-C(3)-H(3B) 109.1 
C(5)-C(4)-C(3) 103.98(16) C(5)-C(4)-H(4A) 111.0 
C(3)-C(4)-H(4A) 111.0 C(5)-C(4)-H(4B) 111.0 
C(3)-C(4)-H(4B) 111.0 H(4A)-C(4)-H(4B) 109.0 
C(4)-C(5)-C(6) 104.53(16) C(4)-C(5)-H(5A) 110.8 
C(6)-C(5)-H(5A) 110.8 C(4)-C(5)-H(5B) 110.8 
C(6)-C(5)-H(5B) 110.8 H(5A)-C(5)-H(5B) 108.9 
N(2)-C(6)-C(7) 108.93(16) N(2)-C(6)-C(5) 102.62(15) 
C(7)-C(6)-C(5) 118.87(16) N(2)-C(6)-H(6A) 108.7 
C(7)-C(6)-H(6A) 108.7 C(5)-C(6)-H(6A) 108.7 
C(8)-C(7)-N(11) 104.31(17) C(8)-C(7)-C(6) 140.27(18) 
N(11)-C(7)-C(6) 115.42(16) C(7)-C(8)-N(9) 110.77(17) 
C(7)-C(8)-C(18) 132.15(19) N(9)-C(8)-C(18) 117.07(17) 
C(10)-N(9)-C(8) 105.30(17) N(9)-C(10)-N(11) 112.15(18) 
N(9)-C(10)-H(10A) 123.9 N(11)-C(10)-H(10A) 123.9 
C(10)-N(11)-C(7) 107.48(16) C(10)-N(11)-C(12) 125.80(17) 
C(7)-N(11)-C(12) 126.27(16) C(13)-C(12)-C(17) 120.20(18) 
C(13)-C(12)-N(11) 117.65(17) C(17)-C(12)-N(11) 122.14(17) 
C(14)-C(13)-C(12) 120.09(18) C(14)-C(13)-H(13A) 120.0 
C(12)-C(13)-H(13A) 120.0 C(13)-C(14)-C(15) 120.33(18) 
C(13)-C(14)-H(14A) 119.8 C(15)-C(14)-H(14A) 119.8 
O(15)-C(15)-C(16) 124.38(19) O(15)-C(15)-C(14) 115.81(18) 
C(16)-C(15)-C(14) 119.80(19) C(15)-O(15)-C(15A) 117.75(16) 
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Table A32. (continued). 
_____________________________________________________ 
 
O(15)-C(15A)-H(15A) 109.5 O(15)-C(15A)-H(15B) 109.5 
H(15A)-C(15A)-H(15B) 109.5 O(15)-C(15A)-H(15C) 109.5 
H(15A)-C(15A)-H(15C) 109.5 H(15B)-C(15A)-H(15C) 109.5 
C(15)-C(16)-C(17) 120.55(18) C(15)-C(16)-H(16A) 119.7 
C(17)-C(16)-H(16A) 119.7 C(16)-C(17)-C(12) 118.96(18) 
C(16)-C(17)-C(1) 115.78(17) C(12)-C(17)-C(1) 125.24(18) 
N(22)-C(18)-O(19) 113.07(18) N(22)-C(18)-C(8) 131.98(19) 
O(19)-C(18)-C(8) 114.95(18) C(18)-O(19)-N(20) 105.81(17) 
C(21)-N(20)-O(19) 103.75(17) N(20)-C(21)-N(22) 114.12(19) 
N(20)-C(21)-C(22) 121.70(19) N(22)-C(21)-C(22) 124.17(19) 
C(21)-C(22)-H(22A) 109.5 C(21)-C(22)-H(22B) 109.5 
H(22A)-C(22)-H(22B) 109.5 C(21)-C(22)-H(22C) 109.5 
H(22A)-C(22)-H(22C) 109.5 H(22B)-C(22)-H(22C) 109.5 





Table A33. Anisotropic displacement parameters (Å2x 103) for 26. The anisotropic 
displacement factor exponent takes the form: -22[h2a*2U11 + ... + 2 h k a* b* U12] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 24(1)  17(1) 20(1)  1(1) -4(1)  -1(1) 
O(1) 46(1)  16(1) 22(1)  0(1) -4(1)  7(1) 
N(2) 25(1)  14(1) 17(1)  2(1) -3(1)  0(1) 
C(3) 29(1)  20(1) 18(1)  4(1) -2(1)  -3(1) 
C(4) 25(1)  25(1) 20(1)  0(1) 5(1)  -2(1) 
C(5) 20(1)  23(1) 24(1)  -2(1) 4(1)  -3(1) 
C(6) 18(1)  16(1) 22(1)  -2(1) -2(1)  1(1) 
C(7) 20(1)  16(1) 17(1)  2(1) -2(1)  5(1) 
C(8) 24(1)  16(1) 20(1)  2(1) -2(1)  2(1) 
N(9) 29(1)  18(1) 22(1)  3(1) -2(1)  -1(1) 
C(10) 26(1)  18(1) 21(1)  3(1) 0(1)  1(1) 
N(11) 24(1)  15(1) 16(1)  -1(1) -1(1)  1(1) 
C(12) 24(1)  16(1) 18(1)  -1(1) -2(1)  1(1) 
C(13) 34(1)  16(1) 21(1)  2(1) 0(1)  1(1) 
C(14) 38(1)  23(1) 17(1)  3(1) -4(1)  1(1) 
C(15) 29(1)  22(1) 19(1)  -3(1) -2(1)  0(1) 
O(15) 46(1)  24(1) 19(1)  -2(1) -6(1)  -8(1) 
C(15A) 52(1)  25(1) 26(1)  -2(1) -7(1)  -8(1) 
C(16) 30(1)  16(1) 21(1)  0(1) -1(1)  0(1) 
C(17) 25(1)  17(1) 19(1)  1(1) -1(1)  3(1) 
C(18) 28(1)  13(1) 23(1)  1(1) -5(1)  -1(1) 
O(19) 78(1)  32(1) 24(1)  -9(1) 12(1)  -31(1) 
N(20) 84(2)  32(1) 21(1)  -11(1) 6(1)  -26(1) 
C(21) 32(1)  17(1) 22(1)  0(1) -6(1)  -1(1) 
C(22) 41(1)  23(1) 25(1)  -6(1) 0(1)  -2(1) 
N(22) 35(1)  19(1) 24(1)  -4(1) 1(1)  -3(1) 




Table A34. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 103) for 26. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(3A) 8877 -338 7062 27 
H(3B) 5426 -584 7026 27 
H(4A) 4933 293 7786 28 
H(4B) 7693 744 7496 28 
H(5A) 3698 1377 7090 27 
H(5B) 1731 668 6980 27 
H(6A) 3346 758 5954 23 
H(10A) 11107 1857 4851 26 
H(13A) 6985 1431 4181 29 
H(14A) 5256 623 3414 31 
H(15A) 2191 -1597 3335 52 
H(15B) 1364 -1315 4047 52 
H(15C) 4639 -1620 3902 52 
H(16A) 5251 -939 4771 27 
H(22A) 7615 3370 8607 44 
H(22B) 6883 2540 8679 44 
H(22C) 4413 3071 8393 44 
H(1SA) 10210(50) -2330(13) 5009(16) 55 




Table A35. Torsion angles [°] for 26. 
________________________________________________________________ 
O(1)-C(1)-N(2)-C(3) -5.8(3) C(17)-C(1)-N(2)-C(3) 172.78(18) 
O(1)-C(1)-N(2)-C(6) -174.34(18) C(17)-C(1)-N(2)-C(6) 4.2(3) 
C(1)-N(2)-C(3)-C(4) 177.59(18) C(6)-N(2)-C(3)-C(4) -12.6(2) 
N(2)-C(3)-C(4)-C(5) 30.0(2) C(3)-C(4)-C(5)-C(6) -36.80(19) 
C(1)-N(2)-C(6)-C(7) -73.5(2) C(3)-N(2)-C(6)-C(7) 117.05(18) 
C(1)-N(2)-C(6)-C(5) 159.64(18) C(3)-N(2)-C(6)-C(5) -9.8(2) 
C(4)-C(5)-C(6)-N(2) 28.39(18) C(4)-C(5)-C(6)-C(7) -91.8(2) 
N(2)-C(6)-C(7)-C(8) -115.8(3) C(5)-C(6)-C(7)-C(8) 1.2(3) 
N(2)-C(6)-C(7)-N(11) 64.1(2) C(5)-C(6)-C(7)-N(11) -178.98(16) 
N(11)-C(7)-C(8)-N(9) -0.3(2) C(6)-C(7)-C(8)-N(9) 179.6(2) 
N(11)-C(7)-C(8)-C(18) 178.3(2) C(6)-C(7)-C(8)-C(18) -1.8(4) 
C(7)-C(8)-N(9)-C(10) 0.3(2) C(18)-C(8)-N(9)-C(10) -178.51(17) 
C(8)-N(9)-C(10)-N(11) -0.2(2) N(9)-C(10)-N(11)-C(7) 0.1(2) 
N(9)-C(10)-N(11)-C(12) 172.76(18) C(8)-C(7)-N(11)-C(10) 0.1(2) 
C(6)-C(7)-N(11)-C(10) -179.75(17) C(8)-C(7)-N(11)-C(12) -172.51(17) 
C(6)-C(7)-N(11)-C(12) 7.6(3) C(10)-N(11)-C(12)-C(13) -35.6(3) 
C(7)-N(11)-C(12)-C(13) 135.8(2) C(10)-N(11)-C(12)-C(17) 143.6(2) 
C(7)-N(11)-C(12)-C(17) -45.1(3) C(17)-C(12)-C(13)-C(14) 1.5(3) 
N(11)-C(12)-C(13)-C(14) -179.33(19) C(12)-C(13)-C(14)-C(15) 0.7(3) 
C(13)-C(14)-C(15)-O(15) 178.4(2) C(13)-C(14)-C(15)-C(16) -2.2(3) 
C(16)-C(15)-O(15)-C(15A) 8.6(3) C(14)-C(15)-O(15)-C(15A) -172.0(2) 
O(15)-C(15)-C(16)-C(17) -179.3(2) C(14)-C(15)-C(16)-C(17) 1.3(3) 
C(15)-C(16)-C(17)-C(12) 0.9(3) C(15)-C(16)-C(17)-C(1) -177.93(19) 
C(13)-C(12)-C(17)-C(16) -2.3(3) N(11)-C(12)-C(17)-C(16) 178.59(18) 
C(13)-C(12)-C(17)-C(1) 176.37(19) N(11)-C(12)-C(17)-C(1) -2.7(3) 
O(1)-C(1)-C(17)-C(16) 38.3(3) N(2)-C(1)-C(17)-C(16) -140.3(2) 
O(1)-C(1)-C(17)-C(12) -140.4(2) N(2)-C(1)-C(17)-C(12) 41.0(3) 
C(7)-C(8)-C(18)-N(22) 2.9(4) N(9)-C(8)-C(18)-N(22) -178.5(2) 
C(7)-C(8)-C(18)-O(19) -177.1(2) N(9)-C(8)-C(18)-O(19) 1.4(3) 
N(22)-C(18)-O(19)-N(20) -1.0(3) C(8)-C(18)-O(19)-N(20) 179.0(2) 
C(18)-O(19)-N(20)-C(21) 0.0(3) O(19)-N(20)-C(21)-N(22) 0.9(3) 
O(19)-N(20)-C(21)-C(22) -179.1(2) O(19)-C(18)-N(22)-C(21) 1.5(2) 
























Table A36. Hydrogen bonds for 26 [Å and °]. 
____________________________________________________________________________ 
        D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 C(4)-H(4A)...O(15)#1 0.99 2.43 3.255(3) 140.8 
 C(4)-H(4B)...O(15)#2 0.99 2.64 3.344(3) 128.1 
 C(5)-H(5A)...N(22) 0.99 2.29 3.094(3) 137.8 
 C(13)-H(13A)...N(9)#3 0.95 2.60 3.446(3) 148.2 
 C(13)-H(13A)...O(19)#3 0.95 2.55 3.194(3) 125.4 
 C(16)-H(16A)...O(1S) 0.95 2.65 3.407(3) 136.6 
 C(22)-H(22A)...O(1)#4 0.98 2.53 3.477(3) 161.8 
 O(1S)-H(1SA)...O(1S)#5 0.869(12) 1.855(12) 2.7223(18) 175(3) 
 O(1S)-H(1SB)...O(1) 0.865(12) 1.980(12) 2.836(2) 170(3) 
 C(13)-H(13A)...N(9)#3 0.95 2.60 3.446(3) 148.2 
 C(13)-H(13A)...O(19)#3 0.95 2.55 3.194(3) 125.4 
 C(16)-H(16A)...O(1S) 0.95 2.65 3.407(3) 136.6 
 O(1S)-H(1SA)...O(1S)#5 0.869(12) 1.855(12) 2.7223(18) 175(3) 
 O(1S)-H(1SB)...O(1) 0.865(12) 1.980(12) 2.836(2) 170(3) 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1/2,-y,z+1/2    #2 -x+3/2,-y,z+1/2    #3 x-1/2,-y+1/2,-z+1  














X-ray Crystal Data for oxazole (KRM-II-68), 28 
Table A37. Crystal data and structure refinement for 28 (KRM-II-68). 
Identification code  cook136 
Empirical formula  C18H16N4O3 
Formula weight  336.35 
Temperature  150(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 10.8051(3) Å = 90°. 
 b = 20.3413(8) Å = 90°. 
 c = 7.0384(3) Å  = 90°. 
Volume 1546.97(10) Å3 
Z 4 
Density (-123ºC) 1.444 Mg/m3 
Absorption coefficient 0.836 mm-1 
F(000) 704 
Crystal size 0.493 x 0.399 x 0.207 mm3 
θ range for data collection 4.347 to 68.135°. 
Index ranges -12<=h<=12, -23<=k<=24, -7<=l<=8 
Reflections collected 8881 
Independent reflections 2708 [R(int) = 0.0603] 
Completeness to θ = 67.679° 97.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7530 and 0.5955 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2708 / 0 / 228 
Goodness-of-fit on F2 1.101 
Final R indices [I>σ(I)] R1 = 0.0431, wR2 = 0.1196 
R indices (all data) R1 = 0.0432, wR2 = 0.1197 
Absolute structure parameter 0.05(11) 
Extinction coefficient 0.0039(8) 
Largest diff. peak and hole 0.580 and -0.259 e.Å-3 
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Table A38. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 28. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
N(1) 2313(2) 563(1) 11013(4) 28(1) 
C(2) 1313(3) 228(1) 10607(5) 25(1) 
N(3) 906(2) 349(1) 8803(4) 21(1) 
C(4) -137(2) 50(1) 7911(4) 19(1) 
C(5) -316(3) -618(1) 8160(4) 23(1) 
C(6) -1392(3) -925(1) 7530(4) 23(1) 
C(7) -2301(3) -547(1) 6665(4) 24(1) 
O(7) -3429(2) -771(1) 6121(4) 37(1) 
C(7A) -3672(3) -1458(2) 6351(5) 35(1) 
C(8) -2092(3) 120(1) 6345(4) 24(1) 
C(9) -1014(3) 424(1) 6917(4) 20(1) 
C(10) -913(3) 1150(1) 6519(4) 21(1) 
O(10) -1851(2) 1498(1) 6501(3) 29(1) 
N(11) 206(2) 1404(1) 6132(3) 20(1) 
C(12) 373(3) 2111(1) 5750(5) 25(1) 
C(13) 1753(3) 2208(2) 5918(5) 34(1) 
C(14) 2284(3) 1556(1) 5227(4) 26(1) 
C(15) 1399(2) 1040(1) 6060(4) 20(1) 
C(16) 1700(2) 800(1) 8010(4) 20(1) 
C(17) 2571(3) 920(1) 9384(4) 22(1) 
C(18) 3663(3) 1349(1) 9311(4) 23(1) 
O(19) 4670(2) 1139(1) 8255(3) 30(1) 
C(20) 5524(3) 1625(2) 8479(5) 31(1) 
N(21) 5171(3) 2101(1) 9524(4) 33(1) 




Table A39. Bond lengths [Å] and angles [°] for 28. 
_____________________________________________________ 
N(1)-C(2)  1.309(4) N(1)-C(17)  1.386(4) 
C(2)-N(3)  1.366(4) C(2)-H(2A)  0.9500 
N(3)-C(16)  1.374(4) N(3)-C(4)  1.426(4) 
C(4)-C(5)  1.383(4) C(4)-C(9)  1.402(4) 
C(5)-C(6)  1.392(4) C(5)-H(5A)  0.9500 
C(6)-C(7)  1.388(4) C(6)-H(6A)  0.9500 
C(7)-O(7)  1.357(4) C(7)-C(8)  1.395(4) 
O(7)-C(7A)  1.430(4) C(7A)-H(7AA)  0.9800 
C(7A)-H(7AB)  0.9800 C(7A)-H(7AC)  0.9800 
C(8)-C(9)  1.378(4) C(8)-H(8A)  0.9500 
C(9)-C(10)  1.507(3) C(10)-O(10)  1.238(3) 
C(10)-N(11)  1.343(4) N(11)-C(12)  1.475(3) 
N(11)-C(15)  1.487(3) C(12)-C(13)  1.509(4) 
C(12)-H(12A)  0.9900 C(12)-H(12B)  0.9900 
C(13)-C(14)  1.525(4) C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 C(14)-C(15)  1.536(4) 
C(14)-H(14A)  0.9900 C(14)-H(14B)  0.9900 
C(15)-C(16)  1.493(4) C(15)-H(15A)  1.0000 
C(16)-C(17)  1.372(4) C(17)-C(18)  1.467(4) 
C(18)-C(22)  1.336(4) C(18)-O(19)  1.385(3) 
O(19)-C(20)  1.361(4) C(20)-N(21)  1.275(4) 
C(20)-H(20A)  0.9500 N(21)-C(22)  1.402(4) 
C(22)-H(22A)  0.9500 
 
C(2)-N(1)-C(17) 104.9(3) N(1)-C(2)-N(3) 112.1(3) 
N(1)-C(2)-H(2A) 124.0 N(3)-C(2)-H(2A) 124.0 
C(2)-N(3)-C(16) 107.2(2) C(2)-N(3)-C(4) 125.9(2) 
C(16)-N(3)-C(4) 126.8(2) C(5)-C(4)-C(9) 120.1(3) 
C(5)-C(4)-N(3) 118.3(2) C(9)-C(4)-N(3) 121.5(2) 
C(4)-C(5)-C(6) 121.2(3) C(4)-C(5)-H(5A) 119.4 
C(6)-C(5)-H(5A) 119.4 C(7)-C(6)-C(5) 118.8(3) 
C(7)-C(6)-H(6A) 120.6 C(5)-C(6)-H(6A) 120.6 
O(7)-C(7)-C(6) 125.0(3) O(7)-C(7)-C(8) 115.3(3) 
C(6)-C(7)-C(8) 119.7(3) C(7)-O(7)-C(7A) 117.4(2) 
O(7)-C(7A)-H(7AA) 109.5 O(7)-C(7A)-H(7AB) 109.5 
H(7AA)-C(7A)-H(7AB) 109.5 O(7)-C(7A)-H(7AC) 109.5 
H(7AA)-C(7A)-H(7AC) 109.5 H(7AB)-C(7A)-H(7AC) 109.5 
C(9)-C(8)-C(7) 121.7(3) C(9)-C(8)-H(8A) 119.1 
C(7)-C(8)-H(8A) 119.1 C(8)-C(9)-C(4) 118.3(3) 
C(8)-C(9)-C(10) 116.5(3) C(4)-C(9)-C(10) 125.1(2) 
O(10)-C(10)-N(11) 121.0(2) O(10)-C(10)-C(9) 120.2(2) 
N(11)-C(10)-C(9) 118.7(2) C(10)-N(11)-C(12) 121.5(2) 
C(10)-N(11)-C(15) 126.5(2) C(12)-N(11)-C(15) 111.9(2) 
N(11)-C(12)-C(13) 103.5(2) N(11)-C(12)-H(12A) 111.1 
C(13)-C(12)-H(12A) 111.1 N(11)-C(12)-H(12B) 111.1 
C(13)-C(12)-H(12B) 111.1 H(12A)-C(12)-H(12B) 109.0 
C(12)-C(13)-C(14) 103.5(2) C(12)-C(13)-H(13A) 111.1 
C(14)-C(13)-H(13A) 111.1 C(12)-C(13)-H(13B) 111.1 
C(14)-C(13)-H(13B) 111.1 H(13A)-C(13)-H(13B) 109.0 
C(13)-C(14)-C(15) 103.8(2) C(13)-C(14)-H(14A) 111.0 
C(15)-C(14)-H(14A) 111.0 C(13)-C(14)-H(14B) 111.0 
C(15)-C(14)-H(14B) 111.0 H(14A)-C(14)-H(14B) 109.0 
N(11)-C(15)-C(16) 108.7(2) N(11)-C(15)-C(14) 102.3(2) 
C(16)-C(15)-C(14) 116.0(2) N(11)-C(15)-H(15A) 109.9 
281 
 
Table A39. (continued). 
_____________________________________________________ 
 
C(16)-C(15)-H(15A) 109.9 C(14)-C(15)-H(15A) 109.9 
C(17)-C(16)-N(3) 105.2(2) C(17)-C(16)-C(15) 137.7(3) 
N(3)-C(16)-C(15) 117.1(2) C(16)-C(17)-N(1) 110.6(2) 
C(16)-C(17)-C(18) 129.3(3) N(1)-C(17)-C(18) 120.1(3) 
C(22)-C(18)-O(19) 107.1(3) C(22)-C(18)-C(17) 135.0(3) 
O(19)-C(18)-C(17) 117.9(2) C(20)-O(19)-C(18) 104.3(2) 
N(21)-C(20)-O(19) 114.6(3) N(21)-C(20)-H(20A) 122.7 
O(19)-C(20)-H(20A) 122.7 C(20)-N(21)-C(22) 104.2(3) 




Table A40. Anisotropic displacement parameters (Å2x 103) for 28. The anisotropic 
displacement factor exponent takes the form: -22[h2a*2U11 + ... + 2 h k a* b* U12] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
N(1) 26(1)  29(1) 28(1)  2(1) -4(1)  -2(1) 
C(2) 22(1)  27(1) 26(2)  7(1) -2(1)  1(1) 
N(3) 16(1)  22(1) 24(1)  2(1) -2(1)  2(1) 
C(4) 18(1)  21(1) 20(1)  0(1) 1(1)  2(1) 
C(5) 21(1)  23(1) 25(1)  0(1) 0(1)  4(1) 
C(6) 27(2)  21(1) 23(1)  -1(1) 2(1)  -2(1) 
C(7) 23(1)  28(1) 22(1)  1(1) -1(1)  -5(1) 
O(7) 33(1)  33(1) 45(2)  11(1) -16(1)  -16(1) 
C(7A) 40(2)  33(2) 32(2)  3(1) -4(2)  -17(1) 
C(8) 23(1)  28(1) 22(1)  5(1) -3(1)  -1(1) 
C(9) 19(1)  22(1) 19(1)  2(1) 3(1)  -1(1) 
C(10) 21(1)  21(1) 21(1)  4(1) 0(1)  1(1) 
O(10) 21(1)  27(1) 39(1)  8(1) -1(1)  3(1) 
N(11) 21(1)  18(1) 22(1)  3(1) 1(1)  1(1) 
C(12) 31(2)  17(1) 28(2)  2(1) -1(1)  -2(1) 
C(13) 37(2)  30(2) 35(2)  1(1) 0(2)  -7(1) 
C(14) 23(1)  29(1) 26(2)  1(1) 2(1)  -4(1) 
C(15) 18(1)  22(1) 21(1)  -2(1) 2(1)  1(1) 
C(16) 16(1)  20(1) 25(1)  -1(1) 3(1)  1(1) 
C(17) 20(1)  22(1) 24(1)  -1(1) -1(1)  1(1) 
C(18) 17(1)  28(1) 24(1)  -1(1) -4(1)  3(1) 
O(19) 21(1)  35(1) 34(1)  -8(1) 0(1)  -3(1) 
C(20) 22(2)  38(2) 33(2)  4(1) -4(1)  -5(1) 
N(21) 29(1)  31(1) 40(2)  5(1) -5(1)  -6(1) 




Table A41. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 103) for 28. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(2A) 917 -64 11465 30 
H(5A) 306 -871 8771 28 
H(6A) -1502 -1385 7690 28 
H(7AA) -4515 -1555 5923 53 
H(7AB) -3587 -1577 7694 53 
H(7AC) -3080 -1712 5593 53 
H(8A) -2709 372 5717 29 
H(12A) -76 2382 6695 30 
H(12B) 78 2227 4461 30 
H(13A) 1996 2296 7251 41 
H(13B) 2037 2577 5109 41 
H(14A) 3137 1490 5706 31 
H(14B) 2292 1535 3822 31 
H(15A) 1326 659 5169 24 
H(20A) 6318 1610 7903 37 




Table A42. Torsion angles [°] for 28. 
________________________________________________________________ 
C(17)-N(1)-C(2)-N(3) -0.1(3) N(1)-C(2)-N(3)-C(16) -0.7(3) 
N(1)-C(2)-N(3)-C(4) 178.2(2) C(2)-N(3)-C(4)-C(5) -42.3(4) 
C(16)-N(3)-C(4)-C(5) 136.3(3) C(2)-N(3)-C(4)-C(9) 133.2(3) 
C(16)-N(3)-C(4)-C(9) -48.2(4) C(9)-C(4)-C(5)-C(6) -3.6(4) 
N(3)-C(4)-C(5)-C(6) 172.0(2) C(4)-C(5)-C(6)-C(7) -1.0(4) 
C(5)-C(6)-C(7)-O(7) -174.6(3) C(5)-C(6)-C(7)-C(8) 3.7(4) 
C(6)-C(7)-O(7)-C(7A) -4.0(4) C(8)-C(7)-O(7)-C(7A) 177.6(3) 
O(7)-C(7)-C(8)-C(9) 176.5(3) C(6)-C(7)-C(8)-C(9) -1.9(4) 
C(7)-C(8)-C(9)-C(4) -2.6(4) C(7)-C(8)-C(9)-C(10) -178.9(3) 
C(5)-C(4)-C(9)-C(8) 5.3(4) N(3)-C(4)-C(9)-C(8) -170.1(3) 
C(5)-C(4)-C(9)-C(10) -178.7(3) N(3)-C(4)-C(9)-C(10) 5.9(4) 
C(8)-C(9)-C(10)-O(10) 30.9(4) C(4)-C(9)-C(10)-O(10) -145.2(3) 
C(8)-C(9)-C(10)-N(11) -147.2(3) C(4)-C(9)-C(10)-N(11) 36.8(4) 
O(10)-C(10)-N(11)-C(12) 2.6(4) C(9)-C(10)-N(11)-C(12) -179.3(3) 
O(10)-C(10)-N(11)-C(15) -178.5(3) C(9)-C(10)-N(11)-C(15) -0.4(4) 
C(10)-N(11)-C(12)-C(13) 165.4(3) C(15)-N(11)-C(12)-C(13) -13.7(3) 
N(11)-C(12)-C(13)-C(14) 32.3(3) C(12)-C(13)-C(14)-C(15) -39.3(3) 
C(10)-N(11)-C(15)-C(16) -66.2(3) C(12)-N(11)-C(15)-C(16) 112.8(3) 
C(10)-N(11)-C(15)-C(14) 170.6(3) C(12)-N(11)-C(15)-C(14) -10.4(3) 
C(13)-C(14)-C(15)-N(11) 30.1(3) C(13)-C(14)-C(15)-C(16) -88.0(3) 
C(2)-N(3)-C(16)-C(17) 1.1(3) C(4)-N(3)-C(16)-C(17) -177.8(2) 
C(2)-N(3)-C(16)-C(15) -176.6(2) C(4)-N(3)-C(16)-C(15) 4.6(4) 
N(11)-C(15)-C(16)-C(17) -112.5(4) C(14)-C(15)-C(16)-C(17) 1.9(5) 
N(11)-C(15)-C(16)-N(3) 64.1(3) C(14)-C(15)-C(16)-N(3) 178.6(2) 
N(3)-C(16)-C(17)-N(1) -1.2(3) C(15)-C(16)-C(17)-N(1) 175.7(3) 
N(3)-C(16)-C(17)-C(18) 178.3(3) C(15)-C(16)-C(17)-C(18) -4.8(6) 
C(2)-N(1)-C(17)-C(16) 0.8(3) C(2)-N(1)-C(17)-C(18) -178.8(3) 
C(16)-C(17)-C(18)-C(22) 107.7(4) N(1)-C(17)-C(18)-C(22) -72.8(4) 
C(16)-C(17)-C(18)-O(19) -73.8(4) N(1)-C(17)-C(18)-O(19) 105.6(3) 
C(22)-C(18)-O(19)-C(20) -0.3(3) C(17)-C(18)-O(19)-C(20) -179.2(3) 
C(18)-O(19)-C(20)-N(21) -0.1(4) O(19)-C(20)-N(21)-C(22) 0.5(4) 
O(19)-C(18)-C(22)-N(21) 0.6(3) C(17)-C(18)-C(22)-N(21) 179.2(3) 
C(20)-N(21)-C(22)-C(18) -0.7(4) 
________________________________________________________________ 
Table A43. Hydrogen bonds for 28 [Å and °]. 
____________________________________________________________________________ 
        D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 C(2)-H(2A)...O(19)#1 0.95 2.60 3.513(4) 160.8 
 C(13)-H(13B)...O(10)#2 0.99 2.50 3.478(4) 168.0 
 C(14)-H(14A)...O(19) 0.99 2.54 3.451(4) 152.1 
 C(20)-H(20A)...O(10)#3 0.95 2.22 3.170(4) 175.7 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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